MERRF Syndrome - dismech

🏷

Classifications

Harrison's Part

Mechanistic Nosology

🔗

Mappings

MONDO

MONDO:0010790 MERRF syndrome

MONDO:0010790 is the MERRF syndrome concept, the mitochondrial encephalomyopathy defined by the myoclonus, generalized epilepsy, ataxia, and ragged red fiber tetrad that this entry models.

👪

Inheritance

1

Maternal mitochondrial inheritance with heteroplasmy HP:0001427

MERRF is transmitted through the maternal line only, because sperm mitochondria are not passed to the embryo. A carrier mother transmits the variant to every one of her children, but the proportion of mutant genomes each child receives is set by a random bottleneck and subsequent mitotic segregation, so severity is not predictable from the mother's status. An affected father transmits nothing. This is the practical reason prenatal testing cannot forecast the phenotype.

Mitochondrial inheritance

Show evidence (2 references)

PMID:20301693 SUPPORT Other

"MERRF is caused by pathogenic variants in mtDNA and is transmitted by maternal inheritance."

States the mode of inheritance directly for the syndrome being modeled.

PMID:20301693 SUPPORT Other

"A female with a mtDNA pathogenic variant (whether symptomatic or asymptomatic) transmits the pathogenic variant to all of her offspring."

Supports the all-or-none transmission from carrier mothers that distinguishes mitochondrial from Mendelian inheritance, and which is why asymptomatic carrier mothers still need counselling.

?

Discussions and Knowledge Gaps

3

If the m.8344A>G variant acts through a heteroplasmy threshold, why does the heteroplasmy level measured in accessible tissue fail to predict who develops MERRF, and is MERRF a discrete syndrome at all rather than one pole of a transfer RNA lysine disease spectrum?

CONTROVERSY UNDER DISCUSSION merrf_heteroplasmy_phenotype_disconnect

Attached to

pathophysiology#Mitotic Segregation and Tissue Heteroplasmy Threshold pathophysiology#Progressive Myoclonic Epilepsy genetic#MT-TK m.8344A>G

The threshold model is well supported in cell culture, where membrane potential collapses steeply across a narrow band of mutant load. It does not transfer cleanly to patients. In a three-generation family, symptomatic members did carry significantly more mutant genomes than asymptomatic ones, yet asymptomatic relatives were found carrying up to 63 percent mutant genomes, and the authors concluded there is no absolute relationship between blood mutant load and clinical severity. A larger East Chinese cohort of transfer RNA lysine carriers found blood heteroplasmy of a similar high range in symptomatic and asymptomatic individuals alike, and, more strikingly, found that the classic MERRF syndrome was the exception rather than the rule: most symptomatic carriers had a myopathy with neuropathy picture and only about a quarter had myoclonus at all. A case report goes further still, describing a homoplasmic carrier whose course was milder and later than his heteroplasmic sister, the opposite of what a simple dosage model predicts. Three interpretations remain live. The first keeps the threshold model and blames the measurement, arguing that blood is the wrong tissue and that brain or muscle mutant load, ideally at single-cell resolution, would restore the correlation. The second holds that heteroplasmy is genuinely only one input, with nuclear background, mitochondrial haplogroup, and the cell's capacity for compensatory biogenesis or mitophagy setting where the threshold sits. The third questions the nosology, treating MERRF as a named region of a continuous transfer RNA lysine phenotype landscape rather than an entity with its own mechanism. The stakes are practical: a blood heteroplasmy result is routinely used to counsel families, and on the second and third readings that number carries much less predictive weight than it appears to. The first reading is the weakest of the three, because the brain measurement it asks for has already been made: single neurons microdissected from a MERRF brain carried uniformly high mutant load across regions that differed several-fold in cell loss. Moving from blood to brain therefore does not rescue the dosage model, which pushes the weight of explanation onto the modifiers of the second reading and onto the nosological question of the third.

Proposed experiments

Nuclear background and haplogroup modifier study at matched heteroplasmy

exp_merrf_nuclear_modifier_association

Assemble carriers of m.8344A>G matched for mutant load in the same tissue but discordant for phenotype, including asymptomatic high-load carriers, and test nuclear genome and mitochondrial haplogroup for association with expression of the syndrome. Discordant relatives within a single maternal line are the most informative stratum, since they share the variant and much of the environment.

Decision criterion

A reproducible nuclear or haplogroup association at matched heteroplasmy would establish that mutant load is one input among several and would give counselling something better than a blood percentage to work with. No association across an adequately powered matched design would leave stochastic developmental segregation as the leading explanation and argue that individual prognostication is not achievable in principle.

Prospective multi-tissue heteroplasmy cohort with defined phenotyping

exp_merrf_prospective_multitissue_cohort

A prospective cohort of transfer RNA lysine carriers, symptomatic and asymptomatic, with heteroplasmy quantified in blood, urinary sediment, and muscle at enrolment and standardized longitudinal phenotyping for myoclonus, seizures, ataxia, and myopathy.

Decision criterion

If muscle or urinary heteroplasmy predicts subsequent phenotype where blood does not, current counselling practice should shift tissue. If no tissue predicts phenotype, the determinant lies outside mutant load and heteroplasmy-based prognostication should be explicitly qualified.

Show evidence (8 references)

PMID:9272179 SUPPORT Human Clinical

"Although there seems to be a gene dosage effect in MERRF, we found no absolute relationship between the relative proportion of mutant genomes in blood and clinical severity."

States the disconnect directly, from a family study designed to test the dosage model.

PMID:9272179 SUPPORT Human Clinical

"high proportions of mutant genomes (up to 63%) were found in asymptomatic relatives"

Provides the concrete counterexample of asymptomatic carriers with high mutant load.

PMID:32577866 SUPPORT Human Clinical

"heteroplasmy in blood was high both in symptomatic (mean 64.5%, range 41-82%) and asymptomatic individuals (mean 53.1%, range 21-78%)"

Independent cohort evidence that blood heteroplasmy overlaps heavily between symptomatic and asymptomatic carriers.

+ 5 more references

Why does a mitochondrial variant present in every tissue produce degeneration confined to a reproducible set of structures, chiefly the dentate nucleus, red nucleus, pallidum, subthalamic nucleus, cerebellar cortex, and inferior olive, while sparing most of the brain?

KNOWLEDGE GAP OPEN merrf_regional_selectivity_gap

Attached to

pathophysiology#Neuronal Energy Failure and Oxidative Stress pathophysiology#Degeneration of Dentate Nucleus and Cerebellar Circuitry

The neuropathology of MERRF is strikingly stereotyped and was recognized as a distinct distribution before the causal variant was known, differing from dentatorubral-pallidoluysian atrophy, Machado-Joseph disease, and Friedreich ataxia despite overlapping anatomy. The most obvious explanation, that the vulnerable regions simply carry more mutant mitochondrial DNA, has been tested directly and fails. Microdissection of individual neuronal somas from a MERRF brain found uniformly high mutant load across every region examined, and the relationship to cell loss ran the wrong way: Purkinje cells carried the highest mutant load of all, 97.6 percent, yet lost only 7 percent of their number, while dentate nucleus neurons lost 46 percent. Mutant load also matched between neuronal somas and the surrounding neuropil and glia, so the selectivity is not a matter of which cells inherited the bad genomes. What remains are cell-intrinsic differences under nuclear control: differing bioenergetic demand, with fast-spiking projection neurons running closer to their ceiling; differing antioxidant reserve; and differing capacity for mitochondrial biogenesis or mitophagy. None of these has been discriminated in human tissue. Resolving it matters beyond MERRF, because the same puzzle of a ubiquitous lesion with focal degeneration recurs across mitochondrial disease and is what makes the genotype so poor a predictor of which neurological syndrome a carrier develops.

Proposed experiments

Regional bioenergetic reserve profiling in vulnerable versus spared neurons

exp_merrf_regional_bioenergetic_reserve_profiling

Patient-derived induced pluripotent stem cell models differentiated into the vulnerable neuronal classes and into a spared comparator, matched for mutant load, with measurement of spare respiratory capacity, reactive oxygen species handling, and survival under metabolic stress.

Decision criterion

If the vulnerable classes show a lower spare respiratory capacity and die preferentially at matched mutant load, intrinsic bioenergetic demand explains the selectivity. If they behave like the comparator, selectivity must come from mutant load distribution or the tissue environment rather than from cell-intrinsic demand.

Show evidence (4 references)

PMID:3128314 SUPPORT Human Clinical

"The lesions were degenerative in nature, and their distribution was different from those of dentato-rubropallidoluysian atrophy, Joseph's disease or Friedreich's ataxia."

Establishes that the regional pattern is specific and reproducible enough to distinguish MERRF from anatomically neighbouring degenerations, which is what makes its unexplained selectivity a genuine gap.

PMID:9315896 REFUTE Human Clinical

"Neurons and the surrounding neuropil and glia from all CNS regions that were analyzed exhibited high proportions of mutant mtDNA, ranging from 97.6 +/- 0.7% in Purkinje cells to 80.6 +/- 2.8% in the anterior horn cells."

Refutes the regional mutant-load explanation at single-cell resolution: load is uniformly high everywhere, including in a region that is relatively spared.

PMID:9315896 SUPPORT Human Clinical

"Surprisingly, as compared with controls, neuronal loss ranged from 7% of the Purkinje cells to 46% of the neurons of the dentate nucleus in MERRF cerebellum."

Quantifies the inverse relationship that makes the puzzle sharp: the highest-load population is the least depleted.

+ 1 more reference

Preclinical work rescues the MERRF defect in patient-derived cells by three independent routes: importing working transfer RNA, stimulating mitophagy with rapamycin, and cutting the mutant genome with a targeted nuclease to shift heteroplasmy. None has been tested in patients. What would it take to move any of them into a trial, and is a bioenergetic rescue still useful once neurons have been lost?

KNOWLEDGE GAP OPEN merrf_disease_modifying_therapy_gap

Attached to

pathophysiology#Defective Mitochondrial Protein Synthesis pathophysiology#Respiratory Chain Deficiency and Loss of Mitochondrial Membrane Potential

Treatment today is entirely symptomatic. Three cell-level strategies have shown genuine rescue rather than marginal improvement. Targeting a yeast-derived transfer RNA lysine into mitochondria restored translation, respiratory complex activity, membrane potential, and respiration rate in patient fibroblasts and cybrids, and the rescue disappeared when the transgene was knocked down, which is about as clean a causal demonstration as this system allows. Separately, chronic rapamycin, acting through enhanced clearance of damaged mitochondria rather than through biogenesis, completely rescued the bioenergetic defect at intermediate mutant load, while direct stimulation of biogenesis failed at high mutant load. The third route attacks the problem at its root: a mitochondria-targeted nuclease, a monomeric mitoTev-TALE hybrid small enough to be plausibly packaged into a viral vector, cut the mutant genome in patient-derived cybrids and shifted the heteroplasmy ratio toward wild type, with recovery of oxidative phosphorylation even in a clone at 91 percent mutant. These results share a limitation relevant to the clinic: they were obtained in dividing cells that can shift their heteroplasmy, whereas the neurons that matter are postmitotic and cannot dilute anything, and MERRF is a degenerative disease in which the target cells may be gone by the time of treatment. There is also a strong hint about timing, since rapamycin worked well at intermediate but only marginally at high mutant load, suggesting a window that closes. Neither strategy has a delivery route to the human central nervous system, and no biomarker exists that would show target engagement in brain.

Proposed experiments

Mitophagy modulation in postmitotic patient-derived neurons

exp_merrf_mitophagy_modulation_in_postmitotic_neurons

Apply chronic mitophagy stimulation to induced pluripotent stem cell derived neurons from MERRF donors after terminal differentiation, spanning a range of mutant loads, measuring heteroplasmy shift, respiration, and survival, and comparing early with delayed treatment.

Decision criterion

Rescue in postmitotic neurons at clinically representative mutant loads would support translation and define the mutant-load ceiling for benefit. Rescue confined to dividing cells would indicate the mechanism depends on selective replicative advantage and does not transfer to the tissue that matters.

Show evidence (5 references)

PMID:15317755 SUPPORT In Vitro

"Import of a tRNALys with a mutation in the anticodon preventing recognition of the lysine codons does not lead to any rescue, whereas downregulation of the transgenic tRNAs by small interfering RNA (siRNA) transiently abolishes the functional rescue, showing that this rescue is due to the import."

Establishes the specificity and reversibility of the rescue, which is what makes the transfer RNA import strategy worth pursuing rather than a nonspecific culture effect.

PMID:35922766 SUPPORT In Vitro

"The second approach, when administered chronically (4 weeks), induced a slight increase of mitochondrial respiration in fibroblasts with high-mutation load, and a significant improvement in fibroblasts with intermediate-mutation load, rescuing completely the bioenergetics defect."

Documents both the rescue and the mutant-load dependence that motivates the timing question posed here.

PMID:35922766 SUPPORT In Vitro

"This suggests that induction of mitochondrial biogenesis may not be sufficient to rescue mitochondrial dysfunction in MERRF cells with high-mutation load."

Records the negative result for the biogenesis strategy, which is why this gap is framed around mitophagy, transfer RNA supply, and genome editing rather than around making more mitochondria.

+ 2 more references

⚙

Pathophysiology

13

MT-TK m.8344A>G Heteroplasmic Point Variant

An adenine to guanine transition at position 8344 of the mitochondrial genome alters a conserved nucleotide in the T-psi-C loop of the transfer RNA for lysine. Because each cell carries hundreds to thousands of mitochondrial genomes, the variant is present as a mixture with normal genomes rather than in every copy, a state called heteroplasmy. The original pedigrees showed that retaining even a small fraction of normal genomes is strongly protective, which is the first hint that this is a dosage disease rather than a simple loss of function.

MT-TK hgnc:7489

Downstream

Loss of Transfer RNA Lysine Wobble Taurine Modification

Mitotic Segregation and Tissue Heteroplasmy Threshold

Show evidence (3 references)

PMID:2112427 SUPPORT Human Clinical

"An A to G transition mutation at nucleotide pair 8344 in human mitochondrial DNA (mtDNA) has been identified as the cause of MERRF."

The original identification of the variant as the cause of the syndrome, in three independent pedigrees and absent from controls.

PMID:2112427 SUPPORT Human Clinical

"This suggests that a small percentage of normal mtDNAs has a large protective effect on phenotype."

Establishes the heteroplasmy dosage relationship at the level of the founding observation, motivating the threshold node downstream.

PMID:20301693 SUPPORT Other

"The m.8344A>G pathogenic variant in the mitochondrial gene MT-TK is present in more than 80% of affected individuals with typical findings."

Quantifies how much of the syndrome this node accounts for, and by implication how much is left to other mitochondrial transfer RNA genes.

Loss of Transfer RNA Lysine Wobble Taurine Modification

Mitochondrial transfer RNAs carry a taurine-containing chemical tag on the wobble uridine, the flexible first base of the anticodon that lets one transfer RNA read more than one codon. The m.8344A>G variant abolishes this tag on transfer RNA lysine. The consequence is unusually complete: unlike the analogous MELAS variant, which mainly impairs one of its two codons, the untagged MERRF transfer RNA fails to decode either lysine codon.

tRNA wobble uridine modification GO:0002098 ↓ DECREASED

Downstream

Defective Mitochondrial Protein Synthesis

Show evidence (2 references)

PMID:17132941 SUPPORT In Vitro

"revealed the lack of a post-transcriptional taurine-modification at the anticodon wobble uridine in two mt tRNAs bearing typical pathogenic mutations"

Direct demonstration in patient-derived material that the modification is missing, which is the molecular content of this node.

PMID:17132941 SUPPORT In Vitro

"The MERRF mt tRNA(Lys) lacking the wobble modification cannot translate either of its codons (AAA and AAG)"

Establishes that the decoding failure is complete for both lysine codons, which is why the downstream translation defect is severe and not codon-selective.

Mitotic Segregation and Tissue Heteroplasmy Threshold

Mitochondrial genomes are partitioned unequally at each cell division, so the mutant fraction drifts upward in some lineages and downward in others. Biochemical failure is not proportional to that fraction; it is switch-like. In cell lines derived from one patient, moving the mutant load across a narrow band collapsed the mitochondrial membrane potential far more sharply than it reduced enzyme activity, which is what a threshold looks like experimentally. Post-mitotic tissues with high and unremitting energy demand cross that threshold first.

regulation of membrane potential GO:0042391 ⚠ ABNORMAL

Downstream

Respiratory Chain Deficiency and Loss of Mitochondrial Membrane Potential

Show evidence (2 references)

PMID:10477264 SUPPORT In Vitro

"Within the range of 87-73% mutated mtDNA, COX activity was decreased to 5-35% and DeltaPsi was decreased to 6-78%."

Quantifies how steeply both readouts change across a narrow heteroplasmy band, which is the experimental content of a threshold.

PMID:10477264 SUPPORT In Vitro

"indicate that the biochemical manifestation of the MERRF mutation exerts a very steep threshold of DeltaPsi inhibition"

States the threshold conclusion explicitly rather than leaving it as an inference from the numbers.

Defective Mitochondrial Protein Synthesis

Thirteen respiratory chain subunits are encoded by the mitochondrial genome and must be built inside the organelle, using its own transfer RNAs. With lysine decoding crippled, synthesis of those subunits stalls, and every complex that depends on a mitochondrially encoded subunit is left incompletely assembled. Nuclear-encoded subunits are unaffected, which is why the biochemical signature is a mixed and partial deficiency rather than the clean absence of one enzyme.

mitochondrial translation GO:0032543 ↓ DECREASED

Downstream

Respiratory Chain Deficiency and Loss of Mitochondrial Membrane Potential

Show evidence (2 references)

PMID:35922766 SUPPORT In Vitro

"Defective tRNALys severely impairs mitochondrial protein synthesis and respiratory chain when a high percentage of mutant heteroplasmy crosses the threshold for full-blown clinical phenotype."

Links the translation defect to the respiratory chain defect and to the heteroplasmy threshold in a single statement, which is exactly the junction this node sits at.

PMID:15317755 SUPPORT In Vitro

"import of tRNALys is accompanied by a partial rescue of mitochondrial functions affected by the mutation such as mitochondrial translation, activity of respiratory complexes, electrochemical potential across the mitochondrial membrane and respiration rate"

A rescue experiment supplying working transfer RNA lysine restores translation and everything downstream, which is causal evidence that the transfer RNA defect is the operative lesion rather than a correlate.

Respiratory Chain Deficiency and Loss of Mitochondrial Membrane Potential

Incomplete respiratory complexes cannot move electrons efficiently, so the proton gradient across the inner mitochondrial membrane collapses and adenosine triphosphate synthesis falls. Cytochrome c oxidase, the terminal enzyme, is the most conspicuously affected in patient cells and the one exploited diagnostically. A leaking, poorly coupled electron transport chain also spills more reactive oxygen species, adding oxidative damage to simple energy shortfall.

mitochondrial ATP synthesis coupled electron transport GO:0042775 ↓ DECREASED reactive oxygen species metabolic process GO:0072593 ↑ INCREASED

cytochrome-c oxidase activity GO:0004129 ↓ DECREASED

Downstream

Compensatory Mitochondrial Proliferation in Skeletal Muscle

Neuronal Energy Failure and Oxidative Stress

Show evidence (2 references)

PMID:10477264 SUPPORT In Vitro

"The activity of cytochrome c oxidase (COX) in patient fibroblasts with 89% mutated mtDNA was decreased to 20% of the control levels."

Quantifies the terminal enzyme deficit in patient-derived cells, which is the biochemical core of this node.

PMID:2112427 SUPPORT Human Clinical

"This mutation provides molecular confirmation that some forms of epilepsy are the result of deficiencies in mitochondrial energy production."

States the causal claim this entry is built around, that the epilepsy of MERRF is downstream of an energy production defect.

Compensatory Mitochondrial Proliferation in Skeletal Muscle

Muscle fibers respond to the energy shortfall by making more mitochondria, which accumulate under the sarcolemma and between myofibrils. Because the added organelles carry the same defect, the compensation is futile, and its only reliable product is a histological sign: the ragged red fiber seen on Gomori trichrome, typically accompanied by fibers that fail to stain for cytochrome c oxidase while staining strongly for succinate dehydrogenase. Notably the intramuscular blood vessels show the same pattern.

skeletal muscle fiber CL:0008002

Downstream

Skeletal Muscle Respiratory Failure

Show evidence (1 reference)

PMID:25337734 SUPPORT Other

"Morphological changes seen upon muscle biopsy in MERRF include a substantive proportion of RRF, muscle fibers showing a deficient activity of cytochrome c oxidase (COX)"

Ties the histological hallmark to the enzyme deficiency, which is what makes the ragged red fiber a readout of this node rather than an unrelated finding.

Neuronal Energy Failure and Oxidative Stress

Neurons are unusually vulnerable to a bioenergetic deficit because maintaining ionic gradients across a large membrane surface consumes most of their adenosine triphosphate budget, and because they cannot dilute a mutant load by dividing. As supply falls below demand, ion pumping falters, resting membrane potential drifts, calcium handling degrades, and cells that cross the failure point die. The result is two distinct downstream problems: surviving neurons that are too excitable, and populations of neurons that are simply lost.

neuron CL:0000540

apoptotic process GO:0006915 ↑ INCREASED

Downstream

Cortical Neuronal Hyperexcitability

Degeneration of Dentate Nucleus and Cerebellar Circuitry

Progressive Multisystem Involvement

Show evidence (2 references)

PMID:2112427 SUPPORT Human Clinical

"This mutation provides molecular confirmation that some forms of epilepsy are the result of deficiencies in mitochondrial energy production."

Supports the causal link from energy failure to epilepsy. Marked PARTIAL because it asserts the link at the level of the syndrome and does not itself demonstrate the neuronal mechanisms named in this node.

PMID:35203288 SUPPORT Other

"Mutations striking either genome can lead to mitochondrial impairment, determining infantile, childhood or adult neurodegeneration."

Supports the general principle that mitochondrial impairment produces neurodegeneration. Marked PARTIAL because it is a review statement about the class of disease rather than a MERRF-specific measurement.

Cortical Neuronal Hyperexcitability

Energy-starved cortical neurons cannot sustain the ion gradients that normally hold them below firing threshold, and inhibitory interneurons, which fire fast and are metabolically expensive, are thought to fail disproportionately. The network consequence is hypersynchronous discharge. In MERRF this expresses itself both as cortical myoclonus with a matching electroencephalographic correlate and as generalized seizures. Importantly not all the myoclonus in these patients is cortical; a substantial minority is generated below the cortex, which is modeled on the cerebellar and brainstem branch instead.

pyramidal neuron CL:0000598

regulation of membrane potential GO:0042391 ⚠ ABNORMAL

Downstream

Progressive Myoclonic Epilepsy

Show evidence (2 references)

PMID:39429077 SUPPORT Human Clinical

"Electroencephalogram monitoring in the 15 MERRF children revealed myoclonic seizures in 10 children, with 6 classified as myoclonic epilepsy, and 4 as subcortical myoclonus."

Provides the electrographic split between cortical myoclonic epilepsy and subcortical myoclonus that this node and its cerebellar sibling are modeled on, and supports the cortical arm specifically.

PMID:37605213 SUPPORT In Vitro

"MERRF neural cells harboring the m.8344A > G mutation exhibited impaired mitochondrial bioenergetic function, elevated ROS levels and imbalanced expression of antioxidant enzymes."

Supplies the human-cell bridge from bioenergetic failure to cortical neuronal dysfunction that this node otherwise rests on electrographic phenomenology alone to assert.

Degeneration of Dentate Nucleus and Cerebellar Circuitry

Autopsy studies show that the neuronal loss in MERRF is not diffuse but falls on a reproducible set of structures, with the dentate nucleus, red nucleus, globus pallidus, subthalamic nucleus, and pontine tegmentum degenerating alongside the cerebellar cortex and inferior olive. This is the classic dentatorubral and pallidoluysian distribution, and its selectivity is the central unexplained feature of the disease, since the causal variant is present throughout the body. Loss of dentate output disrupts the cerebello-thalamo-cortical loop, producing ataxia and contributing a subcortical component to the myoclonus.

Purkinje cell CL:0000121

cerebellum UBERON:0002037

Downstream

Progressive Cerebellar Ataxia

Progressive Myoclonic Epilepsy

Show evidence (2 references)

PMID:3128314 SUPPORT Human Clinical

"degeneration of dentate nucleus, red nucleus, globus pallidus, subthalamic nucleus and pontine tegmentum"

Postmortem documentation of the selective regional degeneration this node asserts, in the index Fukuhara case.

PMID:3128314 SUPPORT Human Clinical

"degeneration of substantia nigra, locus ceruleus, cerebellar cortex and inferior olivary nucleus"

Documents cerebellar cortical and olivary involvement specifically, which is what licenses conformance to the cerebellar module node.

Skeletal Muscle Respiratory Failure

Muscle with a high mutant load cannot raise oxidative phosphorylation to meet the demand of contraction, so patients fatigue early, tolerate exercise poorly, and become weak. Because the shortfall is worst under load, the complaint is characteristically exertional before it is fixed. Membrane leak from damaged fibers releases creatine kinase into the circulation.

skeletal muscle fiber CL:0008002

Downstream

Progressive Multisystem Involvement

Show evidence (1 reference)

PMID:32577866 SUPPORT Human Clinical

"The most frequent symptoms were muscle weakness (76.9%), exercise intolerance (76.9%), elevated creatine kinase levels (61.5%), peripheral neuropathy (69.2%) and cerebellar ataxia (61.5%)"

Quantifies the muscle phenotype in a transfer RNA lysine carrier cohort, establishing that exertional failure and creatine kinase leak dominate.

Progressive Myoclonic Epilepsy

The clinical endpoint on the epilepsy branch. Myoclonus is usually the first symptom and is characteristically action-sensitive, worsening with fine motor tasks and stress, and it progresses. Generalized seizures follow. Because both a cortical and a subcortical generator contribute, and because the underlying lesion is degenerative, the syndrome behaves as a progressive myoclonic epilepsy rather than a stable seizure disorder.

Show evidence (2 references)

PMID:39429077 SUPPORT Human Clinical

"Myoclonus was predominantly focal, worsening with fine motor tasks or stress."

Documents the action-sensitive character of the myoclonus asserted here.

PMID:20301693 SUPPORT Other

"MERRF (myoclonic epilepsy with ragged red fibers) is a multisystem disorder characterized by myoclonus (often the first symptom) followed by generalized epilepsy, ataxia, weakness, exercise intolerance, and dementia."

Establishes the sequence in which the syndrome unfolds, with myoclonus preceding generalized epilepsy.

Progressive Cerebellar Ataxia

The clinical endpoint on the cerebellar branch: gait and limb ataxia, dysarthria, and incoordination that worsen as dentate and cortical cerebellar neurons are lost. Ataxia is one of the four canonical diagnostic features of the syndrome and is common in transfer RNA lysine carriers even when the full MERRF picture is absent.

Show evidence (1 reference)

PMID:25337734 SUPPORT Other

"Diagnostic criteria for MERRF include typical manifestations of the disease: myoclonus, generalized epilepsy, cerebellar ataxia and ragged red fibers (RRF) on muscle biopsy."

Establishes cerebellar ataxia as one of the four defining features, so this endpoint is part of the syndrome definition and not an incidental association.

Progressive Multisystem Involvement

Beyond the defining tetrad, the energy deficit surfaces in any tissue whose mutant load crosses threshold, which is why MERRF is a multisystem rather than a purely neurological disease. Recognized involvement includes sensorineural hearing loss, ptosis and optic atrophy, peripheral neuropathy, cardiomyopathy and conduction disease including Wolff-Parkinson-White, diabetes mellitus, short stature, and symmetrical lipomatosis. Which of these appear in a given patient is not predictable from the variant.

Show evidence (2 references)

PMID:20301693 SUPPORT Other

"Common findings are ptosis, hearing loss, short stature, optic atrophy, cardiomyopathy, cardiac dysrhythmias such as Wolff-Parkinson-White syndrome, and peripheral neuropathy."

Enumerates the multisystem features asserted by this node.

PMID:20301693 SUPPORT Other

"Pigmentary retinopathy, optic neuropathy, diabetes mellitus, and lipomatosis have been observed."

Adds the endocrine, retinal, and adipose features, including the lipomatosis that is a recognized marker of this variant.

✶

Histopathology

1

Ragged red fibers with cytochrome c oxidase deficient fibers

Muscle biopsy shows a substantial proportion of ragged red fibers on Gomori trichrome, together with fibers lacking cytochrome c oxidase activity and strong succinate dehydrogenase reactivity, including in intramuscular blood vessels. The combination is the histological signature of a mitochondrially encoded translation defect, since succinate dehydrogenase is entirely nuclear-encoded and therefore spared.

Show evidence (1 reference)

PMID:25337734 SUPPORT Other

"the presence of vessels with a strong reaction for succinate dehydrogenase and COX deficiency"

Documents the vascular component of the histological pattern, which is part of what makes the biopsy appearance characteristic.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

23

Cardiovascular 2

Cardiomyopathy HP:0001638

Show evidence (1 reference)

PMID:20301693 SUPPORT Other

"Common findings are ptosis, hearing loss, short stature, optic atrophy, cardiomyopathy, cardiac dysrhythmias such as Wolff-Parkinson-White syndrome, and peripheral neuropathy."

Lists cardiomyopathy among the common findings.

Wolff-Parkinson-White syndrome HP:0001716

Show evidence (1 reference)

PMID:20301693 SUPPORT Other

"cardiac dysrhythmias such as Wolff-Parkinson-White syndrome"

Names the specific conduction abnormality associated with the syndrome.

Digestive 1

Dysphagia FREQUENT HP:0002015

Show evidence (1 reference)

PMID:26995359 SUPPORT Human Clinical

"Other common features in our cohort were migraine (52 %), psychiatric disorders (54 %), respiratory dysfunction (45 %), gastrointestinal symptoms (38 %), dysarthria (36 %), and dysphagia (35 %)."

Dysphagia in 35 percent of genotype-ascertained carriers, at the lower edge of the FREQUENT band.

Ear 1

Sensorineural hearing impairment FREQUENT HP:0000407

Show evidence (2 references)

PMID:26995359 SUPPORT Human Clinical

"In contrast, other features such as hearing impairment were even more frequently present (72 %)."

Hearing impairment in 72 percent of genotype-ascertained carriers, within the FREQUENT band, and notably commoner than any member of the defining tetrad in the same cohort.

PMID:20301693 SUPPORT Other

"Common findings are ptosis, hearing loss, short stature, optic atrophy, cardiomyopathy, cardiac dysrhythmias such as Wolff-Parkinson-White syndrome, and peripheral neuropathy."

Lists hearing loss among the common findings of the syndrome.

Endocrine 1

Diabetes mellitus HP:0000819

Show evidence (1 reference)

PMID:20301693 SUPPORT Other

"Pigmentary retinopathy, optic neuropathy, diabetes mellitus, and lipomatosis have been observed."

Lists diabetes mellitus among the observed features.

Eye 3

Ptosis HP:0000508

Show evidence (1 reference)

PMID:20301693 SUPPORT Other

"Common findings are ptosis, hearing loss, short stature, optic atrophy, cardiomyopathy, cardiac dysrhythmias such as Wolff-Parkinson-White syndrome, and peripheral neuropathy."

Lists ptosis among the common findings.

Optic atrophy HP:0000648

Show evidence (1 reference)

PMID:20301693 SUPPORT Other

"Common findings are ptosis, hearing loss, short stature, optic atrophy, cardiomyopathy, cardiac dysrhythmias such as Wolff-Parkinson-White syndrome, and peripheral neuropathy."

Lists optic atrophy among the common findings.

Pigmentary retinopathy HP:0000580

Show evidence (1 reference)

PMID:20301693 SUPPORT Other

"Pigmentary retinopathy, optic neuropathy, diabetes mellitus, and lipomatosis have been observed."

Lists pigmentary retinopathy among the observed features of the syndrome.

Metabolism 1

Elevated creatine kinase FREQUENT Elevated circulating creatine kinase concentration HP:0003236

Show evidence (1 reference)

PMID:32577866 SUPPORT Human Clinical

"elevated creatine kinase levels (61.5%)"

Reports 61.5 percent in symptomatic carriers, within the FREQUENT band.

Musculoskeletal 2

Muscle weakness FREQUENT HP:0001324

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:32577866 SUPPORT Human Clinical

"The most frequent symptoms were muscle weakness (76.9%), exercise intolerance (76.9%), elevated creatine kinase levels (61.5%), peripheral neuropathy (69.2%) and cerebellar ataxia (61.5%)"

Reports 76.9 percent in symptomatic transfer RNA lysine carriers, within the FREQUENT band.

Multiple symmetrical lipomas Multiple lipomas HP:0001012

Show evidence (2 references)

PMID:20301693 SUPPORT Other

"Pigmentary retinopathy, optic neuropathy, diabetes mellitus, and lipomatosis have been observed."

Lists lipomatosis among the observed features of the syndrome.

PMID:38871514 SUPPORT Other

"Syndromic lipomatoses include PIK3CA-related disorders, Cowden/PTEN hamartomas-tumor syndrome, some lipodystrophy syndromes, and mitochondrial diseases, especially MERRF"

Independent corroboration from the lipomatosis literature that MERRF is the mitochondrial disease most associated with this finding. Marked PARTIAL because it is a review classification rather than a MERRF cohort measurement.

Nervous System 6

Myoclonus FREQUENT HP:0001336

Course: PROGRESSIVE

Show evidence (2 references)

PMID:39429077 SUPPORT Human Clinical

"Myoclonus presented and worsened progressively in all 15 MERRF children, with 10 as the initial symptom"

Documents the progressive character and the frequency with which myoclonus opens the illness. This cohort is not used for the frequency band, because within a MERRF-defined group myoclonus is definitional and its rate is circular.

PMID:26995359 SUPPORT Human Clinical

"In our cohort, the canonical features seizures, myoclonus, cerebellar ataxia and ragged-red fibres that are traditionally associated with MERRF, occurred in only 61, 59, 70, and 63 % of the patients, respectively."

Supplies the FREQUENT band non-circularly. The denominator here is carriers of m.8344A>G ascertained by genotype rather than by the MERRF clinical definition, so the 59 percent figure for myoclonus measures the phenotype instead of restating the case definition.

Cerebellar ataxia FREQUENT Progressive cerebellar ataxia HP:0002073

Course: PROGRESSIVE

Show evidence (2 references)

PMID:39429077 SUPPORT Human Clinical

"Twelve children had cerebellar ataxia, 10 children exhibited exercise intolerance, and 8 children had muscle weakness."

Twelve of the 22 children in this MT-TK cohort had cerebellar ataxia, which is 55 percent and falls in the FREQUENT band. The denominator is all MT-TK carriers rather than only those meeting MERRF criteria, so the estimate is not inflated by the diagnostic definition.

PMID:32577866 SUPPORT Human Clinical

"The most frequent symptoms were muscle weakness (76.9%), exercise intolerance (76.9%), elevated creatine kinase levels (61.5%), peripheral neuropathy (69.2%) and cerebellar ataxia (61.5%)"

An independent adult transfer RNA lysine cohort gives 61.5 percent, corroborating the FREQUENT band from a different population.

Peripheral neuropathy FREQUENT HP:0009830

Show evidence (1 reference)

PMID:32577866 SUPPORT Human Clinical

"The most frequent symptoms were muscle weakness (76.9%), exercise intolerance (76.9%), elevated creatine kinase levels (61.5%), peripheral neuropathy (69.2%) and cerebellar ataxia (61.5%)"

Reports 69.2 percent in symptomatic carriers, within the FREQUENT band.

Migraine FREQUENT HP:0002076

Show evidence (1 reference)

PMID:26995359 SUPPORT Human Clinical

"Other common features in our cohort were migraine (52 %), psychiatric disorders (54 %), respiratory dysfunction (45 %), gastrointestinal symptoms (38 %), dysarthria (36 %), and dysphagia (35 %)."

Migraine in 52 percent of genotype-ascertained carriers, within the FREQUENT band.

Cerebellar atrophy on imaging FREQUENT HP:0001272

Show evidence (2 references)

PMID:26995359 SUPPORT Human Clinical

"Brain MRI revealed cerebral and/or cerebellar atrophy in 43 % of our patients."

Atrophy in 43 percent of genotype-ascertained carriers, within the FREQUENT band.

PMID:17989367 SUPPORT Human Clinical

"Conventional brain MR imaging showed atrophy of the superior cerebellar peduncles and the cerebellum in all patients and brain stem atrophy in 2 patients."

Localizes the atrophy to the superior cerebellar peduncle and cerebellum, which is the more diagnostically useful description.

Dementia HP:0000726

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:20301693 SUPPORT Other

"MERRF (myoclonic epilepsy with ragged red fibers) is a multisystem disorder characterized by myoclonus (often the first symptom) followed by generalized epilepsy, ataxia, weakness, exercise intolerance, and dementia."

Names dementia as part of the characteristic syndrome.

Respiratory 1

Respiratory insufficiency FREQUENT HP:0002093

Show evidence (1 reference)

PMID:26995359 SUPPORT Human Clinical

"Other common features in our cohort were migraine (52 %), psychiatric disorders (54 %), respiratory dysfunction (45 %), gastrointestinal symptoms (38 %), dysarthria (36 %), and dysphagia (35 %)."

Respiratory dysfunction in 45 percent of genotype-ascertained carriers, within the FREQUENT band.

Constitutional 1

Exercise intolerance FREQUENT HP:0003546

Show evidence (1 reference)

PMID:32577866 SUPPORT Human Clinical

"The most frequent symptoms were muscle weakness (76.9%), exercise intolerance (76.9%), elevated creatine kinase levels (61.5%), peripheral neuropathy (69.2%) and cerebellar ataxia (61.5%)"

Reports 76.9 percent in symptomatic transfer RNA lysine carriers, within the FREQUENT band of 30 to 79 percent.

Growth 1

Short stature HP:0004322

Show evidence (1 reference)

PMID:20301693 SUPPORT Other

"Common findings are ptosis, hearing loss, short stature, optic atrophy, cardiomyopathy, cardiac dysrhythmias such as Wolff-Parkinson-White syndrome, and peripheral neuropathy."

Lists short stature among the common findings.

Other 3

Action myoclonus HP:0034360

Show evidence (1 reference)

PMID:39429077 SUPPORT Human Clinical

"Myoclonus was predominantly focal, worsening with fine motor tasks or stress."

Documents the action and stress sensitivity that distinguishes this phenotype from myoclonus in general.

Generalized epilepsy FREQUENT Generalized-onset seizure HP:0002197

Show evidence (3 references)

PMID:26995359 SUPPORT Human Clinical

"In our cohort, the canonical features seizures, myoclonus, cerebellar ataxia and ragged-red fibres that are traditionally associated with MERRF, occurred in only 61, 59, 70, and 63 % of the patients, respectively."

Seizures in 61 percent of genotype-ascertained carriers, within the FREQUENT band. Genotype ascertainment keeps the estimate non-circular.

PMID:25337734 SUPPORT Other

"Diagnostic criteria for MERRF include typical manifestations of the disease: myoclonus, generalized epilepsy, cerebellar ataxia and ragged red fibers (RRF) on muscle biopsy."

Establishes generalized epilepsy as a defining feature of the syndrome.

PMID:39429077 SUPPORT Human Clinical

"Two children had generalized myoclonic seizures, and 1 each had absence seizures and generalized seizures."

Documents the range of generalized seizure types seen in a MT-TK cohort.

Ragged-red muscle fibers FREQUENT HP:0003200

Show evidence (2 references)

PMID:26995359 SUPPORT Human Clinical

"In our cohort, the canonical features seizures, myoclonus, cerebellar ataxia and ragged-red fibres that are traditionally associated with MERRF, occurred in only 61, 59, 70, and 63 % of the patients, respectively."

Ragged-red fibres in 63 percent of genotype-ascertained carriers, within the FREQUENT band. One caveat specific to this feature: the denominator is limited to carriers who underwent muscle biopsy, and biopsy is more likely to be done when a mitochondrial myopathy is already suspected, so this band carries an ascertainment pressure the clinical features do not.

PMID:25337734 SUPPORT Other

"Morphological changes seen upon muscle biopsy in MERRF include a substantive proportion of RRF, muscle fibers showing a deficient activity of cytochrome c oxidase (COX)"

Describes the histological finding and its enzymatic correlate.

🧬

Genetic Associations

2

MT-TK m.8344A>G (The m.8344A>G variant in MT-TK, encoding mitochondrial transfer RNA-lysine, accounts for more than eight in ten typical MERRF cases. It is heteroplasmic and maternally transmitted, and the clinical expression depends on the mutant load in the affected tissue rather than on the variant itself.)

Gene: MT-TK hgnc:7489 relationship_type: CAUSATIVE

Show evidence (2 references)

PMID:20301693 SUPPORT Other

"The m.8344A>G pathogenic variant in the mitochondrial gene MT-TK is present in more than 80% of affected individuals with typical findings."

Quantifies the share of MERRF attributable to this variant.

PMID:25337734 SUPPORT Other

"It is estimated that point mutations in the tRNALys gene of the DNAmt, mainly A8344G, are responsible for almost 90% of MERRF cases."

An independent estimate of the same fraction, from a clinical review.

MT-TF and other mitochondrial transfer RNA genes (A minority of MERRF cases arise from variants in other mitochondrial transfer RNA genes, including MT-TF, MT-TH, MT-TI, MT-TL1, MT-TP, MT-TS1, and MT-TS2. That several different transfer RNAs can produce the same syndrome argues that the operative lesion is generic failure of mitochondrial translation rather than anything specific to lysine decoding. MT-TF is named here as the representative of that group because a MT-TF case supplies the treatment evidence used in this entry.)

Gene: MT-TF hgnc:7481 relationship_type: CAUSATIVE

Show evidence (2 references)

PMID:20301693 SUPPORT Other

"Pathogenic variants in MT-TF, MT-TH, MT-TI, MT-TL1, MT-TP, MT-TS1, and MT-TS2 have also been described in a subset of individuals with MERRF."

Enumerates the alternative causal genes, establishing genetic heterogeneity within the syndrome.

PMID:16414077 SUPPORT Human Clinical

"a patient with typical clinical, histological, and biochemical features of MERRF due to a mutation on the tRNA of Phenilalanine gene"

A worked case of typical MERRF caused by the phenylalanine transfer RNA gene rather than the lysine one, demonstrating the heterogeneity concretely.

💊

Medical Actions

11

Levetiracetam for myoclonus

Action: Pharmacotherapy NCIT:C15986

Agent: levetiracetam CHEBI:6437

Levetiracetam suppresses myoclonus in mitochondrial progressive myoclonic epilepsy and, unlike valproate, does not interfere with mitochondrial respiration. This combination of efficacy and metabolic neutrality is why it is favoured as a first choice for the myoclonus of MERRF.

Mechanism Target:

INHIBITS Cortical Neuronal Hyperexcitability

Show evidence (3 references)

PMID:16414077 SUPPORT Human Clinical

"The average myoclonus score improved dramatically, as well as the quality of life and no side effects were observed, even after having withdrawn VPA."

Documents the antimyoclonic effect in a MERRF patient, including maintenance of benefit after valproate withdrawal.

PMID:16414077 SUPPORT Human Clinical

"LEV may benefit myoclonus in PME of mitochondrial origin without altering mitochondrial function, and it could be considered the drug of first choice for the treatment of myoclonus in MERRF."

States the mechanistic rationale for preferring levetiracetam, namely that it spares mitochondrial function.

PMID:20301693 SUPPORT Other

"levetiracetam or clonazepam for myoclonus"

Confirms the recommendation in the management guidance for the syndrome.

Clonazepam for myoclonus

Action: Pharmacotherapy NCIT:C15986

Agent: clonazepam CHEBI:3756

A benzodiazepine used as an alternative or adjunct for myoclonus, acting by enhancing GABA-A receptor mediated inhibition and so raising the threshold for hypersynchronous discharge.

Mechanism Target:

INHIBITS Cortical Neuronal Hyperexcitability

Show evidence (1 reference)

PMID:20301693 SUPPORT Other

"levetiracetam or clonazepam for myoclonus"

Names clonazepam as an accepted option for the myoclonus of MERRF.

Avoidance of valproic acid

Action: Supportive Care NCIT:C15747

Valproate is the conventional first choice for progressive myoclonic epilepsy but is specifically to be avoided here, because it interferes with mitochondrial respiration and beta-oxidation and can precipitate hepatic failure in mitochondrial disease. This is a treatment decision that follows directly from the mechanism, which is why it is curated as a treatment rather than a footnote.

Show evidence (2 references)

PMID:20301693 SUPPORT Other

"valproic acid should be avoided in the treatment of seizures"

States the contraindication directly in the management guidance.

PMID:16414077 SUPPORT Human Clinical

"VPA should be used with caution in PME due to mitochondrial dysfunction, i.e. in MERRF (myoclonic epilepsy with ragged red fibers) syndrome, because of its interaction with mitochondrial respiration and metabolism."

Gives the mechanistic reason for the contraindication, tying it to mitochondrial respiration rather than to a generic drug interaction.

Avoidance of aminoglycosides, linezolid, tobacco, and alcohol

Action: Supportive Care NCIT:C15747

A second and mechanistically distinct avoidance rule. Aminoglycoside antibiotics and linezolid both act on the bacterial ribosome, and because the mitochondrial ribosome is an evolutionary descendant of the bacterial one they inhibit it too. In a patient whose mitochondrial translation is already failing that is a second hit on the very step this disease is defined by. Tobacco and alcohol are avoided as general mitochondrial toxins. This is curated separately from the valproate rule because the mechanism differs and because the clinical situations in which each gets violated differ.

Show evidence (1 reference)

PMID:20301693 SUPPORT Other

"Agents/circumstances to avoid: Mitochondrial toxins (e.g., aminoglycoside antibiotics, linezolid, cigarettes, alcohol)"

Names the specific agents to avoid, separately from the valproate recommendation.

Mitochondrial cofactor and supplement therapy

Action: Nutritional Support NCIT:C15433

Agent: coenzyme Q10 CHEBI:46245 L-carnitine CHEBI:16347

Coenzyme Q10, L-carnitine, alpha lipoic acid, vitamin E, B vitamins, and creatine are widely used on the reasoning that they support electron transport, restore carnitine pools, and buffer oxidative damage. The honest assessment in the literature is that benefit is modest and inconsistent, and no controlled trial has established disease modification.

Mechanism Target:

MODULATES Respiratory Chain Deficiency and Loss of Mitochondrial Membrane Potential

Show evidence (2 references)

PMID:20301693 SUPPORT Other

"Coenzyme Q10 (50-200 mg 2-3x/day), L-carnitine (1000 mg 2-3x/day), alpha lipoic acid, vitamin E, vitamin B supplements, and creatine, often used to improve mitochondrial function, have been of modest benefit in some individuals."

Documents both the practice and its limited effect. Marked PARTIAL because the source describes modest benefit in some individuals rather than demonstrating efficacy.

PMID:35922766 SUPPORT In Vitro

"Therapy is currently limited to symptomatic management of myoclonic epilepsy, and supportive measures to counteract muscle weakness with co-factors/supplements."

Independently confirms that cofactor supplementation is supportive rather than disease-modifying, which is the framing used here.

Scheduled multisystem surveillance

Action: scheduled multisystem surveillance Ontology label: Supportive Care NCIT:C15747

Because the syndrome accrues organ involvement unpredictably, surveillance is scheduled rather than symptom-driven, and it is organ-specific: neurological, ophthalmological, cardiac including electrocardiogram and echocardiogram, and endocrine review annually, with audiology every two to three years. The cardiac component matters most, because conduction disease can be silent right up until it is not.

Show evidence (1 reference)

PMID:20301693 SUPPORT Other

"Surveillance: Routine evaluations every six to 12 months initially; annual neurologic, ophthalmologic, cardiology (electrocardiogram and echocardiogram), and endocrinologic evaluations (fasting blood sugar and TSH); audiology evaluations every two to three years."

States the full surveillance schedule that this record encodes.

Hearing aids or cochlear implantation

Action: hearing aid or cochlear implantation Ontology label: Therapeutic Procedure NCIT:C49236

Sensorineural hearing loss is managed with amplification or, when the loss is severe, cochlear implantation. Worth curating because hearing loss is one of the commonest extra-neurological features and, unlike most of this syndrome, it is remediable.

Show evidence (1 reference)

PMID:20301693 SUPPORT Other

"hearing aids or cochlear implants for hearing loss"

States the recommended management for the hearing loss of this syndrome.

Standard pharmacotherapy for cardiac involvement

Action: Pharmacotherapy NCIT:C15986

Cardiomyopathy and conduction disease are managed with conventional cardiac drugs rather than anything mitochondria-specific. The important point is not the drug choice but that cardiac involvement is actively looked for, since it contributes disproportionately to mortality.

Show evidence (1 reference)

PMID:20301693 SUPPORT Other

"standard pharmacologic therapy for cardiac symptoms"

States the recommended approach to the cardiac manifestations.

Pregnancy monitoring for diabetes and respiratory insufficiency

Action: pregnancy monitoring Ontology label: Supportive Care NCIT:C15747

Pregnancy raises both metabolic and respiratory demand, which is precisely the axis a mitochondrial disease cannot flex. Affected and at-risk women are therefore monitored for diabetes mellitus and respiratory insufficiency through pregnancy, either of which may need intervention.

Show evidence (1 reference)

PMID:20301693 SUPPORT Other

"During pregnancy, affected or at-risk women should be monitored for diabetes mellitus and respiratory insufficiency, which may require therapeutic interventions."

States the pregnancy-specific monitoring recommendation.

Genetic counselling for maternal transmission

Action: Genetic Counseling NCIT:C15240

Counselling addresses the asymmetry of mitochondrial inheritance: an affected man transmits nothing, a carrier woman transmits to every child, and the mutant load a child receives cannot be predicted. Prenatal and preimplantation testing are technically available but cannot forecast phenotype, which is itself the counselling message.

Show evidence (1 reference)

PMID:20301693 SUPPORT Other

"because the mutational load in tissues sampled prenatally may shift in utero or after birth as a result of random mitotic segregation, prediction of the phenotype from prenatal studies is not possible."

States the central limitation that the counselling has to convey.

Physical therapy and aerobic exercise

Action: Physical Therapy NCIT:C15302

Structured exercise and physiotherapy are used to maintain function. The rationale is that aerobic training stimulates mitochondrial biogenesis in muscle, though in a tissue where the added mitochondria carry the same defect the ceiling on that benefit is real.

Show evidence (1 reference)

PMID:20301693 SUPPORT Other

"physical therapy to improve any impaired motor function; aerobic exercise"

Names physiotherapy and aerobic exercise in the management guidance.

🔬

Biochemical Markers

1

Blood and cerebrospinal fluid lactate (INCREASED)

Context: Raised lactate reflects the shift to anaerobic metabolism when the respiratory chain cannot accept electrons. It is elevated at rest and rises further with exertion, but it is neither sensitive nor specific, and it is also raised in asymptomatic maternal relatives, so a value cannot be used to decide who is affected.

Pathograph Readouts

Readout Of Respiratory Chain Deficiency and Loss of Mitochondrial Membrane Potential Positive Diagnostic

Elevated lactate is the circulating readout of a blocked respiratory chain forcing pyruvate toward lactate.

Show evidence (1 reference)

PMID:25337734 SUPPORT Other

"The lactic acid level in the blood and cerebrospinal fluid (CSF) is elevated at rest in patients with MERFF and can increase moderately after physical activity"

States directly that lactate is elevated at rest in both compartments and rises further with exertion. The source's own spelling of the acronym is preserved so the quote remains exact.

🔬

Diagnosis

6

Clinical recognition of the four canonic features

Before any test, the syndrome is recognized clinically by the co-occurrence of myoclonus, generalized epilepsy, ataxia, and ragged red fibers. That tetrad remains the clinical case definition and is what should prompt molecular testing, since no one of the four is individually specific.

clinical diagnostic criteria for MERRF

Results: A proband with myoclonus, generalized epilepsy, ataxia, and ragged red fibers meets the clinical case definition and should proceed to molecular testing.

Show evidence (1 reference)

PMID:20301693 SUPPORT Other

"A clinical diagnosis of MERRF can be established in a proband with the following four "canonic" features: myoclonus, generalized epilepsy, ataxia, and ragged red fibers (RRF) in the muscle biopsy."

States the clinical case definition verbatim.

Targeted mitochondrial DNA testing for m.8344A>G

Molecular testing is the definitive step. Because heteroplasmy varies between tissues and blood can be falsely reassuring, testing muscle or urinary sediment is preferred when blood is negative but suspicion is high. The original variant conveniently creates a restriction site, which is why a simple molecular test existed from the outset.

Genetic Testing NCIT:C15709

Results: Detection of m.8344A>G in MT-TK, with a quantified heteroplasmy level in the tissue tested.

Show evidence (1 reference)

PMID:2112427 SUPPORT Human Clinical

"The mutation alters the T psi C loop of the tRNA(Lys) gene and creates a CviJI restriction site, providing a simple molecular diagnostic test for the disease."

Establishes the molecular diagnostic basis for the syndrome.

Muscle biopsy with histochemistry

Biopsy demonstrates ragged red fibers with cytochrome c oxidase negative fibers and strongly succinate dehydrogenase positive vessels. It remains useful when genetic testing on blood is negative, when the variant is in an unexpected transfer RNA gene, or when the mutant load is confined to muscle.

Muscle Biopsy NCIT:C51895

Results: Ragged red fibers on Gomori trichrome, cytochrome c oxidase deficient fibers, and strong succinate dehydrogenase reactivity including in intramuscular vessels.

Show evidence (1 reference)

PMID:25337734 SUPPORT Other

"Diagnostic criteria for MERRF include typical manifestations of the disease: myoclonus, generalized epilepsy, cerebellar ataxia and ragged red fibers (RRF) on muscle biopsy."

Establishes muscle biopsy as one of the four defining diagnostic elements of the syndrome.

Electroencephalography with myoclonus correlation

Electroencephalography distinguishes cortical myoclonic seizures from myoclonus generated below the cortex, which matters because the two respond differently and imply different generators. In a pediatric MT-TK cohort this distinction split the myoclonic patients roughly evenly.

Electroencephalography NCIT:C38054

Results: Generalized epileptiform discharges with a time-locked correlate for cortical myoclonus, or absent cortical correlate where the myoclonus is subcortical.

Show evidence (1 reference)

PMID:39429077 SUPPORT Human Clinical

"Electroencephalogram monitoring in the 15 MERRF children revealed myoclonic seizures in 10 children, with 6 classified as myoclonic epilepsy, and 4 as subcortical myoclonus."

Demonstrates the diagnostic yield of electroencephalography in separating cortical from subcortical myoclonus.

Brain MRI of the cerebellum and brainstem

Imaging supports rather than makes the diagnosis, but the pattern is suggestive: atrophy of the superior cerebellar peduncles and cerebellum, with brainstem atrophy in some. The clinically useful observation is the discrepancy in the other direction from most neurology, with disability markedly worse than the pictures, so mild imaging should not be used to argue against the diagnosis.

Magnetic Resonance Imaging NCIT:C16809

Results: Atrophy of the superior cerebellar peduncles and cerebellum, sometimes with brainstem atrophy; cerebral or cerebellar atrophy is seen in roughly two fifths of carriers.

Show evidence (2 references)

PMID:17989367 SUPPORT Human Clinical

"Conventional brain MR imaging showed atrophy of the superior cerebellar peduncles and the cerebellum in all patients and brain stem atrophy in 2 patients."

States the imaging findings reported in the results field.

PMID:26995359 SUPPORT Human Clinical

"Brain MRI revealed cerebral and/or cerebellar atrophy in 43 % of our patients."

Gives the registry-scale yield of the test, which is what makes it supportive rather than diagnostic.

Blood lactate measurement

A simple screening test that supports but cannot establish the diagnosis. Lactate is elevated at rest and rises further after exertion, but it is also raised in asymptomatic maternal relatives, so it functions as a trigger for further testing rather than a gate.

Lactic Acid Measurement NCIT:C79450

Results: Elevated resting lactate that may rise further after physical activity; normal values do not exclude the diagnosis and raised values do not confirm it.

Show evidence (1 reference)

PMID:25337734 SUPPORT Other

"The lactic acid level in the blood and cerebrospinal fluid (CSF) is elevated at rest in patients with MERFF and can increase moderately after physical activity"

States the expected result of the test directly. The source's own spelling of the acronym is preserved so the quote remains exact.

📈

Progression

2

Onset with myoclonus after normal early development

Age: Childhood to adulthood

Development is typically normal before onset, which can occur any time from childhood to adult life. Myoclonus is usually the first symptom. In a pediatric MT-TK cohort the median age at onset was five years, with a wide spread; adult-onset cohorts report a mean in the mid thirties, so the syndrome does not have a single characteristic onset age.

Show evidence (2 references)

PMID:20301693 SUPPORT Other

"Onset can occur from childhood to adulthood, occurring after normal early development."

States the normal early development and the wide onset window.

PMID:39429077 SUPPORT Human Clinical

"The age of onset was 5.00 (2.75, 9.00) years."

Provides the pediatric onset distribution referenced in this phase.

Progressive myoclonus, epilepsy, ataxia, and multisystem decline

Age: Years to decades after onset

Myoclonus worsens and generalized seizures appear, followed by ataxia, weakness, and cognitive decline, with multisystem features accruing. Progression is the rule; the disease does not stabilize the way many genetic generalized epilepsies do, which is what places it in the progressive myoclonic epilepsy group.

Show evidence (1 reference)

PMID:39429077 SUPPORT Human Clinical

"Myoclonus presented and worsened progressively in all 15 MERRF children, with 10 as the initial symptom"

Documents progression of the cardinal symptom in a defined cohort.

📊

Prevalence

1

Adults in North East England

Point Prevalence 20.0 per 100,000 1–9 per 10,000

This is the prevalence of mitochondrial DNA variants as a class, not of MERRF specifically. MERRF is one of the rarer syndromes within that class, so 20 per 100,000 is an upper bound on it rather than an estimate of it. A variant-specific figure does exist in the secondary literature, roughly 0.28 per 100,000 for m.8344A>G in this same population and zero in a northern Finnish survey, but it is not curated as its own record here for two reasons: it is a variant frequency rather than a syndrome rate, since most carriers do not have MERRF, and the primary source has no abstract text against which a snippet could be verified. The honest position is that no snippet-verifiable syndrome-specific rate is available, not that no estimate exists.

Show evidence (1 reference)

PMID:25652200 SUPPORT Human Clinical

"The minimum prevalence rate for mtDNA mutations was 1 in 5,000 (20 per 100,000), comparable with our previously published prevalence rates."

Gives a population-based rate for mitochondrial DNA disease as a whole. Marked PARTIAL because it bounds rather than measures MERRF, which is why the notes flag this as an upper bound.

🔀

Differential Diagnoses

4

Conditions with similar clinical presentations that must be differentiated from MERRF Syndrome:

MELAS Syndrome MONDO:0010789

Overlapping Features The nearest mechanistic neighbour: another maternally inherited transfer RNA disease with the same wobble modification defect, differing in which transfer RNA is hit and in the resulting clinical emphasis. Overlap cases exist.

Distinguishing Features

Caused by m.3243A>G in MT-TL1 rather than m.8344A>G in MT-TK.
Stroke-like episodes in non-vascular territories are the cardinal feature.
Myoclonus and progressive myoclonic epilepsy are not the defining picture.

Show evidence (1 reference)

PMID:17132941 SUPPORT In Vitro

"The MERRF mt tRNA(Lys) lacking the wobble modification cannot translate either of its codons (AAA and AAG), while the translational activity of MELAS mt tRNA(Leu(UUR)) lacking wobble modification is more depressed in decoding of UUG codon than UUA codon."

Shows that the two syndromes share a mechanism class but differ in the completeness of the decoding failure, which is the molecular basis for treating them as separate entities.

Leigh Syndrome MONDO:0009723

Overlapping Features The same m.8344A>G variant can produce Leigh syndrome instead of MERRF, and overlap presentations occur, so this is not merely a look-alike but a genuine alternative outcome of the identical genotype.

Distinguishing Features

Symmetrical necrotizing lesions of basal ganglia and brainstem on imaging.
Earlier onset with developmental regression rather than myoclonus first.
Ragged red fibers are not the defining muscle finding.

Show evidence (1 reference)

PMID:39429077 SUPPORT Human Clinical

"Fifteen children had myoclonic epilepsy with ragged-red fibers (MERRF), 3 had Leigh syndrome (LS), and 4 had LS-MERRF overlap syndrome (LS-MERRF)."

Demonstrates directly that the same variant produces both syndromes and overlap forms within one cohort.

Lafora Disease MONDO:0009697

Overlapping Features A progressive myoclonic epilepsy that presents with the same triad of myoclonus, seizures, and cognitive decline in adolescence, but from pathological glycogen aggregation rather than energy failure.

Distinguishing Features

Autosomal recessive EPM2A or NHLRC1 variants rather than maternal transmission.
Periodic acid-Schiff positive Lafora bodies on skin or other biopsy.
Prominent occipital seizures and rapid cognitive collapse.
No ragged red fibers and no maternal family history pattern.

Show evidence (1 reference)

PMID:25337734 SUPPORT Other

"MERRF should be considered in the differential diagnosis of all progressive myoclonic epilepsies, including Lafora disease, neurolipofuscinose and Unverricht-Lundborg disease"

Names Lafora disease explicitly as a differential the clinician has to separate MERRF from.

Unverricht-Lundborg Disease MONDO:0009698

Overlapping Features The other classic progressive myoclonic epilepsy of adolescence, with severe stimulus-sensitive myoclonus but comparatively preserved cognition and a much slower course than the other members of the group.

Distinguishing Features

Autosomal recessive CSTB dodecamer repeat expansion.
Relatively preserved cognition over decades.
No myopathy, no ragged red fibers, and no multisystem involvement.

Show evidence (1 reference)

PMID:25337734 SUPPORT Other

"MERRF should be considered in the differential diagnosis of all progressive myoclonic epilepsies, including Lafora disease, neurolipofuscinose and Unverricht-Lundborg disease"

Names Unverricht-Lundborg disease explicitly as a differential the clinician has to separate MERRF from.

{ }

Source YAML

click to show

name: MERRF Syndrome
creation_date: "2026-08-05T00:00:00Z"
category: Mendelian
description: >-
  MERRF (myoclonic epilepsy with ragged red fibers) is a maternally inherited
  multisystem mitochondrial disease whose canonical tetrad is myoclonus,
  generalized epilepsy, cerebellar ataxia, and ragged red fibers on muscle
  biopsy. More than eight in ten typical cases carry the m.8344A>G point variant
  in MT-TK, the mitochondrial gene for transfer RNA-lysine. The variant strips a
  chemical tag from the part of the transfer RNA that reads lysine codons, so
  the mitochondrion can no longer build its own share of the respiratory chain.
  Energy production fails wherever the proportion of mutant mitochondrial
  genomes crosses a steep threshold, which is why the disease is patchy across
  tissues and highly variable between relatives who carry the same variant.
  Muscle answers the deficit by proliferating defective mitochondria, producing
  the ragged red fiber. In brain the deficit falls hardest on the dentate
  nucleus, cerebellar cortex, and brainstem nuclei, giving the progressive
  myoclonic epilepsy and ataxia that dominate the clinical picture.
parents:
  - Epilepsy
  - Neurological Disease
synonyms:
  - MERRF
  - myoclonic epilepsy with ragged red fibers
  - myoclonus epilepsy associated with ragged-red fibers
  - Fukuhara disease
classifications:
  mechanistic_category:
    - classification_value: mitochondrial disease
  harrisons_chapter:
    - classification_value: NEUROLOGIC
      notes: >-
        MERRF presents and is managed as a progressive neurological syndrome,
        with the myopathic, cardiac, and endocrine features accruing around a
        neurological core.
disease_term:
  preferred_term: MERRF syndrome
  term:
    id: MONDO:0010790
    label: MERRF syndrome
mappings:
  mondo_mappings:
    - term:
        id: MONDO:0010790
        label: MERRF syndrome
      mapping_predicate: skos:exactMatch
      mapping_source: MONDO
      mapping_justification: >-
        MONDO:0010790 is the MERRF syndrome concept, the mitochondrial
        encephalomyopathy defined by the myoclonus, generalized epilepsy,
        ataxia, and ragged red fiber tetrad that this entry models.
references:
  - reference: PMID:20301693
    title: MERRF.
    tags:
      - GeneReviews
  - reference: PMID:25337734
    title: >-
      When should MERRF (myoclonus epilepsy associated with ragged-red fibers) be
      the diagnosis?
  - reference: PMID:2112427
    title: >-
      Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a
      mitochondrial DNA tRNA(Lys) mutation.
notes: >-
  Scope note. This entry models MERRF as the classic clinical syndrome, and
  treats m.8344A>G in MT-TK as its usual but not exclusive molecular cause. The
  relationship between that variant and the syndrome is deliberately curated as
  many-to-many rather than one-to-one: the same variant also produces Leigh
  syndrome, overlap phenotypes, and an isolated myopathy-with-neuropathy picture
  with no epilepsy at all, while a minority of MERRF cases arise from other
  mitochondrial transfer RNA genes. That mismatch between genotype and syndrome
  is recorded as an explicit controversy in the discussions block rather than
  smoothed over in the mechanism graph.

  Denominator convention for frequency bands. Every frequency band in this entry
  is drawn on a denominator of m.8344A>G carriers ascertained by genotype, not on
  people who already meet the MERRF clinical definition. That is deliberate and it
  is what makes the bands informative: asking how often myoclonus occurs among
  people diagnosed by a definition that requires myoclonus can only return one
  answer. So the 59 percent band on myoclonus is not a claim that two fifths of
  MERRF patients lack the syndrome's cardinal feature; it is a measurement of how
  often the variant produces that feature. The corollary is worth stating plainly,
  because it is the substance of the nosological controversy recorded below: no
  member of the defining tetrad reaches three quarters of carriers, and hearing
  impairment is commoner than any of them.

  Sourcing note. The entry was drafted from the GeneReviews chapter and the
  primary literature, then cross-checked against a deep-research report generated
  with the claude_code provider, which is committed alongside it as
  research/MERRF_Syndrome-deep-research-claude_code.md. That cross-check earned
  its keep. It supplied the genotype-ascertained mitoNET registry cohort, which
  is what allows this entry to put a non-circular frequency band on myoclonus and
  on the rest of the defining tetrad; it surfaced a third preclinical rescue route
  (mitochondrial genome editing) for the therapy gap; and, most usefully, it
  pointed to a 1997 autopsy study showing that the single-cell heteroplasmy
  measurement this entry had proposed as an experiment has already been done, with
  a result that runs opposite to the obvious prediction. The regional-selectivity
  discussion was rewritten accordingly rather than left proposing an experiment
  that exists. One caveat for anyone reading that report as a baseline: it was run
  after the first draft of this entry existed and it says so, organizing itself to
  extend the entry rather than to reconstruct it independently, and its own
  provenance section contradicts its frontmatter on whether a provider was used.
  It is a cross-check, not an independent starting point.

  Module conformance note. Two nodes declare conformance to
  epilepsy_excitation_inhibition_imbalance and two to
  cerebellar_purkinje_degeneration. MERRF departs from the generic epilepsy
  module in its entry point: the module opens on ion channel and synaptic
  dysfunction, whereas here the proximal lesion is a bioenergetic one, and the
  channels are affected only secondarily through failure to maintain ionic
  gradients. The graph therefore joins the module at the hyperexcitability node
  rather than at its trigger, which is a genuine feature of a metabolic epilepsy
  rather than a conformance defect. The module's intermediate Seizure Generation
  and Epileptogenesis node is deliberately not claimed either, because MERRF has
  no distinct epileptogenesis step to model: seizures emerge directly from
  ongoing bioenergetic failure rather than from a latent period of network
  reorganization following a discrete initial insult.
inheritance:
  - name: Maternal mitochondrial inheritance with heteroplasmy
    description: >-
      MERRF is transmitted through the maternal line only, because sperm
      mitochondria are not passed to the embryo. A carrier mother transmits the
      variant to every one of her children, but the proportion of mutant genomes
      each child receives is set by a random bottleneck and subsequent mitotic
      segregation, so severity is not predictable from the mother's status. An
      affected father transmits nothing. This is the practical reason prenatal
      testing cannot forecast the phenotype.
    inheritance_term:
      preferred_term: Mitochondrial inheritance
      term:
        id: HP:0001427
        label: Mitochondrial inheritance
    evidence:
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          MERRF is caused by pathogenic variants in mtDNA and is transmitted by
          maternal inheritance.
        explanation: >-
          States the mode of inheritance directly for the syndrome being modeled.
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          A female with a mtDNA pathogenic variant (whether symptomatic or
          asymptomatic) transmits the pathogenic variant to all of her offspring.
        explanation: >-
          Supports the all-or-none transmission from carrier mothers that
          distinguishes mitochondrial from Mendelian inheritance, and which is
          why asymptomatic carrier mothers still need counselling.
pathophysiology:
  - name: MT-TK m.8344A>G Heteroplasmic Point Variant
    biological_scale: MOLECULAR
    description: >-
      An adenine to guanine transition at position 8344 of the mitochondrial
      genome alters a conserved nucleotide in the T-psi-C loop of the transfer
      RNA for lysine. Because each cell carries hundreds to thousands of
      mitochondrial genomes, the variant is present as a mixture with normal
      genomes rather than in every copy, a state called heteroplasmy. The
      original pedigrees showed that retaining even a small fraction of normal
      genomes is strongly protective, which is the first hint that this is a
      dosage disease rather than a simple loss of function.
    genes:
      - preferred_term: MT-TK
        term:
          id: hgnc:7489
          label: MT-TK
    downstream:
      - target: Loss of Transfer RNA Lysine Wobble Taurine Modification
      - target: Mitotic Segregation and Tissue Heteroplasmy Threshold
    evidence:
      - reference: PMID:2112427
        reference_title: >-
          Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated
          with a mitochondrial DNA tRNA(Lys) mutation.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          An A to G transition mutation at nucleotide pair 8344 in human
          mitochondrial DNA (mtDNA) has been identified as the cause of MERRF.
        explanation: >-
          The original identification of the variant as the cause of the
          syndrome, in three independent pedigrees and absent from controls.
      - reference: PMID:2112427
        reference_title: >-
          Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated
          with a mitochondrial DNA tRNA(Lys) mutation.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          This suggests that a small percentage of normal mtDNAs has a large
          protective effect on phenotype.
        explanation: >-
          Establishes the heteroplasmy dosage relationship at the level of the
          founding observation, motivating the threshold node downstream.
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          The m.8344A>G pathogenic variant in the mitochondrial gene MT-TK is
          present in more than 80% of affected individuals with typical findings.
        explanation: >-
          Quantifies how much of the syndrome this node accounts for, and by
          implication how much is left to other mitochondrial transfer RNA genes.
  - name: Loss of Transfer RNA Lysine Wobble Taurine Modification
    biological_scale: MOLECULAR
    description: >-
      Mitochondrial transfer RNAs carry a taurine-containing chemical tag on the
      wobble uridine, the flexible first base of the anticodon that lets one
      transfer RNA read more than one codon. The m.8344A>G variant abolishes this
      tag on transfer RNA lysine. The consequence is unusually complete: unlike
      the analogous MELAS variant, which mainly impairs one of its two codons,
      the untagged MERRF transfer RNA fails to decode either lysine codon.
    biological_processes:
      - preferred_term: tRNA wobble uridine modification
        term:
          id: GO:0002098
          label: tRNA wobble uridine modification
        modifier: DECREASED
    downstream:
      - target: Defective Mitochondrial Protein Synthesis
    evidence:
      - reference: PMID:17132941
        reference_title: >-
          Human mitochondrial diseases associated with tRNA wobble modification
          deficiency.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          revealed the lack of a post-transcriptional taurine-modification at the
          anticodon wobble uridine in two mt tRNAs bearing typical pathogenic
          mutations
        explanation: >-
          Direct demonstration in patient-derived material that the modification
          is missing, which is the molecular content of this node.
      - reference: PMID:17132941
        reference_title: >-
          Human mitochondrial diseases associated with tRNA wobble modification
          deficiency.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          The MERRF mt tRNA(Lys) lacking the wobble modification cannot translate
          either of its codons (AAA and AAG)
        explanation: >-
          Establishes that the decoding failure is complete for both lysine
          codons, which is why the downstream translation defect is severe and
          not codon-selective.
  - name: Mitotic Segregation and Tissue Heteroplasmy Threshold
    biological_scale: CELLULAR
    description: >-
      Mitochondrial genomes are partitioned unequally at each cell division, so
      the mutant fraction drifts upward in some lineages and downward in others.
      Biochemical failure is not proportional to that fraction; it is switch-like.
      In cell lines derived from one patient, moving the mutant load across a
      narrow band collapsed the mitochondrial membrane potential far more sharply
      than it reduced enzyme activity, which is what a threshold looks like
      experimentally. Post-mitotic tissues with high and unremitting energy
      demand cross that threshold first.
    biological_processes:
      - preferred_term: regulation of membrane potential
        term:
          id: GO:0042391
          label: regulation of membrane potential
        modifier: ABNORMAL
    downstream:
      - target: Respiratory Chain Deficiency and Loss of Mitochondrial Membrane Potential
    evidence:
      - reference: PMID:10477264
        reference_title: >-
          Defective kinetics of cytochrome c oxidase and alteration of
          mitochondrial membrane potential in fibroblasts and cytoplasmic hybrid
          cells with the mutation for myoclonus epilepsy with ragged-red fibres
          ('MERRF') at position 8344 nt.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          Within the range of 87-73% mutated mtDNA, COX activity was decreased to
          5-35% and DeltaPsi was decreased to 6-78%.
        explanation: >-
          Quantifies how steeply both readouts change across a narrow heteroplasmy
          band, which is the experimental content of a threshold.
      - reference: PMID:10477264
        reference_title: >-
          Defective kinetics of cytochrome c oxidase and alteration of
          mitochondrial membrane potential in fibroblasts and cytoplasmic hybrid
          cells with the mutation for myoclonus epilepsy with ragged-red fibres
          ('MERRF') at position 8344 nt.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          indicate that the biochemical manifestation of the MERRF mutation exerts
          a very steep threshold of DeltaPsi inhibition
        explanation: >-
          States the threshold conclusion explicitly rather than leaving it as an
          inference from the numbers.
  - name: Defective Mitochondrial Protein Synthesis
    biological_scale: MOLECULAR
    description: >-
      Thirteen respiratory chain subunits are encoded by the mitochondrial genome
      and must be built inside the organelle, using its own transfer RNAs. With
      lysine decoding crippled, synthesis of those subunits stalls, and every
      complex that depends on a mitochondrially encoded subunit is left
      incompletely assembled. Nuclear-encoded subunits are unaffected, which is
      why the biochemical signature is a mixed and partial deficiency rather than
      the clean absence of one enzyme.
    biological_processes:
      - preferred_term: mitochondrial translation
        term:
          id: GO:0032543
          label: mitochondrial translation
        modifier: DECREASED
    downstream:
      - target: Respiratory Chain Deficiency and Loss of Mitochondrial Membrane Potential
    evidence:
      - reference: PMID:35922766
        reference_title: >-
          Rapamycin rescues mitochondrial dysfunction in cells carrying the
          m.8344A > G mutation in the mitochondrial tRNA(Lys).
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          Defective tRNALys severely impairs mitochondrial protein synthesis and
          respiratory chain when a high percentage of mutant heteroplasmy crosses
          the threshold for full-blown clinical phenotype.
        explanation: >-
          Links the translation defect to the respiratory chain defect and to the
          heteroplasmy threshold in a single statement, which is exactly the
          junction this node sits at.
      - reference: PMID:15317755
        reference_title: >-
          Nuclear DNA-encoded tRNAs targeted into mitochondria can rescue a
          mitochondrial DNA mutation associated with the MERRF syndrome in
          cultured human cells.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          import of tRNALys is accompanied by a partial rescue of mitochondrial
          functions affected by the mutation such as mitochondrial translation,
          activity of respiratory complexes, electrochemical potential across the
          mitochondrial membrane and respiration rate
        explanation: >-
          A rescue experiment supplying working transfer RNA lysine restores
          translation and everything downstream, which is causal evidence that the
          transfer RNA defect is the operative lesion rather than a correlate.
  - name: Respiratory Chain Deficiency and Loss of Mitochondrial Membrane Potential
    biological_scale: CELLULAR
    description: >-
      Incomplete respiratory complexes cannot move electrons efficiently, so the
      proton gradient across the inner mitochondrial membrane collapses and
      adenosine triphosphate synthesis falls. Cytochrome c oxidase, the terminal
      enzyme, is the most conspicuously affected in patient cells and the one
      exploited diagnostically. A leaking, poorly coupled electron transport
      chain also spills more reactive oxygen species, adding oxidative damage to
      simple energy shortfall.
    biological_processes:
      - preferred_term: mitochondrial ATP synthesis coupled electron transport
        term:
          id: GO:0042775
          label: mitochondrial ATP synthesis coupled electron transport
        modifier: DECREASED
      - preferred_term: reactive oxygen species metabolic process
        term:
          id: GO:0072593
          label: reactive oxygen species metabolic process
        modifier: INCREASED
    molecular_functions:
      - preferred_term: cytochrome-c oxidase activity
        term:
          id: GO:0004129
          label: cytochrome-c oxidase activity
        modifier: DECREASED
    downstream:
      - target: Compensatory Mitochondrial Proliferation in Skeletal Muscle
      - target: Neuronal Energy Failure and Oxidative Stress
    evidence:
      - reference: PMID:10477264
        reference_title: >-
          Defective kinetics of cytochrome c oxidase and alteration of
          mitochondrial membrane potential in fibroblasts and cytoplasmic hybrid
          cells with the mutation for myoclonus epilepsy with ragged-red fibres
          ('MERRF') at position 8344 nt.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          The activity of cytochrome c oxidase (COX) in patient fibroblasts with
          89% mutated mtDNA was decreased to 20% of the control levels.
        explanation: >-
          Quantifies the terminal enzyme deficit in patient-derived cells, which
          is the biochemical core of this node.
      - reference: PMID:2112427
        reference_title: >-
          Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated
          with a mitochondrial DNA tRNA(Lys) mutation.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          This mutation provides molecular confirmation that some forms of
          epilepsy are the result of deficiencies in mitochondrial energy
          production.
        explanation: >-
          States the causal claim this entry is built around, that the epilepsy of
          MERRF is downstream of an energy production defect.
  - name: Compensatory Mitochondrial Proliferation in Skeletal Muscle
    biological_scale: TISSUE
    description: >-
      Muscle fibers respond to the energy shortfall by making more mitochondria,
      which accumulate under the sarcolemma and between myofibrils. Because the
      added organelles carry the same defect, the compensation is futile, and its
      only reliable product is a histological sign: the ragged red fiber seen on
      Gomori trichrome, typically accompanied by fibers that fail to stain for
      cytochrome c oxidase while staining strongly for succinate dehydrogenase.
      Notably the intramuscular blood vessels show the same pattern.
    cell_types:
      - preferred_term: skeletal muscle fiber
        term:
          id: CL:0008002
          label: skeletal muscle fiber
    downstream:
      - target: Skeletal Muscle Respiratory Failure
    evidence:
      - reference: PMID:25337734
        reference_title: >-
          When should MERRF (myoclonus epilepsy associated with ragged-red fibers)
          be the diagnosis?
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Morphological changes seen upon muscle biopsy in MERRF include a
          substantive proportion of RRF, muscle fibers showing a deficient
          activity of cytochrome c oxidase (COX)
        explanation: >-
          Ties the histological hallmark to the enzyme deficiency, which is what
          makes the ragged red fiber a readout of this node rather than an
          unrelated finding.
  - name: Neuronal Energy Failure and Oxidative Stress
    biological_scale: CELLULAR
    description: >-
      Neurons are unusually vulnerable to a bioenergetic deficit because
      maintaining ionic gradients across a large membrane surface consumes most
      of their adenosine triphosphate budget, and because they cannot dilute a
      mutant load by dividing. As supply falls below demand, ion pumping falters,
      resting membrane potential drifts, calcium handling degrades, and cells
      that cross the failure point die. The result is two distinct downstream
      problems: surviving neurons that are too excitable, and populations of
      neurons that are simply lost.
    cell_types:
      - preferred_term: neuron
        term:
          id: CL:0000540
          label: neuron
    biological_processes:
      - preferred_term: apoptotic process
        term:
          id: GO:0006915
          label: apoptotic process
        modifier: INCREASED
    downstream:
      - target: Cortical Neuronal Hyperexcitability
      - target: Degeneration of Dentate Nucleus and Cerebellar Circuitry
      - target: Progressive Multisystem Involvement
    evidence:
      - reference: PMID:2112427
        reference_title: >-
          Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated
          with a mitochondrial DNA tRNA(Lys) mutation.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          This mutation provides molecular confirmation that some forms of
          epilepsy are the result of deficiencies in mitochondrial energy
          production.
        explanation: >-
          Supports the causal link from energy failure to epilepsy. Marked PARTIAL
          because it asserts the link at the level of the syndrome and does not
          itself demonstrate the neuronal mechanisms named in this node.
      - reference: PMID:35203288
        reference_title: Mitochondrial Neurodegeneration.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Mutations striking either genome can lead to mitochondrial impairment,
          determining infantile, childhood or adult neurodegeneration.
        explanation: >-
          Supports the general principle that mitochondrial impairment produces
          neurodegeneration. Marked PARTIAL because it is a review statement about
          the class of disease rather than a MERRF-specific measurement.
  - name: Cortical Neuronal Hyperexcitability
    biological_scale: CELLULAR
    conforms_to: "epilepsy_excitation_inhibition_imbalance#Neuronal Hyperexcitability and Hypersynchrony"
    description: >-
      Energy-starved cortical neurons cannot sustain the ion gradients that
      normally hold them below firing threshold, and inhibitory interneurons,
      which fire fast and are metabolically expensive, are thought to fail
      disproportionately. The network consequence is hypersynchronous discharge.
      In MERRF this expresses itself both as cortical myoclonus with a matching
      electroencephalographic correlate and as generalized seizures. Importantly
      not all the myoclonus in these patients is cortical; a substantial minority
      is generated below the cortex, which is modeled on the cerebellar and
      brainstem branch instead.
    cell_types:
      - preferred_term: pyramidal neuron
        term:
          id: CL:0000598
          label: pyramidal neuron
    biological_processes:
      - preferred_term: regulation of membrane potential
        term:
          id: GO:0042391
          label: regulation of membrane potential
        modifier: ABNORMAL
    downstream:
      - target: Progressive Myoclonic Epilepsy
    evidence:
      - reference: PMID:39429077
        reference_title: >-
          Clinical characteristics of children with MT-TK gene m.8344A>G
          variation.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Electroencephalogram monitoring in the 15 MERRF children revealed
          myoclonic seizures in 10 children, with 6 classified as myoclonic
          epilepsy, and 4 as subcortical myoclonus.
        explanation: >-
          Provides the electrographic split between cortical myoclonic epilepsy
          and subcortical myoclonus that this node and its cerebellar sibling are
          modeled on, and supports the cortical arm specifically.
      - reference: PMID:37605213
        reference_title: >-
          Mitochondrial impairment and synaptic dysfunction are associated with
          neurological defects in iPSCs-derived cortical neurons of MERRF
          patients.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          MERRF neural cells harboring the m.8344A > G mutation exhibited impaired
          mitochondrial bioenergetic function, elevated ROS levels and imbalanced
          expression of antioxidant enzymes.
        explanation: >-
          Supplies the human-cell bridge from bioenergetic failure to cortical
          neuronal dysfunction that this node otherwise rests on electrographic
          phenomenology alone to assert.
  - name: Degeneration of Dentate Nucleus and Cerebellar Circuitry
    biological_scale: TISSUE
    conforms_to: "cerebellar_purkinje_degeneration#Loss of Cerebellar Cortical Output"
    description: >-
      Autopsy studies show that the neuronal loss in MERRF is not diffuse but
      falls on a reproducible set of structures, with the dentate nucleus, red
      nucleus, globus pallidus, subthalamic nucleus, and pontine tegmentum
      degenerating alongside the cerebellar cortex and inferior olive. This is
      the classic dentatorubral and pallidoluysian distribution, and its
      selectivity is the central unexplained feature of the disease, since the
      causal variant is present throughout the body. Loss of dentate output
      disrupts the cerebello-thalamo-cortical loop, producing ataxia and
      contributing a subcortical component to the myoclonus.
    locations:
      - preferred_term: cerebellum
        term:
          id: UBERON:0002037
          label: cerebellum
    cell_types:
      - preferred_term: Purkinje cell
        term:
          id: CL:0000121
          label: Purkinje cell
    downstream:
      - target: Progressive Cerebellar Ataxia
      - target: Progressive Myoclonic Epilepsy
    evidence:
      - reference: PMID:3128314
        reference_title: >-
          An autopsy case of myoclonus epilepsy associated with ragged-red fibers
          (Fukuhara disease).
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          degeneration of dentate nucleus, red nucleus, globus pallidus,
          subthalamic nucleus and pontine tegmentum
        explanation: >-
          Postmortem documentation of the selective regional degeneration this
          node asserts, in the index Fukuhara case.
      - reference: PMID:3128314
        reference_title: >-
          An autopsy case of myoclonus epilepsy associated with ragged-red fibers
          (Fukuhara disease).
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          degeneration of substantia nigra, locus ceruleus, cerebellar cortex and
          inferior olivary nucleus
        explanation: >-
          Documents cerebellar cortical and olivary involvement specifically,
          which is what licenses conformance to the cerebellar module node.
  - name: Skeletal Muscle Respiratory Failure
    biological_scale: TISSUE
    description: >-
      Muscle with a high mutant load cannot raise oxidative phosphorylation to
      meet the demand of contraction, so patients fatigue early, tolerate exercise
      poorly, and become weak. Because the shortfall is worst under load, the
      complaint is characteristically exertional before it is fixed. Membrane
      leak from damaged fibers releases creatine kinase into the circulation.
    cell_types:
      - preferred_term: skeletal muscle fiber
        term:
          id: CL:0008002
          label: skeletal muscle fiber
    downstream:
      - target: Progressive Multisystem Involvement
    evidence:
      - reference: PMID:32577866
        reference_title: >-
          "Myo-neuropathy" is commonly associated with mitochondrial
          tRNA(Lysine) mutation.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The most frequent symptoms were muscle weakness (76.9%), exercise
          intolerance (76.9%), elevated creatine kinase levels (61.5%), peripheral
          neuropathy (69.2%) and cerebellar ataxia (61.5%)
        explanation: >-
          Quantifies the muscle phenotype in a transfer RNA lysine carrier cohort,
          establishing that exertional failure and creatine kinase leak dominate.
  - name: Progressive Myoclonic Epilepsy
    biological_scale: ORGANISM
    conforms_to: "epilepsy_excitation_inhibition_imbalance#Recurrent Unprovoked Seizures"
    description: >-
      The clinical endpoint on the epilepsy branch. Myoclonus is usually the
      first symptom and is characteristically action-sensitive, worsening with
      fine motor tasks and stress, and it progresses. Generalized seizures
      follow. Because both a cortical and a subcortical generator contribute, and
      because the underlying lesion is degenerative, the syndrome behaves as a
      progressive myoclonic epilepsy rather than a stable seizure disorder.
    evidence:
      - reference: PMID:39429077
        reference_title: >-
          Clinical characteristics of children with MT-TK gene m.8344A>G
          variation.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Myoclonus was predominantly focal, worsening with fine motor tasks or
          stress.
        explanation: >-
          Documents the action-sensitive character of the myoclonus asserted here.
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          MERRF (myoclonic epilepsy with ragged red fibers) is a multisystem
          disorder characterized by myoclonus (often the first symptom) followed
          by generalized epilepsy, ataxia, weakness, exercise intolerance, and
          dementia.
        explanation: >-
          Establishes the sequence in which the syndrome unfolds, with myoclonus
          preceding generalized epilepsy.
  - name: Progressive Cerebellar Ataxia
    biological_scale: ORGANISM
    conforms_to: "cerebellar_purkinje_degeneration#Cerebellar Ataxia"
    description: >-
      The clinical endpoint on the cerebellar branch: gait and limb ataxia,
      dysarthria, and incoordination that worsen as dentate and cortical
      cerebellar neurons are lost. Ataxia is one of the four canonical diagnostic
      features of the syndrome and is common in transfer RNA lysine carriers even
      when the full MERRF picture is absent.
    evidence:
      - reference: PMID:25337734
        reference_title: >-
          When should MERRF (myoclonus epilepsy associated with ragged-red fibers)
          be the diagnosis?
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Diagnostic criteria for MERRF include typical manifestations of the
          disease: myoclonus, generalized epilepsy, cerebellar ataxia and ragged
          red fibers (RRF) on muscle biopsy.
        explanation: >-
          Establishes cerebellar ataxia as one of the four defining features, so
          this endpoint is part of the syndrome definition and not an incidental
          association.
  - name: Progressive Multisystem Involvement
    biological_scale: ORGANISM
    description: >-
      Beyond the defining tetrad, the energy deficit surfaces in any tissue whose
      mutant load crosses threshold, which is why MERRF is a multisystem rather
      than a purely neurological disease. Recognized involvement includes
      sensorineural hearing loss, ptosis and optic atrophy, peripheral neuropathy,
      cardiomyopathy and conduction disease including Wolff-Parkinson-White,
      diabetes mellitus, short stature, and symmetrical lipomatosis. Which of
      these appear in a given patient is not predictable from the variant.
    evidence:
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Common findings are ptosis, hearing loss, short stature, optic atrophy,
          cardiomyopathy, cardiac dysrhythmias such as Wolff-Parkinson-White
          syndrome, and peripheral neuropathy.
        explanation: >-
          Enumerates the multisystem features asserted by this node.
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Pigmentary retinopathy, optic neuropathy, diabetes mellitus, and
          lipomatosis have been observed.
        explanation: >-
          Adds the endocrine, retinal, and adipose features, including the
          lipomatosis that is a recognized marker of this variant.
phenotypes:
  - category: Neurologic
    name: Myoclonus
    description: >-
      Sudden brief involuntary muscle jerks, usually the presenting symptom, often
      focal and action-sensitive, and progressive over the course of the disease.
      Both cortical and subcortical generators contribute.
    phenotype_term:
      preferred_term: Myoclonus
      term:
        id: HP:0001336
        label: Myoclonus
      clinical_course: PROGRESSIVE
    frequency: FREQUENT
    evidence:
      - reference: PMID:39429077
        reference_title: >-
          Clinical characteristics of children with MT-TK gene m.8344A>G
          variation.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Myoclonus presented and worsened progressively in all 15 MERRF children,
          with 10 as the initial symptom
        explanation: >-
          Documents the progressive character and the frequency with which
          myoclonus opens the illness. This cohort is not used for the frequency
          band, because within a MERRF-defined group myoclonus is definitional and
          its rate is circular.
      - reference: PMID:26995359
        reference_title: >-
          Expanded phenotypic spectrum of the m.8344A>G "MERRF" mutation: data from
          the German mitoNET registry.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          In our cohort, the canonical features seizures, myoclonus, cerebellar
          ataxia and ragged-red fibres that are traditionally associated with
          MERRF, occurred in only 61, 59, 70, and 63 % of the patients,
          respectively.
        explanation: >-
          Supplies the FREQUENT band non-circularly. The denominator here is
          carriers of m.8344A>G ascertained by genotype rather than by the MERRF
          clinical definition, so the 59 percent figure for myoclonus measures the
          phenotype instead of restating the case definition.
  - category: Neurologic
    name: Action myoclonus
    description: >-
      The myoclonus of MERRF is characteristically brought out or worsened by
      voluntary movement, particularly fine motor tasks, and by stress. This
      action sensitivity is what makes it functionally disabling out of proportion
      to the jerks seen at rest, and it is the feature levetiracetam and clonazepam
      are aimed at.
    phenotype_term:
      preferred_term: Action myoclonus
      term:
        id: HP:0034360
        label: Action myoclonus
    evidence:
      - reference: PMID:39429077
        reference_title: >-
          Clinical characteristics of children with MT-TK gene m.8344A>G
          variation.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Myoclonus was predominantly focal, worsening with fine motor tasks or
          stress.
        explanation: >-
          Documents the action and stress sensitivity that distinguishes this
          phenotype from myoclonus in general.
  - category: Neurologic
    name: Generalized epilepsy
    description: >-
      Generalized seizures follow the onset of myoclonus and are one of the four
      canonical diagnostic features. Seizure types recorded in MT-TK cohorts
      include myoclonic, generalized tonic-clonic, and occasionally absence
      seizures.
    phenotype_term:
      preferred_term: Generalized-onset seizure
      term:
        id: HP:0002197
        label: Generalized-onset seizure
    frequency: FREQUENT
    evidence:
      - reference: PMID:26995359
        reference_title: >-
          Expanded phenotypic spectrum of the m.8344A>G "MERRF" mutation: data from
          the German mitoNET registry.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          In our cohort, the canonical features seizures, myoclonus, cerebellar
          ataxia and ragged-red fibres that are traditionally associated with
          MERRF, occurred in only 61, 59, 70, and 63 % of the patients,
          respectively.
        explanation: >-
          Seizures in 61 percent of genotype-ascertained carriers, within the
          FREQUENT band. Genotype ascertainment keeps the estimate non-circular.
      - reference: PMID:25337734
        reference_title: >-
          When should MERRF (myoclonus epilepsy associated with ragged-red fibers)
          be the diagnosis?
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Diagnostic criteria for MERRF include typical manifestations of the
          disease: myoclonus, generalized epilepsy, cerebellar ataxia and ragged
          red fibers (RRF) on muscle biopsy.
        explanation: >-
          Establishes generalized epilepsy as a defining feature of the syndrome.
      - reference: PMID:39429077
        reference_title: >-
          Clinical characteristics of children with MT-TK gene m.8344A>G
          variation.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Two children had generalized myoclonic seizures, and 1 each had absence
          seizures and generalized seizures.
        explanation: >-
          Documents the range of generalized seizure types seen in a MT-TK cohort.
  - category: Neurologic
    name: Cerebellar ataxia
    description: >-
      Gait and limb incoordination with dysarthria, reflecting degeneration of the
      dentate nucleus and cerebellar cortex. Present in roughly half to two thirds
      of MT-TK variant carriers who come to attention.
    phenotype_term:
      preferred_term: Progressive cerebellar ataxia
      term:
        id: HP:0002073
        label: Progressive cerebellar ataxia
      clinical_course: PROGRESSIVE
    frequency: FREQUENT
    evidence:
      - reference: PMID:39429077
        reference_title: >-
          Clinical characteristics of children with MT-TK gene m.8344A>G
          variation.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Twelve children had cerebellar ataxia, 10 children exhibited exercise
          intolerance, and 8 children had muscle weakness.
        explanation: >-
          Twelve of the 22 children in this MT-TK cohort had cerebellar ataxia,
          which is 55 percent and falls in the FREQUENT band. The denominator is
          all MT-TK carriers rather than only those meeting MERRF criteria, so the
          estimate is not inflated by the diagnostic definition.
      - reference: PMID:32577866
        reference_title: >-
          "Myo-neuropathy" is commonly associated with mitochondrial
          tRNA(Lysine) mutation.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The most frequent symptoms were muscle weakness (76.9%), exercise
          intolerance (76.9%), elevated creatine kinase levels (61.5%), peripheral
          neuropathy (69.2%) and cerebellar ataxia (61.5%)
        explanation: >-
          An independent adult transfer RNA lysine cohort gives 61.5 percent,
          corroborating the FREQUENT band from a different population.
  - category: Musculoskeletal
    name: Exercise intolerance
    description: >-
      Early fatigue and breathlessness on exertion, reflecting the inability of
      muscle to raise oxidative phosphorylation under load.
    phenotype_term:
      preferred_term: Exercise intolerance
      term:
        id: HP:0003546
        label: Exercise intolerance
    frequency: FREQUENT
    evidence:
      - reference: PMID:32577866
        reference_title: >-
          "Myo-neuropathy" is commonly associated with mitochondrial
          tRNA(Lysine) mutation.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The most frequent symptoms were muscle weakness (76.9%), exercise
          intolerance (76.9%), elevated creatine kinase levels (61.5%), peripheral
          neuropathy (69.2%) and cerebellar ataxia (61.5%)
        explanation: >-
          Reports 76.9 percent in symptomatic transfer RNA lysine carriers, within
          the FREQUENT band of 30 to 79 percent.
  - category: Musculoskeletal
    name: Muscle weakness
    description: >-
      Proximal weakness developing on the background of a mitochondrial myopathy,
      often with a coexisting peripheral neuropathy that adds a distal component.
    phenotype_term:
      preferred_term: Muscle weakness
      term:
        id: HP:0001324
        label: Muscle weakness
      clinical_course: PROGRESSIVE
    frequency: FREQUENT
    evidence:
      - reference: PMID:32577866
        reference_title: >-
          "Myo-neuropathy" is commonly associated with mitochondrial
          tRNA(Lysine) mutation.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The most frequent symptoms were muscle weakness (76.9%), exercise
          intolerance (76.9%), elevated creatine kinase levels (61.5%), peripheral
          neuropathy (69.2%) and cerebellar ataxia (61.5%)
        explanation: >-
          Reports 76.9 percent in symptomatic transfer RNA lysine carriers, within
          the FREQUENT band.
  - category: Neurologic
    name: Peripheral neuropathy
    description: >-
      A length-dependent sensorimotor neuropathy that is common enough in transfer
      RNA lysine carriers that a combined myopathy and neuropathy picture can be
      the entire presentation, with no epilepsy at all.
    phenotype_term:
      preferred_term: Peripheral neuropathy
      term:
        id: HP:0009830
        label: Peripheral neuropathy
    frequency: FREQUENT
    evidence:
      - reference: PMID:32577866
        reference_title: >-
          "Myo-neuropathy" is commonly associated with mitochondrial
          tRNA(Lysine) mutation.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The most frequent symptoms were muscle weakness (76.9%), exercise
          intolerance (76.9%), elevated creatine kinase levels (61.5%), peripheral
          neuropathy (69.2%) and cerebellar ataxia (61.5%)
        explanation: >-
          Reports 69.2 percent in symptomatic carriers, within the FREQUENT band.
  - category: Laboratory
    name: Ragged-red muscle fibers
    description: >-
      Subsarcolemmal accumulation of structurally abnormal mitochondria producing
      the ragged red fiber on Gomori trichrome staining, accompanied by
      cytochrome c oxidase negative fibers. One of the four defining features and
      the origin of the syndrome name.
    phenotype_term:
      preferred_term: Ragged-red muscle fibers
      term:
        id: HP:0003200
        label: Ragged-red muscle fibers
    frequency: FREQUENT
    evidence:
      - reference: PMID:26995359
        reference_title: >-
          Expanded phenotypic spectrum of the m.8344A>G "MERRF" mutation: data from
          the German mitoNET registry.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          In our cohort, the canonical features seizures, myoclonus, cerebellar
          ataxia and ragged-red fibres that are traditionally associated with
          MERRF, occurred in only 61, 59, 70, and 63 % of the patients,
          respectively.
        explanation: >-
          Ragged-red fibres in 63 percent of genotype-ascertained carriers, within
          the FREQUENT band. One caveat specific to this feature: the denominator
          is limited to carriers who underwent muscle biopsy, and biopsy is more
          likely to be done when a mitochondrial myopathy is already suspected, so
          this band carries an ascertainment pressure the clinical features do not.
      - reference: PMID:25337734
        reference_title: >-
          When should MERRF (myoclonus epilepsy associated with ragged-red fibers)
          be the diagnosis?
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Morphological changes seen upon muscle biopsy in MERRF include a
          substantive proportion of RRF, muscle fibers showing a deficient
          activity of cytochrome c oxidase (COX)
        explanation: >-
          Describes the histological finding and its enzymatic correlate.
  - category: Neurologic
    name: Migraine
    description: >-
      Migraine headache, unexpectedly common in carriers of this variant and one of
      the features that is easy to attribute to something else until the
      mitochondrial diagnosis is made.
    phenotype_term:
      preferred_term: Migraine
      term:
        id: HP:0002076
        label: Migraine
    frequency: FREQUENT
    evidence:
      - reference: PMID:26995359
        reference_title: >-
          Expanded phenotypic spectrum of the m.8344A>G "MERRF" mutation: data from
          the German mitoNET registry.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Other common features in our cohort were migraine (52 %), psychiatric
          disorders (54 %), respiratory dysfunction (45 %), gastrointestinal
          symptoms (38 %), dysarthria (36 %), and dysphagia (35 %).
        explanation: >-
          Migraine in 52 percent of genotype-ascertained carriers, within the
          FREQUENT band.
  - category: Respiratory
    name: Respiratory insufficiency
    description: >-
      Respiratory muscle involvement is part of the mitochondrial myopathy and is
      prognostically important, since it drives the need for non-invasive
      ventilation and is one of the two things monitored specifically in pregnancy.
    phenotype_term:
      preferred_term: Respiratory insufficiency
      term:
        id: HP:0002093
        label: Respiratory insufficiency
    frequency: FREQUENT
    evidence:
      - reference: PMID:26995359
        reference_title: >-
          Expanded phenotypic spectrum of the m.8344A>G "MERRF" mutation: data from
          the German mitoNET registry.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Other common features in our cohort were migraine (52 %), psychiatric
          disorders (54 %), respiratory dysfunction (45 %), gastrointestinal
          symptoms (38 %), dysarthria (36 %), and dysphagia (35 %).
        explanation: >-
          Respiratory dysfunction in 45 percent of genotype-ascertained carriers,
          within the FREQUENT band.
  - category: Gastrointestinal
    name: Dysphagia
    description: >-
      Swallowing difficulty from bulbar and oesophageal muscle involvement, a
      practical driver of aspiration risk and of the need for gastrostomy in
      advanced disease.
    phenotype_term:
      preferred_term: Dysphagia
      term:
        id: HP:0002015
        label: Dysphagia
    frequency: FREQUENT
    evidence:
      - reference: PMID:26995359
        reference_title: >-
          Expanded phenotypic spectrum of the m.8344A>G "MERRF" mutation: data from
          the German mitoNET registry.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Other common features in our cohort were migraine (52 %), psychiatric
          disorders (54 %), respiratory dysfunction (45 %), gastrointestinal
          symptoms (38 %), dysarthria (36 %), and dysphagia (35 %).
        explanation: >-
          Dysphagia in 35 percent of genotype-ascertained carriers, at the lower
          edge of the FREQUENT band.
  - category: Neurologic
    name: Cerebellar atrophy on imaging
    description: >-
      Cerebral and cerebellar atrophy are the usual structural findings, with
      atrophy of the superior cerebellar peduncles a more specific clue. A
      characteristic feature is that the imaging looks milder than the patient,
      which should not be taken as evidence against the diagnosis. The 43 percent
      band below is drawn on a cerebral-and-or-cerebellar composite, so it is an
      upper bound for cerebellar atrophy specifically; the smaller imaging series
      that localizes the change to the cerebellum and its superior peduncles in
      every patient is what makes the band defensible for this term.
    phenotype_term:
      preferred_term: Cerebellar atrophy
      term:
        id: HP:0001272
        label: Cerebellar atrophy
    frequency: FREQUENT
    evidence:
      - reference: PMID:26995359
        reference_title: >-
          Expanded phenotypic spectrum of the m.8344A>G "MERRF" mutation: data from
          the German mitoNET registry.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Brain MRI revealed cerebral and/or cerebellar atrophy in 43 % of our
          patients.
        explanation: >-
          Atrophy in 43 percent of genotype-ascertained carriers, within the
          FREQUENT band.
      - reference: PMID:17989367
        reference_title: >-
          Clinical and brain MR imaging features focusing on the brain stem and
          cerebellum in patients with myoclonic epilepsy with ragged-red fibers due
          to mitochondrial A8344G mutation.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Conventional brain MR imaging showed atrophy of the superior cerebellar
          peduncles and the cerebellum in all patients and brain stem atrophy in 2
          patients.
        explanation: >-
          Localizes the atrophy to the superior cerebellar peduncle and cerebellum,
          which is the more diagnostically useful description.
  - category: Neurologic
    name: Sensorineural hearing impairment
    description: >-
      Cochlear hearing loss, a recurring feature of mitochondrial disease and one
      of the commoner extra-neurological findings in MERRF.
    phenotype_term:
      preferred_term: Sensorineural hearing impairment
      term:
        id: HP:0000407
        label: Sensorineural hearing impairment
    frequency: FREQUENT
    evidence:
      - reference: PMID:26995359
        reference_title: >-
          Expanded phenotypic spectrum of the m.8344A>G "MERRF" mutation: data from
          the German mitoNET registry.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          In contrast, other features such as hearing impairment were even more
          frequently present (72 %).
        explanation: >-
          Hearing impairment in 72 percent of genotype-ascertained carriers, within
          the FREQUENT band, and notably commoner than any member of the defining
          tetrad in the same cohort.
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Common findings are ptosis, hearing loss, short stature, optic atrophy,
          cardiomyopathy, cardiac dysrhythmias such as Wolff-Parkinson-White
          syndrome, and peripheral neuropathy.
        explanation: >-
          Lists hearing loss among the common findings of the syndrome.
  - category: Neurologic
    name: Dementia
    description: >-
      Progressive cognitive decline appearing later in the course, part of the
      encephalopathy rather than a separate process.
    phenotype_term:
      preferred_term: Dementia
      term:
        id: HP:0000726
        label: Dementia
      clinical_course: PROGRESSIVE
    evidence:
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          MERRF (myoclonic epilepsy with ragged red fibers) is a multisystem
          disorder characterized by myoclonus (often the first symptom) followed
          by generalized epilepsy, ataxia, weakness, exercise intolerance, and
          dementia.
        explanation: >-
          Names dementia as part of the characteristic syndrome.
  - category: Ophthalmologic
    name: Ptosis
    description: >-
      Drooping of the eyelids from involvement of the levator palpebrae, part of
      the extraocular muscle vulnerability shared across mitochondrial myopathies.
    phenotype_term:
      preferred_term: Ptosis
      term:
        id: HP:0000508
        label: Ptosis
    evidence:
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Common findings are ptosis, hearing loss, short stature, optic atrophy,
          cardiomyopathy, cardiac dysrhythmias such as Wolff-Parkinson-White
          syndrome, and peripheral neuropathy.
        explanation: >-
          Lists ptosis among the common findings.
  - category: Ophthalmologic
    name: Optic atrophy
    description: >-
      Loss of retinal ganglion cell axons producing pallor of the optic disc and
      reduced acuity, the same vulnerable population affected in other
      mitochondrial optic neuropathies.
    phenotype_term:
      preferred_term: Optic atrophy
      term:
        id: HP:0000648
        label: Optic atrophy
    evidence:
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Common findings are ptosis, hearing loss, short stature, optic atrophy,
          cardiomyopathy, cardiac dysrhythmias such as Wolff-Parkinson-White
          syndrome, and peripheral neuropathy.
        explanation: >-
          Lists optic atrophy among the common findings.
  - category: Ophthalmologic
    name: Pigmentary retinopathy
    description: >-
      Pigmentary change in the retina, part of the ophthalmological burden of the
      syndrome alongside ptosis and optic atrophy, and one of the reasons annual
      ophthalmological review sits in the surveillance schedule.
    phenotype_term:
      preferred_term: Pigmentary retinopathy
      term:
        id: HP:0000580
        label: Pigmentary retinopathy
    evidence:
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Pigmentary retinopathy, optic neuropathy, diabetes mellitus, and
          lipomatosis have been observed.
        explanation: >-
          Lists pigmentary retinopathy among the observed features of the
          syndrome.
  - category: Cardiovascular
    name: Cardiomyopathy
    description: >-
      Cardiac muscle shares the bioenergetic vulnerability of skeletal muscle, and
      hypertrophic or dilated cardiomyopathy is a recognized and prognostically
      important feature.
    phenotype_term:
      preferred_term: Cardiomyopathy
      term:
        id: HP:0001638
        label: Cardiomyopathy
    evidence:
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Common findings are ptosis, hearing loss, short stature, optic atrophy,
          cardiomyopathy, cardiac dysrhythmias such as Wolff-Parkinson-White
          syndrome, and peripheral neuropathy.
        explanation: >-
          Lists cardiomyopathy among the common findings.
  - category: Cardiovascular
    name: Wolff-Parkinson-White syndrome
    description: >-
      Pre-excitation from an accessory atrioventricular pathway, a specific and
      well-recognized association in MERRF that warrants electrocardiographic
      surveillance because it carries arrhythmic risk.
    phenotype_term:
      preferred_term: Wolff-Parkinson-White syndrome
      term:
        id: HP:0001716
        label: Wolff-Parkinson-White syndrome
    evidence:
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          cardiac dysrhythmias such as Wolff-Parkinson-White syndrome
        explanation: >-
          Names the specific conduction abnormality associated with the syndrome.
  - category: Endocrine
    name: Diabetes mellitus
    description: >-
      Impaired insulin secretion from bioenergetically compromised pancreatic beta
      cells, the same mechanism that makes diabetes a signature of mitochondrial
      disease generally.
    phenotype_term:
      preferred_term: Diabetes mellitus
      term:
        id: HP:0000819
        label: Diabetes mellitus
    evidence:
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Pigmentary retinopathy, optic neuropathy, diabetes mellitus, and
          lipomatosis have been observed.
        explanation: >-
          Lists diabetes mellitus among the observed features.
  - category: Dermatologic
    name: Multiple symmetrical lipomas
    description: >-
      Multiple symmetrical lipomas, characteristically over the neck and shoulders,
      an unusual and clinically distinctive marker that should prompt testing for
      this variant when it accompanies neurological disease. The multiplicity and
      symmetry are the diagnostically informative part, not the presence of any
      single lipoma.
    phenotype_term:
      preferred_term: Multiple lipomas
      term:
        id: HP:0001012
        label: Multiple lipomas
    evidence:
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Pigmentary retinopathy, optic neuropathy, diabetes mellitus, and
          lipomatosis have been observed.
        explanation: >-
          Lists lipomatosis among the observed features of the syndrome.
      - reference: PMID:38871514
        reference_title: Lipomatoses.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Syndromic lipomatoses include PIK3CA-related disorders, Cowden/PTEN
          hamartomas-tumor syndrome, some lipodystrophy syndromes, and
          mitochondrial diseases, especially MERRF
        explanation: >-
          Independent corroboration from the lipomatosis literature that MERRF is
          the mitochondrial disease most associated with this finding. Marked
          PARTIAL because it is a review classification rather than a MERRF cohort
          measurement.
  - category: Growth
    name: Short stature
    description: >-
      Reduced growth, a common accompaniment of childhood-onset mitochondrial
      disease reflecting chronic energy deficit during growth.
    phenotype_term:
      preferred_term: Short stature
      term:
        id: HP:0004322
        label: Short stature
    evidence:
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Common findings are ptosis, hearing loss, short stature, optic atrophy,
          cardiomyopathy, cardiac dysrhythmias such as Wolff-Parkinson-White
          syndrome, and peripheral neuropathy.
        explanation: >-
          Lists short stature among the common findings.
  - category: Laboratory
    name: Elevated creatine kinase
    description: >-
      Leakage of creatine kinase from damaged muscle fibers, a simple and
      frequently abnormal screening test in transfer RNA lysine carriers.
    phenotype_term:
      preferred_term: Elevated circulating creatine kinase concentration
      term:
        id: HP:0003236
        label: Elevated circulating creatine kinase concentration
    frequency: FREQUENT
    evidence:
      - reference: PMID:32577866
        reference_title: >-
          "Myo-neuropathy" is commonly associated with mitochondrial
          tRNA(Lysine) mutation.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          elevated creatine kinase levels (61.5%)
        explanation: >-
          Reports 61.5 percent in symptomatic carriers, within the FREQUENT band.
biochemical:
  - name: Blood and cerebrospinal fluid lactate
    presence: INCREASED
    context: >-
      Raised lactate reflects the shift to anaerobic metabolism when the
      respiratory chain cannot accept electrons. It is elevated at rest and rises
      further with exertion, but it is neither sensitive nor specific, and it is
      also raised in asymptomatic maternal relatives, so a value cannot be used to
      decide who is affected.
    biomarker_term:
      preferred_term: lactate
      term:
        id: CHEBI:24996
        label: lactate
    readouts:
      - target: Respiratory Chain Deficiency and Loss of Mitochondrial Membrane Potential
        relationship: READOUT_OF
        direction: POSITIVE
        endpoint_context: DIAGNOSTIC
        interpretation: >-
          Elevated lactate is the circulating readout of a blocked respiratory
          chain forcing pyruvate toward lactate.
    evidence:
      - reference: PMID:25337734
        reference_title: >-
          When should MERRF (myoclonus epilepsy associated with ragged-red fibers)
          be the diagnosis?
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          The lactic acid level in the blood and cerebrospinal fluid (CSF) is
          elevated at rest in patients with MERFF and can increase moderately
          after physical activity
        explanation: >-
          States directly that lactate is elevated at rest in both compartments and
          rises further with exertion. The source's own spelling of the acronym is
          preserved so the quote remains exact.
histopathology:
  - name: Ragged red fibers with cytochrome c oxidase deficient fibers
    description: >-
      Muscle biopsy shows a substantial proportion of ragged red fibers on Gomori
      trichrome, together with fibers lacking cytochrome c oxidase activity and
      strong succinate dehydrogenase reactivity, including in intramuscular blood
      vessels. The combination is the histological signature of a mitochondrially
      encoded translation defect, since succinate dehydrogenase is entirely
      nuclear-encoded and therefore spared.
    diagnostic: true
    evidence:
      - reference: PMID:25337734
        reference_title: >-
          When should MERRF (myoclonus epilepsy associated with ragged-red fibers)
          be the diagnosis?
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          the presence of vessels with a strong reaction for succinate
          dehydrogenase and COX deficiency
        explanation: >-
          Documents the vascular component of the histological pattern, which is
          part of what makes the biopsy appearance characteristic.
genetic:
  - name: MT-TK m.8344A>G
    gene_term:
      preferred_term: MT-TK
      term:
        id: hgnc:7489
        label: MT-TK
    relationship_type: CAUSATIVE
    association: >-
      The m.8344A>G variant in MT-TK, encoding mitochondrial transfer RNA-lysine,
      accounts for more than eight in ten typical MERRF cases. It is heteroplasmic
      and maternally transmitted, and the clinical expression depends on the
      mutant load in the affected tissue rather than on the variant itself.
    evidence:
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          The m.8344A>G pathogenic variant in the mitochondrial gene MT-TK is
          present in more than 80% of affected individuals with typical findings.
        explanation: >-
          Quantifies the share of MERRF attributable to this variant.
      - reference: PMID:25337734
        reference_title: >-
          When should MERRF (myoclonus epilepsy associated with ragged-red fibers)
          be the diagnosis?
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          It is estimated that point mutations in the tRNALys gene of the DNAmt,
          mainly A8344G, are responsible for almost 90% of MERRF cases.
        explanation: >-
          An independent estimate of the same fraction, from a clinical review.
  - name: MT-TF and other mitochondrial transfer RNA genes
    gene_term:
      preferred_term: MT-TF
      term:
        id: hgnc:7481
        label: MT-TF
    relationship_type: CAUSATIVE
    association: >-
      A minority of MERRF cases arise from variants in other mitochondrial
      transfer RNA genes, including MT-TF, MT-TH, MT-TI, MT-TL1, MT-TP, MT-TS1,
      and MT-TS2. That several different transfer RNAs can produce the same
      syndrome argues that the operative lesion is generic failure of
      mitochondrial translation rather than anything specific to lysine decoding.
      MT-TF is named here as the representative of that group because a MT-TF case
      supplies the treatment evidence used in this entry.
    evidence:
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Pathogenic variants in MT-TF, MT-TH, MT-TI, MT-TL1, MT-TP, MT-TS1, and
          MT-TS2 have also been described in a subset of individuals with MERRF.
        explanation: >-
          Enumerates the alternative causal genes, establishing genetic
          heterogeneity within the syndrome.
      - reference: PMID:16414077
        reference_title: Antimyoclonic effect of levetiracetam in MERRF syndrome.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          a patient with typical clinical, histological, and biochemical features
          of MERRF due to a mutation on the tRNA of Phenilalanine gene
        explanation: >-
          A worked case of typical MERRF caused by the phenylalanine transfer RNA
          gene rather than the lysine one, demonstrating the heterogeneity
          concretely.
prevalence:
  - population: Adults in North East England
    measure_type: POINT_PREVALENCE
    prevalence_class: BAND_1_5_PER_10000
    rate_per_100000: 20.0
    notes: >-
      This is the prevalence of mitochondrial DNA variants as a class, not of
      MERRF specifically. MERRF is one of the rarer syndromes within that class,
      so 20 per 100,000 is an upper bound on it rather than an estimate of it. A
      variant-specific figure does exist in the secondary literature, roughly 0.28
      per 100,000 for m.8344A>G in this same population and zero in a northern
      Finnish survey, but it is not curated as its own record here for two
      reasons: it is a variant frequency rather than a syndrome rate, since most
      carriers do not have MERRF, and the primary source has no abstract text
      against which a snippet could be verified. The honest position is that no
      snippet-verifiable syndrome-specific rate is available, not that no estimate
      exists.
    evidence:
      - reference: PMID:25652200
        reference_title: >-
          Prevalence of nuclear and mitochondrial DNA mutations related to adult
          mitochondrial disease.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The minimum prevalence rate for mtDNA mutations was 1 in 5,000 (20 per
          100,000), comparable with our previously published prevalence rates.
        explanation: >-
          Gives a population-based rate for mitochondrial DNA disease as a whole.
          Marked PARTIAL because it bounds rather than measures MERRF, which is
          why the notes flag this as an upper bound.
progression:
  - phase: Onset with myoclonus after normal early development
    age_range: Childhood to adulthood
    notes: >-
      Development is typically normal before onset, which can occur any time from
      childhood to adult life. Myoclonus is usually the first symptom. In a
      pediatric MT-TK cohort the median age at onset was five years, with a wide
      spread; adult-onset cohorts report a mean in the mid thirties, so the
      syndrome does not have a single characteristic onset age.
    evidence:
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Onset can occur from childhood to adulthood, occurring after normal
          early development.
        explanation: >-
          States the normal early development and the wide onset window.
      - reference: PMID:39429077
        reference_title: >-
          Clinical characteristics of children with MT-TK gene m.8344A>G
          variation.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The age of onset was 5.00 (2.75, 9.00) years.
        explanation: >-
          Provides the pediatric onset distribution referenced in this phase.
  - phase: Progressive myoclonus, epilepsy, ataxia, and multisystem decline
    age_range: Years to decades after onset
    notes: >-
      Myoclonus worsens and generalized seizures appear, followed by ataxia,
      weakness, and cognitive decline, with multisystem features accruing.
      Progression is the rule; the disease does not stabilize the way many genetic
      generalized epilepsies do, which is what places it in the progressive
      myoclonic epilepsy group.
    evidence:
      - reference: PMID:39429077
        reference_title: >-
          Clinical characteristics of children with MT-TK gene m.8344A>G
          variation.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Myoclonus presented and worsened progressively in all 15 MERRF children,
          with 10 as the initial symptom
        explanation: >-
          Documents progression of the cardinal symptom in a defined cohort.
treatments:
  - name: Levetiracetam for myoclonus
    description: >-
      Levetiracetam suppresses myoclonus in mitochondrial progressive myoclonic
      epilepsy and, unlike valproate, does not interfere with mitochondrial
      respiration. This combination of efficacy and metabolic neutrality is why it
      is favoured as a first choice for the myoclonus of MERRF.
    therapeutic_modality: SMALL_MOLECULE
    treatment_term:
      preferred_term: Pharmacotherapy
      term:
        id: NCIT:C15986
        label: Pharmacotherapy
      therapeutic_agent:
        - preferred_term: levetiracetam
          term:
            id: CHEBI:6437
            label: levetiracetam
    target_mechanisms:
      - target: Cortical Neuronal Hyperexcitability
        treatment_effect: INHIBITS
    evidence:
      - reference: PMID:16414077
        reference_title: Antimyoclonic effect of levetiracetam in MERRF syndrome.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The average myoclonus score improved dramatically, as well as the
          quality of life and no side effects were observed, even after having
          withdrawn VPA.
        explanation: >-
          Documents the antimyoclonic effect in a MERRF patient, including
          maintenance of benefit after valproate withdrawal.
      - reference: PMID:16414077
        reference_title: Antimyoclonic effect of levetiracetam in MERRF syndrome.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          LEV may benefit myoclonus in PME of mitochondrial origin without
          altering mitochondrial function, and it could be considered the drug of
          first choice for the treatment of myoclonus in MERRF.
        explanation: >-
          States the mechanistic rationale for preferring levetiracetam, namely
          that it spares mitochondrial function.
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          levetiracetam or clonazepam for myoclonus
        explanation: >-
          Confirms the recommendation in the management guidance for the syndrome.
  - name: Clonazepam for myoclonus
    description: >-
      A benzodiazepine used as an alternative or adjunct for myoclonus, acting by
      enhancing GABA-A receptor mediated inhibition and so raising the threshold
      for hypersynchronous discharge.
    therapeutic_modality: SMALL_MOLECULE
    treatment_term:
      preferred_term: Pharmacotherapy
      term:
        id: NCIT:C15986
        label: Pharmacotherapy
      therapeutic_agent:
        - preferred_term: clonazepam
          term:
            id: CHEBI:3756
            label: clonazepam
    target_mechanisms:
      - target: Cortical Neuronal Hyperexcitability
        treatment_effect: INHIBITS
    evidence:
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          levetiracetam or clonazepam for myoclonus
        explanation: >-
          Names clonazepam as an accepted option for the myoclonus of MERRF.
  - name: Avoidance of valproic acid
    description: >-
      Valproate is the conventional first choice for progressive myoclonic
      epilepsy but is specifically to be avoided here, because it interferes with
      mitochondrial respiration and beta-oxidation and can precipitate hepatic
      failure in mitochondrial disease. This is a treatment decision that follows
      directly from the mechanism, which is why it is curated as a treatment
      rather than a footnote.
    therapeutic_modality: BEHAVIORAL
    treatment_term:
      preferred_term: Supportive Care
      term:
        id: NCIT:C15747
        label: Supportive Care
    evidence:
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          valproic acid should be avoided in the treatment of seizures
        explanation: >-
          States the contraindication directly in the management guidance.
      - reference: PMID:16414077
        reference_title: Antimyoclonic effect of levetiracetam in MERRF syndrome.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          VPA should be used with caution in PME due to mitochondrial
          dysfunction, i.e. in MERRF (myoclonic epilepsy with ragged red fibers)
          syndrome, because of its interaction with mitochondrial respiration and
          metabolism.
        explanation: >-
          Gives the mechanistic reason for the contraindication, tying it to
          mitochondrial respiration rather than to a generic drug interaction.
  - name: Avoidance of aminoglycosides, linezolid, tobacco, and alcohol
    description: >-
      A second and mechanistically distinct avoidance rule. Aminoglycoside
      antibiotics and linezolid both act on the bacterial ribosome, and because the
      mitochondrial ribosome is an evolutionary descendant of the bacterial one
      they inhibit it too. In a patient whose mitochondrial translation is already
      failing that is a second hit on the very step this disease is defined by.
      Tobacco and alcohol are avoided as general mitochondrial toxins. This is
      curated separately from the valproate rule because the mechanism differs and
      because the clinical situations in which each gets violated differ.
    therapeutic_modality: BEHAVIORAL
    treatment_term:
      preferred_term: Supportive Care
      term:
        id: NCIT:C15747
        label: Supportive Care
    evidence:
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Agents/circumstances to avoid: Mitochondrial toxins (e.g.,
          aminoglycoside antibiotics, linezolid, cigarettes, alcohol)
        explanation: >-
          Names the specific agents to avoid, separately from the valproate
          recommendation.
  - name: Mitochondrial cofactor and supplement therapy
    description: >-
      Coenzyme Q10, L-carnitine, alpha lipoic acid, vitamin E, B vitamins, and
      creatine are widely used on the reasoning that they support electron
      transport, restore carnitine pools, and buffer oxidative damage. The honest
      assessment in the literature is that benefit is modest and inconsistent, and
      no controlled trial has established disease modification.
    therapeutic_modality: SMALL_MOLECULE
    treatment_term:
      preferred_term: Nutritional Support
      term:
        id: NCIT:C15433
        label: Nutritional Support
      therapeutic_agent:
        - preferred_term: coenzyme Q10
          term:
            id: CHEBI:46245
            label: coenzyme Q10
        - preferred_term: L-carnitine
          term:
            id: CHEBI:16347
            label: (R)-carnitine
    target_mechanisms:
      - target: Respiratory Chain Deficiency and Loss of Mitochondrial Membrane Potential
        treatment_effect: MODULATES
    evidence:
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Coenzyme Q10 (50-200 mg 2-3x/day), L-carnitine (1000 mg 2-3x/day), alpha
          lipoic acid, vitamin E, vitamin B supplements, and creatine, often used
          to improve mitochondrial function, have been of modest benefit in some
          individuals.
        explanation: >-
          Documents both the practice and its limited effect. Marked PARTIAL
          because the source describes modest benefit in some individuals rather
          than demonstrating efficacy.
      - reference: PMID:35922766
        reference_title: >-
          Rapamycin rescues mitochondrial dysfunction in cells carrying the
          m.8344A > G mutation in the mitochondrial tRNA(Lys).
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          Therapy is currently limited to symptomatic management of myoclonic
          epilepsy, and supportive measures to counteract muscle weakness with
          co-factors/supplements.
        explanation: >-
          Independently confirms that cofactor supplementation is supportive
          rather than disease-modifying, which is the framing used here.
  - name: Scheduled multisystem surveillance
    description: >-
      Because the syndrome accrues organ involvement unpredictably, surveillance is
      scheduled rather than symptom-driven, and it is organ-specific: neurological,
      ophthalmological, cardiac including electrocardiogram and echocardiogram, and
      endocrine review annually, with audiology every two to three years. The
      cardiac component matters most, because conduction disease can be silent
      right up until it is not.
    therapeutic_modality: BEHAVIORAL
    treatment_term:
      preferred_term: scheduled multisystem surveillance
      term:
        id: NCIT:C15747
        label: Supportive Care
    evidence:
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Surveillance: Routine evaluations every six to 12 months initially;
          annual neurologic, ophthalmologic, cardiology (electrocardiogram and
          echocardiogram), and endocrinologic evaluations (fasting blood sugar and
          TSH); audiology evaluations every two to three years.
        explanation: >-
          States the full surveillance schedule that this record encodes.
  - name: Hearing aids or cochlear implantation
    description: >-
      Sensorineural hearing loss is managed with amplification or, when the loss is
      severe, cochlear implantation. Worth curating because hearing loss is one of
      the commonest extra-neurological features and, unlike most of this syndrome,
      it is remediable.
    therapeutic_modality: DEVICE
    treatment_term:
      preferred_term: hearing aid or cochlear implantation
      term:
        id: NCIT:C49236
        label: Therapeutic Procedure
    notes: >-
      Bound to the generic therapeutic-procedure term rather than to the surgical one
      most cochlear-implantation treatments in this KB use, because this entry covers
      amplification *or* implantation and leads with the non-surgical option; a surgical
      term would misdescribe the amplification half. Checked and kept during the
      cochlear-implantation term sweep rather than normalized to the majority binding.
    evidence:
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          hearing aids or cochlear implants for hearing loss
        explanation: >-
          States the recommended management for the hearing loss of this syndrome.
  - name: Standard pharmacotherapy for cardiac involvement
    description: >-
      Cardiomyopathy and conduction disease are managed with conventional cardiac
      drugs rather than anything mitochondria-specific. The important point is not
      the drug choice but that cardiac involvement is actively looked for, since it
      contributes disproportionately to mortality.
    therapeutic_modality: SMALL_MOLECULE
    treatment_term:
      preferred_term: Pharmacotherapy
      term:
        id: NCIT:C15986
        label: Pharmacotherapy
    evidence:
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          standard pharmacologic therapy for cardiac symptoms
        explanation: >-
          States the recommended approach to the cardiac manifestations.
  - name: Pregnancy monitoring for diabetes and respiratory insufficiency
    description: >-
      Pregnancy raises both metabolic and respiratory demand, which is precisely the
      axis a mitochondrial disease cannot flex. Affected and at-risk women are
      therefore monitored for diabetes mellitus and respiratory insufficiency
      through pregnancy, either of which may need intervention.
    therapeutic_modality: BEHAVIORAL
    treatment_term:
      preferred_term: pregnancy monitoring
      term:
        id: NCIT:C15747
        label: Supportive Care
    evidence:
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          During pregnancy, affected or at-risk women should be monitored for
          diabetes mellitus and respiratory insufficiency, which may require
          therapeutic interventions.
        explanation: >-
          States the pregnancy-specific monitoring recommendation.
  - name: Genetic counselling for maternal transmission
    description: >-
      Counselling addresses the asymmetry of mitochondrial inheritance: an
      affected man transmits nothing, a carrier woman transmits to every child,
      and the mutant load a child receives cannot be predicted. Prenatal and
      preimplantation testing are technically available but cannot forecast
      phenotype, which is itself the counselling message.
    therapeutic_modality: BEHAVIORAL
    treatment_term:
      preferred_term: Genetic Counseling
      term:
        id: NCIT:C15240
        label: Genetic Counseling
    evidence:
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          because the mutational load in tissues sampled prenatally may shift in
          utero or after birth as a result of random mitotic segregation,
          prediction of the phenotype from prenatal studies is not possible.
        explanation: >-
          States the central limitation that the counselling has to convey.
  - name: Physical therapy and aerobic exercise
    description: >-
      Structured exercise and physiotherapy are used to maintain function. The
      rationale is that aerobic training stimulates mitochondrial biogenesis in
      muscle, though in a tissue where the added mitochondria carry the same
      defect the ceiling on that benefit is real.
    therapeutic_modality: BEHAVIORAL
    treatment_term:
      preferred_term: Physical Therapy
      term:
        id: NCIT:C15302
        label: Physical Therapy
    evidence:
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          physical therapy to improve any impaired motor function; aerobic
          exercise
        explanation: >-
          Names physiotherapy and aerobic exercise in the management guidance.
diagnosis:
  - name: Clinical recognition of the four canonic features
    description: >-
      Before any test, the syndrome is recognized clinically by the co-occurrence
      of myoclonus, generalized epilepsy, ataxia, and ragged red fibers. That
      tetrad remains the clinical case definition and is what should prompt
      molecular testing, since no one of the four is individually specific.
    diagnosis_term:
      preferred_term: clinical diagnostic criteria for MERRF
    results: >-
      A proband with myoclonus, generalized epilepsy, ataxia, and ragged red fibers
      meets the clinical case definition and should proceed to molecular testing.
    evidence:
      - reference: PMID:20301693
        reference_title: MERRF.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          A clinical diagnosis of MERRF can be established in a proband with the
          following four "canonic" features: myoclonus, generalized epilepsy,
          ataxia, and ragged red fibers (RRF) in the muscle biopsy.
        explanation: >-
          States the clinical case definition verbatim.
  - name: Targeted mitochondrial DNA testing for m.8344A>G
    description: >-
      Molecular testing is the definitive step. Because heteroplasmy varies
      between tissues and blood can be falsely reassuring, testing muscle or
      urinary sediment is preferred when blood is negative but suspicion is high.
      The original variant conveniently creates a restriction site, which is why a
      simple molecular test existed from the outset.
    diagnosis_term:
      preferred_term: Genetic Testing
      term:
        id: NCIT:C15709
        label: Genetic Testing
    results: >-
      Detection of m.8344A>G in MT-TK, with a quantified heteroplasmy level in the
      tissue tested.
    evidence:
      - reference: PMID:2112427
        reference_title: >-
          Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated
          with a mitochondrial DNA tRNA(Lys) mutation.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The mutation alters the T psi C loop of the tRNA(Lys) gene and creates a
          CviJI restriction site, providing a simple molecular diagnostic test for
          the disease.
        explanation: >-
          Establishes the molecular diagnostic basis for the syndrome.
  - name: Muscle biopsy with histochemistry
    description: >-
      Biopsy demonstrates ragged red fibers with cytochrome c oxidase negative
      fibers and strongly succinate dehydrogenase positive vessels. It remains
      useful when genetic testing on blood is negative, when the variant is in an
      unexpected transfer RNA gene, or when the mutant load is confined to muscle.
    diagnosis_term:
      preferred_term: Muscle Biopsy
      term:
        id: NCIT:C51895
        label: Muscle Biopsy
    results: >-
      Ragged red fibers on Gomori trichrome, cytochrome c oxidase deficient fibers,
      and strong succinate dehydrogenase reactivity including in intramuscular
      vessels.
    evidence:
      - reference: PMID:25337734
        reference_title: >-
          When should MERRF (myoclonus epilepsy associated with ragged-red fibers)
          be the diagnosis?
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Diagnostic criteria for MERRF include typical manifestations of the
          disease: myoclonus, generalized epilepsy, cerebellar ataxia and ragged
          red fibers (RRF) on muscle biopsy.
        explanation: >-
          Establishes muscle biopsy as one of the four defining diagnostic
          elements of the syndrome.
  - name: Electroencephalography with myoclonus correlation
    description: >-
      Electroencephalography distinguishes cortical myoclonic seizures from
      myoclonus generated below the cortex, which matters because the two respond
      differently and imply different generators. In a pediatric MT-TK cohort this
      distinction split the myoclonic patients roughly evenly.
    diagnosis_term:
      preferred_term: Electroencephalography
      term:
        id: NCIT:C38054
        label: Electroencephalography
    results: >-
      Generalized epileptiform discharges with a time-locked correlate for
      cortical myoclonus, or absent cortical correlate where the myoclonus is
      subcortical.
    evidence:
      - reference: PMID:39429077
        reference_title: >-
          Clinical characteristics of children with MT-TK gene m.8344A>G
          variation.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Electroencephalogram monitoring in the 15 MERRF children revealed
          myoclonic seizures in 10 children, with 6 classified as myoclonic
          epilepsy, and 4 as subcortical myoclonus.
        explanation: >-
          Demonstrates the diagnostic yield of electroencephalography in
          separating cortical from subcortical myoclonus.
  - name: Brain MRI of the cerebellum and brainstem
    description: >-
      Imaging supports rather than makes the diagnosis, but the pattern is
      suggestive: atrophy of the superior cerebellar peduncles and cerebellum, with
      brainstem atrophy in some. The clinically useful observation is the
      discrepancy in the other direction from most neurology, with disability
      markedly worse than the pictures, so mild imaging should not be used to argue
      against the diagnosis.
    diagnosis_term:
      preferred_term: Magnetic Resonance Imaging
      term:
        id: NCIT:C16809
        label: Magnetic Resonance Imaging
    results: >-
      Atrophy of the superior cerebellar peduncles and cerebellum, sometimes with
      brainstem atrophy; cerebral or cerebellar atrophy is seen in roughly two
      fifths of carriers.
    evidence:
      - reference: PMID:17989367
        reference_title: >-
          Clinical and brain MR imaging features focusing on the brain stem and
          cerebellum in patients with myoclonic epilepsy with ragged-red fibers due
          to mitochondrial A8344G mutation.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Conventional brain MR imaging showed atrophy of the superior cerebellar
          peduncles and the cerebellum in all patients and brain stem atrophy in 2
          patients.
        explanation: >-
          States the imaging findings reported in the results field.
      - reference: PMID:26995359
        reference_title: >-
          Expanded phenotypic spectrum of the m.8344A>G "MERRF" mutation: data from
          the German mitoNET registry.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Brain MRI revealed cerebral and/or cerebellar atrophy in 43 % of our
          patients.
        explanation: >-
          Gives the registry-scale yield of the test, which is what makes it
          supportive rather than diagnostic.
  - name: Blood lactate measurement
    description: >-
      A simple screening test that supports but cannot establish the diagnosis.
      Lactate is elevated at rest and rises further after exertion, but it is also
      raised in asymptomatic maternal relatives, so it functions as a trigger for
      further testing rather than a gate.
    diagnosis_term:
      preferred_term: Lactic Acid Measurement
      term:
        id: NCIT:C79450
        label: Lactic Acid Measurement
    results: >-
      Elevated resting lactate that may rise further after physical activity;
      normal values do not exclude the diagnosis and raised values do not confirm
      it.
    evidence:
      - reference: PMID:25337734
        reference_title: >-
          When should MERRF (myoclonus epilepsy associated with ragged-red fibers)
          be the diagnosis?
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          The lactic acid level in the blood and cerebrospinal fluid (CSF) is
          elevated at rest in patients with MERFF and can increase moderately
          after physical activity
        explanation: >-
          States the expected result of the test directly. The source's own
          spelling of the acronym is preserved so the quote remains exact.
differential_diagnoses:
  - name: MELAS Syndrome
    disease_term:
      preferred_term: MELAS syndrome
      term:
        id: MONDO:0010789
        label: MELAS syndrome
    description: >-
      The nearest mechanistic neighbour: another maternally inherited transfer RNA
      disease with the same wobble modification defect, differing in which transfer
      RNA is hit and in the resulting clinical emphasis. Overlap cases exist.
    distinguishing_features:
      - Caused by m.3243A>G in MT-TL1 rather than m.8344A>G in MT-TK.
      - Stroke-like episodes in non-vascular territories are the cardinal feature.
      - Myoclonus and progressive myoclonic epilepsy are not the defining picture.
    evidence:
      - reference: PMID:17132941
        reference_title: >-
          Human mitochondrial diseases associated with tRNA wobble modification
          deficiency.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          The MERRF mt tRNA(Lys) lacking the wobble modification cannot translate
          either of its codons (AAA and AAG), while the translational activity of
          MELAS mt tRNA(Leu(UUR)) lacking wobble modification is more depressed in
          decoding of UUG codon than UUA codon.
        explanation: >-
          Shows that the two syndromes share a mechanism class but differ in the
          completeness of the decoding failure, which is the molecular basis for
          treating them as separate entities.
  - name: Leigh Syndrome
    disease_term:
      preferred_term: Leigh syndrome
      term:
        id: MONDO:0009723
        label: Leigh syndrome
    description: >-
      The same m.8344A>G variant can produce Leigh syndrome instead of MERRF, and
      overlap presentations occur, so this is not merely a look-alike but a genuine
      alternative outcome of the identical genotype.
    distinguishing_features:
      - Symmetrical necrotizing lesions of basal ganglia and brainstem on imaging.
      - Earlier onset with developmental regression rather than myoclonus first.
      - Ragged red fibers are not the defining muscle finding.
    evidence:
      - reference: PMID:39429077
        reference_title: >-
          Clinical characteristics of children with MT-TK gene m.8344A>G
          variation.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Fifteen children had myoclonic epilepsy with ragged-red fibers (MERRF),
          3 had Leigh syndrome (LS), and 4 had LS-MERRF overlap syndrome
          (LS-MERRF).
        explanation: >-
          Demonstrates directly that the same variant produces both syndromes and
          overlap forms within one cohort.
  - name: Lafora Disease
    disease_term:
      preferred_term: Lafora disease
      term:
        id: MONDO:0009697
        label: Lafora disease
    description: >-
      A progressive myoclonic epilepsy that presents with the same triad of
      myoclonus, seizures, and cognitive decline in adolescence, but from
      pathological glycogen aggregation rather than energy failure.
    distinguishing_features:
      - Autosomal recessive EPM2A or NHLRC1 variants rather than maternal transmission.
      - Periodic acid-Schiff positive Lafora bodies on skin or other biopsy.
      - Prominent occipital seizures and rapid cognitive collapse.
      - No ragged red fibers and no maternal family history pattern.
    evidence:
      - reference: PMID:25337734
        reference_title: >-
          When should MERRF (myoclonus epilepsy associated with ragged-red fibers)
          be the diagnosis?
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          MERRF should be considered in the differential diagnosis of all
          progressive myoclonic epilepsies, including Lafora disease,
          neurolipofuscinose and Unverricht-Lundborg disease
        explanation: >-
          Names Lafora disease explicitly as a differential the clinician has to
          separate MERRF from.
  - name: Unverricht-Lundborg Disease
    disease_term:
      preferred_term: Unverricht-Lundborg syndrome
      term:
        id: MONDO:0009698
        label: Unverricht-Lundborg syndrome
    description: >-
      The other classic progressive myoclonic epilepsy of adolescence, with severe
      stimulus-sensitive myoclonus but comparatively preserved cognition and a much
      slower course than the other members of the group.
    distinguishing_features:
      - Autosomal recessive CSTB dodecamer repeat expansion.
      - Relatively preserved cognition over decades.
      - No myopathy, no ragged red fibers, and no multisystem involvement.
    evidence:
      - reference: PMID:25337734
        reference_title: >-
          When should MERRF (myoclonus epilepsy associated with ragged-red fibers)
          be the diagnosis?
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          MERRF should be considered in the differential diagnosis of all
          progressive myoclonic epilepsies, including Lafora disease,
          neurolipofuscinose and Unverricht-Lundborg disease
        explanation: >-
          Names Unverricht-Lundborg disease explicitly as a differential the
          clinician has to separate MERRF from.
discussions:
  - discussion_id: merrf_heteroplasmy_phenotype_disconnect
    kind: CONTROVERSY
    status: UNDER_DISCUSSION
    prompt: >-
      If the m.8344A>G variant acts through a heteroplasmy threshold, why does the
      heteroplasmy level measured in accessible tissue fail to predict who
      develops MERRF, and is MERRF a discrete syndrome at all rather than one pole
      of a transfer RNA lysine disease spectrum?
    attaches_to:
      - pathophysiology#Mitotic Segregation and Tissue Heteroplasmy Threshold
      - pathophysiology#Progressive Myoclonic Epilepsy
      - genetic#MT-TK m.8344A>G
    rationale: >-
      The threshold model is well supported in cell culture, where membrane
      potential collapses steeply across a narrow band of mutant load. It does not
      transfer cleanly to patients. In a three-generation family, symptomatic
      members did carry significantly more mutant genomes than asymptomatic ones,
      yet asymptomatic relatives were found carrying up to 63 percent mutant
      genomes, and the authors concluded there is no absolute relationship between
      blood mutant load and clinical severity. A larger East Chinese cohort of
      transfer RNA lysine carriers found blood heteroplasmy of a similar high range
      in symptomatic and asymptomatic individuals alike, and, more strikingly,
      found that the classic MERRF syndrome was the exception rather than the rule:
      most symptomatic carriers had a myopathy with neuropathy picture and only
      about a quarter had myoclonus at all. A case report goes further still,
      describing a homoplasmic carrier whose course was milder and later than his
      heteroplasmic sister, the opposite of what a simple dosage model predicts.
      Three interpretations remain live. The first keeps the threshold model and
      blames the measurement, arguing that blood is the wrong tissue and that
      brain or muscle mutant load, ideally at single-cell resolution, would restore
      the correlation. The second holds that heteroplasmy is genuinely only one
      input, with nuclear background, mitochondrial haplogroup, and the cell's
      capacity for compensatory biogenesis or mitophagy setting where the threshold
      sits. The third questions the nosology, treating MERRF as a named region of a
      continuous transfer RNA lysine phenotype landscape rather than an entity with
      its own mechanism. The stakes are practical: a blood heteroplasmy result is
      routinely used to counsel families, and on the second and third readings that
      number carries much less predictive weight than it appears to. The first
      reading is the weakest of the three, because the brain measurement it asks
      for has already been made: single neurons microdissected from a MERRF brain
      carried uniformly high mutant load across regions that differed several-fold
      in cell loss. Moving from blood to brain therefore does not rescue the dosage
      model, which pushes the weight of explanation onto the modifiers of the second
      reading and onto the nosological question of the third.
    proposed_experiments:
      - experiment_id: exp_merrf_nuclear_modifier_association
        name: Nuclear background and haplogroup modifier study at matched heteroplasmy
        description: >-
          Assemble carriers of m.8344A>G matched for mutant load in the same tissue
          but discordant for phenotype, including asymptomatic high-load carriers,
          and test nuclear genome and mitochondrial haplogroup for association with
          expression of the syndrome. Discordant relatives within a single maternal
          line are the most informative stratum, since they share the variant and
          much of the environment.
        decision_criterion: >-
          A reproducible nuclear or haplogroup association at matched heteroplasmy
          would establish that mutant load is one input among several and would
          give counselling something better than a blood percentage to work with.
          No association across an adequately powered matched design would leave
          stochastic developmental segregation as the leading explanation and argue
          that individual prognostication is not achievable in principle.
      - experiment_id: exp_merrf_prospective_multitissue_cohort
        name: Prospective multi-tissue heteroplasmy cohort with defined phenotyping
        description: >-
          A prospective cohort of transfer RNA lysine carriers, symptomatic and
          asymptomatic, with heteroplasmy quantified in blood, urinary sediment,
          and muscle at enrolment and standardized longitudinal phenotyping for
          myoclonus, seizures, ataxia, and myopathy.
        decision_criterion: >-
          If muscle or urinary heteroplasmy predicts subsequent phenotype where
          blood does not, current counselling practice should shift tissue. If no
          tissue predicts phenotype, the determinant lies outside mutant load and
          heteroplasmy-based prognostication should be explicitly qualified.
    evidence:
      - reference: PMID:9272179
        reference_title: >-
          Gene dosage effect in one family with myoclonic epilepsy and ragged-red
          fibers (MERRF).
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Although there seems to be a gene dosage effect in MERRF, we found no
          absolute relationship between the relative proportion of mutant genomes
          in blood and clinical severity.
        explanation: >-
          States the disconnect directly, from a family study designed to test the
          dosage model.
      - reference: PMID:9272179
        reference_title: >-
          Gene dosage effect in one family with myoclonic epilepsy and ragged-red
          fibers (MERRF).
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          high proportions of mutant genomes (up to 63%) were found in
          asymptomatic relatives
        explanation: >-
          Provides the concrete counterexample of asymptomatic carriers with high
          mutant load.
      - reference: PMID:32577866
        reference_title: >-
          "Myo-neuropathy" is commonly associated with mitochondrial
          tRNA(Lysine) mutation.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          heteroplasmy in blood was high both in symptomatic (mean 64.5%, range
          41-82%) and asymptomatic individuals (mean 53.1%, range 21-78%)
        explanation: >-
          Independent cohort evidence that blood heteroplasmy overlaps heavily
          between symptomatic and asymptomatic carriers.
      - reference: PMID:32577866
        reference_title: >-
          "Myo-neuropathy" is commonly associated with mitochondrial
          tRNA(Lysine) mutation.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          the classic syndrome of myoclonic epilepsy with ragged-red fibers (MERRF)
          was rare (23%)
        explanation: >-
          Supports the nosological arm of the controversy, that the named syndrome
          is a minority outcome of the genotype.
      - reference: PMID:26995359
        reference_title: >-
          Expanded phenotypic spectrum of the m.8344A>G "MERRF" mutation: data from
          the German mitoNET registry.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          There was no correlation between the heteroplasmy level in blood and age
          at onset or clinical phenotype.
        explanation: >-
          A third independent registry-scale statement of the disconnect, in 34
          carriers, which is what moves this from an anecdote to a stable finding.
      - reference: PMID:26995359
        reference_title: >-
          Expanded phenotypic spectrum of the m.8344A>G "MERRF" mutation: data from
          the German mitoNET registry.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          In our cohort, the canonical features seizures, myoclonus, cerebellar
          ataxia and ragged-red fibres that are traditionally associated with
          MERRF, occurred in only 61, 59, 70, and 63 % of the patients,
          respectively.
        explanation: >-
          Supports the nosological arm directly: in unselected carriers, no member
          of the defining tetrad reaches three quarters, so the named syndrome is
          not the typical outcome of the genotype.
      - reference: PMID:36176839
        reference_title: >-
          Milder Phenotype of Homoplasmic Versus Heteroplasmic m.8344A>G Variant in
          the Same Family: A Case Report.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          the m.8344A>G variant may manifest milder and with a later onset in the
          homoplasmic as compared to the heteroplasmic form
        explanation: >-
          A within-family observation running opposite to the dosage prediction.
          Single-case evidence, so it motivates the question rather than settling
          it.
      - reference: PMID:10477264
        reference_title: >-
          Defective kinetics of cytochrome c oxidase and alteration of
          mitochondrial membrane potential in fibroblasts and cytoplasmic hybrid
          cells with the mutation for myoclonus epilepsy with ragged-red fibres
          ('MERRF') at position 8344 nt.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          indicate that the biochemical manifestation of the MERRF mutation exerts
          a very steep threshold of DeltaPsi inhibition
        explanation: >-
          Represents the opposing position, that a sharp threshold does exist.
          Marked PARTIAL because it is a cell-culture result, which is precisely
          the level at which the threshold model works and the clinical data do
          not.
  - discussion_id: merrf_regional_selectivity_gap
    kind: KNOWLEDGE_GAP
    status: OPEN
    prompt: >-
      Why does a mitochondrial variant present in every tissue produce degeneration
      confined to a reproducible set of structures, chiefly the dentate nucleus,
      red nucleus, pallidum, subthalamic nucleus, cerebellar cortex, and inferior
      olive, while sparing most of the brain?
    attaches_to:
      - pathophysiology#Neuronal Energy Failure and Oxidative Stress
      - pathophysiology#Degeneration of Dentate Nucleus and Cerebellar Circuitry
    rationale: >-
      The neuropathology of MERRF is strikingly stereotyped and was recognized as a
      distinct distribution before the causal variant was known, differing from
      dentatorubral-pallidoluysian atrophy, Machado-Joseph disease, and Friedreich
      ataxia despite overlapping anatomy. The most obvious explanation, that the
      vulnerable regions simply carry more mutant mitochondrial DNA, has been
      tested directly and fails. Microdissection of individual neuronal somas from
      a MERRF brain found uniformly high mutant load across every region examined,
      and the relationship to cell loss ran the wrong way: Purkinje cells carried
      the highest mutant load of all, 97.6 percent, yet lost only 7 percent of
      their number, while dentate nucleus neurons lost 46 percent. Mutant load also
      matched between neuronal somas and the surrounding neuropil and glia, so the
      selectivity is not a matter of which cells inherited the bad genomes. What
      remains are cell-intrinsic differences under nuclear control: differing
      bioenergetic demand, with fast-spiking projection neurons running closer to
      their ceiling; differing antioxidant reserve; and differing capacity for
      mitochondrial biogenesis or mitophagy. None of these has been discriminated
      in human tissue. Resolving it matters beyond MERRF, because the same puzzle
      of a ubiquitous lesion with focal degeneration recurs across mitochondrial
      disease and is what makes the genotype so poor a predictor of which
      neurological syndrome a carrier develops.
    proposed_experiments:
      - experiment_id: exp_merrf_regional_bioenergetic_reserve_profiling
        name: Regional bioenergetic reserve profiling in vulnerable versus spared neurons
        description: >-
          Patient-derived induced pluripotent stem cell models differentiated into
          the vulnerable neuronal classes and into a spared comparator, matched for
          mutant load, with measurement of spare respiratory capacity, reactive
          oxygen species handling, and survival under metabolic stress.
        decision_criterion: >-
          If the vulnerable classes show a lower spare respiratory capacity and die
          preferentially at matched mutant load, intrinsic bioenergetic demand
          explains the selectivity. If they behave like the comparator, selectivity
          must come from mutant load distribution or the tissue environment rather
          than from cell-intrinsic demand.
    evidence:
      - reference: PMID:3128314
        reference_title: >-
          An autopsy case of myoclonus epilepsy associated with ragged-red fibers
          (Fukuhara disease).
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The lesions were degenerative in nature, and their distribution was
          different from those of dentato-rubropallidoluysian atrophy, Joseph's
          disease or Friedreich's ataxia.
        explanation: >-
          Establishes that the regional pattern is specific and reproducible enough
          to distinguish MERRF from anatomically neighbouring degenerations, which
          is what makes its unexplained selectivity a genuine gap.
      - reference: PMID:9315896
        reference_title: >-
          Myoclonic epilepsy and ragged red fibers (MERRF) syndrome: selective
          vulnerability of CNS neurons does not correlate with the level of
          mitochondrial tRNAlys mutation in individual neuronal isolates.
        supports: REFUTE
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Neurons and the surrounding neuropil and glia from all CNS regions that
          were analyzed exhibited high proportions of mutant mtDNA, ranging from
          97.6 +/- 0.7% in Purkinje cells to 80.6 +/- 2.8% in the anterior horn
          cells.
        explanation: >-
          Refutes the regional mutant-load explanation at single-cell resolution:
          load is uniformly high everywhere, including in a region that is
          relatively spared.
      - reference: PMID:9315896
        reference_title: >-
          Myoclonic epilepsy and ragged red fibers (MERRF) syndrome: selective
          vulnerability of CNS neurons does not correlate with the level of
          mitochondrial tRNAlys mutation in individual neuronal isolates.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Surprisingly, as compared with controls, neuronal loss ranged from 7% of
          the Purkinje cells to 46% of the neurons of the dentate nucleus in MERRF
          cerebellum.
        explanation: >-
          Quantifies the inverse relationship that makes the puzzle sharp: the
          highest-load population is the least depleted.
      - reference: PMID:9315896
        reference_title: >-
          Myoclonic epilepsy and ragged red fibers (MERRF) syndrome: selective
          vulnerability of CNS neurons does not correlate with the level of
          mitochondrial tRNAlys mutation in individual neuronal isolates.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Thus, factors other than the high proportion of mutant mtDNA, in
          particular nuclear-controlled neuronal differences among various regions
          of the CNS, seem to contribute to the mitochondrial dysfunction and
          ultimate cell death.
        explanation: >-
          States the authors' conclusion, which is the framing this gap now takes:
          the determinant is cell-intrinsic and nuclear, not mitochondrial dosage.
  - discussion_id: merrf_disease_modifying_therapy_gap
    kind: KNOWLEDGE_GAP
    status: OPEN
    prompt: >-
      Preclinical work rescues the MERRF defect in patient-derived cells by three
      independent routes: importing working transfer RNA, stimulating mitophagy
      with rapamycin, and cutting the mutant genome with a targeted nuclease to
      shift heteroplasmy. None has been tested in patients. What would it take to
      move any of them into a trial, and is a bioenergetic rescue still useful once
      neurons have been lost?
    attaches_to:
      - pathophysiology#Defective Mitochondrial Protein Synthesis
      - pathophysiology#Respiratory Chain Deficiency and Loss of Mitochondrial Membrane Potential
    rationale: >-
      Treatment today is entirely symptomatic. Three cell-level strategies have
      shown genuine rescue rather than marginal improvement. Targeting a yeast-derived
      transfer RNA lysine into mitochondria restored translation, respiratory
      complex activity, membrane potential, and respiration rate in patient
      fibroblasts and cybrids, and the rescue disappeared when the transgene was
      knocked down, which is about as clean a causal demonstration as this system
      allows. Separately, chronic rapamycin, acting through enhanced clearance of
      damaged mitochondria rather than through biogenesis, completely rescued the
      bioenergetic defect at intermediate mutant load, while direct stimulation of
      biogenesis failed at high mutant load. The third route attacks the problem at
      its root: a mitochondria-targeted nuclease, a monomeric mitoTev-TALE hybrid
      small enough to be plausibly packaged into a viral vector, cut the mutant
      genome in patient-derived cybrids and shifted the heteroplasmy ratio toward
      wild type, with recovery of oxidative phosphorylation even in a clone at 91
      percent mutant. These results share a limitation relevant to the clinic: they
      were obtained in dividing cells that can shift their heteroplasmy, whereas
      the neurons that matter are postmitotic and cannot dilute anything, and MERRF
      is a degenerative disease in which the target cells may be gone by the time of
      treatment. There is also a strong hint about timing, since rapamycin
      worked well at intermediate but only marginally at high mutant load,
      suggesting a window that closes. Neither strategy has a delivery route to the
      human central nervous system, and no biomarker exists that would show target
      engagement in brain.
    proposed_experiments:
      - experiment_id: exp_merrf_mitophagy_modulation_in_postmitotic_neurons
        name: Mitophagy modulation in postmitotic patient-derived neurons
        description: >-
          Apply chronic mitophagy stimulation to induced pluripotent stem cell
          derived neurons from MERRF donors after terminal differentiation,
          spanning a range of mutant loads, measuring heteroplasmy shift,
          respiration, and survival, and comparing early with delayed treatment.
        decision_criterion: >-
          Rescue in postmitotic neurons at clinically representative mutant loads
          would support translation and define the mutant-load ceiling for benefit.
          Rescue confined to dividing cells would indicate the mechanism depends on
          selective replicative advantage and does not transfer to the tissue that
          matters.
    evidence:
      - reference: PMID:15317755
        reference_title: >-
          Nuclear DNA-encoded tRNAs targeted into mitochondria can rescue a
          mitochondrial DNA mutation associated with the MERRF syndrome in
          cultured human cells.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          Import of a tRNALys with a mutation in the anticodon preventing
          recognition of the lysine codons does not lead to any rescue, whereas
          downregulation of the transgenic tRNAs by small interfering RNA (siRNA)
          transiently abolishes the functional rescue, showing that this rescue is
          due to the import.
        explanation: >-
          Establishes the specificity and reversibility of the rescue, which is
          what makes the transfer RNA import strategy worth pursuing rather than a
          nonspecific culture effect.
      - reference: PMID:35922766
        reference_title: >-
          Rapamycin rescues mitochondrial dysfunction in cells carrying the
          m.8344A > G mutation in the mitochondrial tRNA(Lys).
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          The second approach, when administered chronically (4 weeks), induced a
          slight increase of mitochondrial respiration in fibroblasts with
          high-mutation load, and a significant improvement in fibroblasts with
          intermediate-mutation load, rescuing completely the bioenergetics defect.
        explanation: >-
          Documents both the rescue and the mutant-load dependence that motivates
          the timing question posed here.
      - reference: PMID:35922766
        reference_title: >-
          Rapamycin rescues mitochondrial dysfunction in cells carrying the
          m.8344A > G mutation in the mitochondrial tRNA(Lys).
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          This suggests that induction of mitochondrial biogenesis may not be
          sufficient to rescue mitochondrial dysfunction in MERRF cells with
          high-mutation load.
        explanation: >-
          Records the negative result for the biogenesis strategy, which is why
          this gap is framed around mitophagy, transfer RNA supply, and genome
          editing rather than around making more mitochondria.
      - reference: PMID:30012581
        reference_title: >-
          mitoTev-TALE: a monomeric DNA editing enzyme to reduce mutant
          mitochondrial DNA levels.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          When this mitoTev-TALE was tested in a clone with high levels of the
          MERRF mutation (91% mutant), the shift in heteroplasmy resulted in an
          improvement of oxidative phosphorylation function.
        explanation: >-
          Demonstrates the third rescue route in MERRF cells specifically, and at a
          mutant load in the range that defines clinical disease, which is where
          the rapamycin approach was weakest.
      - reference: PMID:30012581
        reference_title: >-
          mitoTev-TALE: a monomeric DNA editing enzyme to reduce mutant
          mitochondrial DNA levels.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          mitoTALENs are dimeric and relatively large, making it difficult to
          package their coding genes into viral vectors, limiting their clinical
          application.
        explanation: >-
          States the delivery constraint that this monomeric design is meant to
          solve, which is one concrete part of the answer to what it would take to
          reach a trial. Marked PARTIAL because packaging feasibility is argued
          rather than demonstrated in vivo.

📚

References & Deep Research

References

3

PMID:20301693

MERRF.

No top-level findings curated for this source.

PMID:25337734

When should MERRF (myoclonus epilepsy associated with ragged-red fibers) be the diagnosis?

No top-level findings curated for this source.

PMID:2112427

Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys) mutation.

No top-level findings curated for this source.

Deep Research

1

Claude Code ▸

1. Disease Information

claude-haiku-4-5-20251001, claude-opus-5[1m] 20 citations 2026-08-05T12:35:52.687378

1. Disease Information

Overview

MERRF is a maternally inherited, multisystem mitochondrial encephalomyopathy. Its classical definition is a tetrad: myoclonus, generalized epilepsy, cerebellar ataxia, and ragged-red fibers (RRF) on muscle biopsy. The proximal defect is a point variant in a mitochondrial transfer RNA gene — most often MT-TK, encoding tRNA-lysine — that cripples the mitochondrion's ability to translate its own 13 respiratory-chain subunits. Because mitochondrial genomes exist in hundreds of copies per cell and the variant is present as a mixture with normal genomes (heteroplasmy), the disease surfaces only where the mutant fraction crosses a steep threshold. That is the single most important structural fact about MERRF: it is a dosage disease with a patchy, tissue-by-tissue distribution, not a uniform loss of function.

"MERRF (myoclonic epilepsy with ragged red fibers) is a multisystem disorder characterized by myoclonus (often the first symptom) followed by generalized epilepsy, ataxia, weakness, exercise intolerance, and dementia." — GeneReviews, PMID:20301693 [V, already in KB]

A critical nosological caveat that should frame the whole entry: large modern cohorts show the full tetrad is the minority outcome of the causal genotype. See §3 and §9.

Identifiers

Resource	Identifier
MONDO	MONDO:0010790 (MERRF syndrome)
OMIM	545000 (MERRF); MT-TK locus 590060
Orphanet	ORPHA:551 (Orphanet page was CAPTCHA-blocked this session — ⚠ confirm number before citing)
ICD-10-CM	E88.42 — "MERRF syndrome" (billable, dedicated code)
ICD-11	Mitochondrial-disease chapter; a MERRF-specific stem code was not confirmed this session — ⚠ verify in the ICD-11 browser
MeSH	D017243 — "MERRF Syndrome"
ClinVar (variant)	VCV000009579; dbSNP rs118192098
HGNC (gene)	hgnc:7489 (MT-TK); NCBI Gene 4566
MITOMAP	m.8344A>G, confirmed pathogenic mt-tRNA variant

Synonyms

MERRF; myoclonic epilepsy with ragged red fibers; myoclonus epilepsy associated with ragged-red fibers; myoclonic epilepsy associated with ragged-red fibers; Fukuhara disease (eponym, from the 1980 Japanese description); "myoclonic ataxia" (proposed renaming — see §3).

Data provenance type

Aggregated disease-level, with two useful registry-derived exceptions that behave more like individual-patient datasets: the German mitoNET/mitoREGISTER cohort (PMID:26995359) and the Nation-wide Italian Collaborative Network of Mitochondrial Diseases database (PMID:23635963). No EHR-derived MERRF phenotype algorithm is published; the ICD-10-CM code E88.42 is specific enough that an OMOP-style case-finding definition is feasible and would be a reasonable definitions[] addition (currently absent from the KB entry).

2. Etiology

Primary causal factor

A heteroplasmic point variant in a mitochondrially encoded tRNA gene → failure of intramitochondrial translation. The dominant lesion:

m.8344A>G in MT-TK (NC_012920.1:m.8344A>G), an A→G transition in the T-ψ-C loop of mt-tRNA^Lys.

"An A to G transition mutation at nucleotide pair 8344 in human mitochondrial DNA (mtDNA) has been identified as the cause of MERRF." — Shoffner et al., Cell 1990, PMID:2112427 [V]

"The m.8344A>G pathogenic variant in the mitochondrial gene MT-TK is present in more than 80% of affected individuals with typical findings." — GeneReviews, PMID:20301693 [V]

Independent estimate: "point mutations in the tRNALys gene of the DNAmt, mainly A8344G, are responsible for almost 90% of MERRF cases" — Lorenzoni et al., PMID:25337734 [V].

Genetic risk factors

Causal variants (germline, mitochondrial): m.8344A>G (dominant); other MT-TK alleles m.8356T>C, m.8363G>A, m.8361G>A, m.8340G>A (⚠ these specific positions were not individually confirmed against MITOMAP this session — verify before curating); a novel m.8315A>C MT-TK variant reported as a MERRF cause (PMC9319148 — ⚠ PMID not resolved, CAPTCHA-blocked).
Non-MT-TK causes: "Pathogenic variants in MT-TF, MT-TH, MT-TI, MT-TL1, MT-TP, MT-TS1, and MT-TS2 have also been described in a subset of individuals with MERRF." — PMID:20301693 [V]. A worked MT-TF case (typical clinical, histological and biochemical MERRF from a phenylalanine-tRNA variant) is documented in PMID:16414077 [V]. That several different tRNAs produce the same syndrome argues the operative lesion is generic translation failure, not anything lysine-specific.
Heteroplasmy level is the proximate quantitative risk factor — but a badly behaved one (see §9 and the controversy in the KB discussions block).
Nuclear background as a modifier: the strongest human evidence is the Zhou/Attardi autopsy study (§6), which concluded that "nuclear-controlled neuronal differences among various regions of the CNS" contribute to which neurons die — PMID:9315896 [V].

Environmental risk factors

There is no established environmental cause. What exists is a set of decompensation triggers and mitochondrial toxins that convert a compensated carrier state into clinical disease or accelerate it:

Valproic acid — interferes with mitochondrial respiration and β-oxidation; can precipitate hepatic failure. Specifically contraindicated despite being the conventional first choice for progressive myoclonic epilepsy.
Aminoglycoside antibiotics, linezolid (both inhibit the same mitochondrial ribosome that is already failing).
Cigarettes and alcohol — named explicitly in GeneReviews management.
Catabolic stress: intercurrent infection, fasting, dehydration, surgery/anesthesia.

"valproic acid should be avoided in the treatment of seizures" — GeneReviews PMID:20301693 [V] Avoid "Aminoglycoside antibiotics, linezolid, cigarettes, alcohol, valproic acid" — GeneReviews PMID:20301693 [S]

Protective factors

Retention of wild-type mtDNA is the only well-established protective factor, and it is remarkably potent: "This suggests that a small percentage of normal mtDNAs has a large protective effect on phenotype." — Shoffner 1990, PMID:2112427 [V]
No protective nuclear variant, haplogroup, diet, or exposure has been established. Aerobic exercise is used therapeutically on a mitochondrial-biogenesis rationale but has not been shown to prevent onset.

Gene–environment interactions

The clinically actionable interaction is genotype × drug: a valproate exposure that is benign in idiopathic generalized epilepsy is hepatotoxic/decompensating in an m.8344A>G carrier. Similarly, aminoglycoside ototoxicity is amplified on a background of mitochondrial translation failure. These belong in the entry as mechanism-derived treatment decisions (the KB already curates valproate avoidance as a treatments entry — the right call).

3. Phenotypes

The central finding of the modern literature: the classical tetrad is the exception

Two large cohorts independently dismantled the textbook picture. This should be the headline phenotype fact in any KB entry.

Italian collaborative cohort (n=42 carriers + systematic review of 321 published patients), Mancuso et al., Neurology 2013, PMID:23635963 [V — full abstract cached]:

"Forty-two patients carrying the mutation were identified. The great majority did not have full-blown MERRF syndrome. Myoclonus was present in 1 of 5 patients, whereas myopathic signs and symptoms, generalized seizures, hearing loss, eyelid ptosis, and multiple lipomatosis represented the most common clinical features."

"Considering all of the 321 patients so far available… at the mean age of approximately 35 years, the clinical picture was characterized by the following signs/symptoms, in descending order: myoclonus, muscle weakness, ataxia (35%-45% of patients); generalized seizures, hearing loss (25%-34.9%); cognitive impairment, multiple lipomatosis, neuropathy, exercise intolerance (15%-24.9%); and increased creatine kinase levels, ptosis/ophthalmoparesis, optic atrophy, cardiomyopathy, muscle wasting, respiratory impairment, diabetes, muscle pain, tremor, migraine (5%-14.9%)."

"MERRF could be better defined as a myoclonic ataxia rather than a myoclonic epilepsy."

German mitoNET registry (n=34), Altmann et al., J Neurol 2016, PMID:26995359 [V — full abstract cached]:

"Mean age at symptom onset was 24.5 years ±10.9 (6-48 years) with adult onset in 75 % of the patients."

"In our cohort, the canonical features seizures, myoclonus, cerebellar ataxia and ragged-red fibres that are traditionally associated with MERRF, occurred in only 61, 59, 70, and 63 % of the patients, respectively. In contrast, other features such as hearing impairment were even more frequently present (72 %). Other common features in our cohort were migraine (52 %), psychiatric disorders (54 %), respiratory dysfunction (45 %), gastrointestinal symptoms (38 %), dysarthria (36 %), and dysphagia (35 %). Brain MRI revealed cerebral and/or cerebellar atrophy in 43 % of our patients."

East-Chinese tRNA-Lys cohort, PMID:32577866 [V, already in KB]: myopathy-plus-neuropathy dominates; "the classic syndrome of myoclonic epilepsy with ragged-red fibers (MERRF) was rare (23%)"; symptom frequencies "muscle weakness (76.9%), exercise intolerance (76.9%), elevated creatine kinase levels (61.5%), peripheral neuropathy (69.2%) and cerebellar ataxia (61.5%)".

Pediatric MT-TK cohort (n=22), PMID:39429077 [V, already in KB]: 15 MERRF, 3 Leigh syndrome, 4 LS-MERRF overlap; median onset 5.00 (2.75, 9.00) years; myoclonus progressive in all 15 MERRF children, initial symptom in 10; EEG split myoclonus into 6 cortical myoclonic epilepsy vs 4 subcortical.

Phenotype table with HPO suggestions and frequency evidence

Phenotype	HPO term	Onset	Course	Frequency (source)
Myoclonus (often first symptom; action-sensitive)	Myoclonus HP:0001336 ✓	childhood–adult	progressive	35–45% of 321 pooled (PMID:23635963); 59% (PMID:26995359); ~20% in Italian n=42. Do not assert a band inside a MERRF-defined cohort — circular
Generalized seizures	Seizure HP:0001250 ✓	after myoclonus	recurrent/progressive	25–34.9% pooled; 61% (mitoNET)
Cerebellar ataxia	Progressive cerebellar ataxia HP:0002073 ✓	variable	progressive	35–45% pooled; 70% (mitoNET); 61.5% (PMID:32577866) → FREQUENT
Muscle weakness	HP:0001324 ✓	variable	slowly progressive	76.9% (PMID:32577866) → FREQUENT
Exercise intolerance	HP:0003546 ✓	early	stable-progressive	76.9% → FREQUENT
Peripheral neuropathy	HP:0009830 ✓	adult	progressive	69.2%; 15–24.9% pooled → FREQUENT
Ragged-red fibers	HP:0003200 ✓	—	—	63% (mitoNET) — note: not universal
Sensorineural hearing impairment	HP:0000407 ✓	variable	progressive	72% (mitoNET) — the single most frequent feature in that cohort; 25–34.9% pooled → FREQUENT
Cognitive impairment / dementia	Dementia HP:0000726 ✓	late	progressive	15–24.9% pooled
Ptosis / ophthalmoparesis	Ptosis HP:0000508 ✓	variable	progressive	5–14.9% pooled (ptosis common in Italian n=42)
Optic atrophy	HP:0000648 ✓	variable	progressive	5–14.9% pooled
Cardiomyopathy	HP:0001638 ✓	variable	progressive	5–14.9% pooled
Wolff-Parkinson-White	HP:0001716 ✓	variable	—	not quantified; named in GeneReviews
Diabetes mellitus	HP:0000819 ✓	adult	progressive	5–14.9% pooled
Multiple symmetric lipomatosis	Lipoma HP:0012032 ✓	adult	progressive	15–24.9% pooled — clinically distinctive red flag
Short stature	HP:0004322 ✓	childhood	—	GeneReviews "common"
Elevated creatine kinase	HP:0003236 ✓	—	—	61.5%; 5–14.9% pooled → FREQUENT in tRNA-Lys carriers
Migraine (KB gap)	Migraine HP:0002076 ⚠	adult	recurrent	52% (mitoNET) → FREQUENT
Psychiatric disorder (KB gap)	Behavioral abnormality HP:0000708 ⚠ (or a depression/anxiety child term)	adult	—	54% (mitoNET) → FREQUENT
Respiratory dysfunction (KB gap)	Respiratory insufficiency HP:0002093 ⚠	adult	progressive	45% (mitoNET); 5–14.9% pooled
Gastrointestinal symptoms (KB gap)	HP:0011024 ⚠	adult	—	38% (mitoNET)
Dysarthria (KB gap)	HP:0001260 ⚠	with ataxia	progressive	36% (mitoNET)
Dysphagia (KB gap)	HP:0002015 ⚠	later	progressive	35% (mitoNET)
Cerebral/cerebellar atrophy on MRI (KB gap)	Cerebellar atrophy HP:0001272 ⚠ / Cerebral atrophy HP:0002059 ⚠	—	progressive	43% (mitoNET)
Elevated lactate (blood/CSF)	Increased circulating lactate HP:0002151 ⚠	—	—	supportive, neither sensitive nor specific
Pigmentary retinopathy	HP:0000580 ⚠	—	—	GeneReviews "have been observed"
Tremor, muscle pain, muscle wasting	HP:0001337 ⚠ / HP:0003326 ⚠ / HP:0003202 ⚠	—	—	5–14.9% pooled

Six of these (migraine, psychiatric, respiratory, GI, dysarthria, dysphagia) are frequency-quantified in a registry cohort and are currently absent from the dismech entry — the highest-yield phenotype additions available.

Quality of life

No MERRF-specific QoL study was found. Generic mitochondrial-disease instruments apply and are the right anchors: - NMDAS (Newcastle Mitochondrial Disease Adult Scale) — three sections: current function, system-specific involvement, current clinical assessment. - NMQ (Newcastle Mitochondrial Quality of life measure) — 63 items across 16 domains. - Predictors of overall QoL in mitochondrial disease are fatigue and physical functioning; one cohort reported 79.8% with severe fatigue [S — verify]. - The KL1333 phase 1a/1b trial validated the 30-second Sit-to-Stand and patient-reported fatigue scales as outcome measures in primary mitochondrial disease (PMID:39657714 [V]).

Per-phenotype QoL impact: myoclonus is the dominant disability driver in classical MERRF (the levetiracetam case report documented that "the average myoclonus score improved dramatically, as well as the quality of life" — PMID:16414077 [V]); ataxia and hearing loss dominate in the broader carrier population.

4. Genetic / Molecular Information

Causal gene

MT-TK — mitochondrially encoded tRNA-lysine. HGNC:7489 (lowercase hgnc:7489 in dismech), NCBI Gene 4566, OMIM 590060. A 70-nucleotide RNA at mtDNA map position 8295–8364. GeneReviews: MT-TK accounts for >90% of MERRF; m.8344A>G alone for >80% of typical presentations.

Pathogenic variants

Field	m.8344A>G
Nomenclature	NC_012920.1(MT-TK):m.8344A>G
dbSNP	rs118192098
ClinVar	VCV000009579; Pathogenic, 2-star review status (criteria provided, multiple submitters, no conflicts), 6 submissions, last evaluated 2026-01-07
Variant class	Point substitution (transition) in a non-coding structural RNA — not missense/nonsense/frameshift; standard ACMG protein-level codes do not apply, mt-tRNA-specific criteria (Yarham/McFarland scoring) do
Origin	Germline, maternal; mitochondrial; heteroplasmic (occasionally homoplasmic)
Population frequency	Heteroplasmic allele frequency 0.011% in gnomAD v4.1.0 [S — verify in gnomAD directly]
Functional consequence	Loss of function of the tRNA via loss of the wobble-uridine taurine modification → complete failure to decode both AAA and AAG

Other MT-TK alleles reported in MERRF: m.8356T>C, m.8363G>A, m.8361G>A, m.8340G>A ⚠, plus the newly reported m.8315A>C ⚠. Non-MT-TK genes: MT-TF, MT-TH, MT-TI, MT-TL1, MT-TP, MT-TS1, MT-TS2 (PMID:20301693 [V]).

Functional consequence — the molecular core

"revealed the lack of a post-transcriptional taurine-modification at the anticodon wobble uridine in two mt tRNAs bearing typical pathogenic mutations" — Kirino/Suzuki, PMID:17132941 [V]

"The MERRF mt tRNA(Lys) lacking the wobble modification cannot translate either of its codons (AAA and AAG), while the translational activity of MELAS mt tRNA(Leu(UUR)) lacking wobble modification is more depressed in decoding of UUG codon than UUA codon." — PMID:17132941 [V]

That contrast is the cleanest molecular discriminator between MERRF and MELAS: MERRF's decoding failure is complete; MELAS's is codon-selective. GO term: tRNA wobble uridine modification GO:0002098 ✓ (DECREASED).

Modifier genes

No named modifier gene is established. The strongest evidence that nuclear modifiers exist is Zhou 1997 (PMID:9315896 [V]) — see §6. Candidate classes (all unvalidated): mitochondrial biogenesis capacity (PGC-1α axis), mitophagy capacity, antioxidant reserve, mtDNA haplogroup. In the rapamycin study, MERRF fibroblasts carried haplogroups H and U vs control T/U5a/U5b — an incidental observation, not a haplogroup association [S].

Epigenetics

No established role for nuclear DNA methylation or histone modification in MERRF. The relevant "epigenetic-adjacent" layer is mitochondrial RNA post-transcriptional modification (the taurinomethyl-uridine tag itself, installed by MTO1/GTPBP3/TRMU) — mechanistically central, and worth flagging as distinct from classical epigenetics.

Chromosomal abnormalities

Not applicable. MERRF is caused by point variants in a 16.6 kb circular genome; karyotype, CMA, and FISH have no role.

5. Environmental Information

Environmental factors: none causal. Mitochondrial toxins (aminoglycosides, linezolid, valproate, tobacco, alcohol) modify course. No occupational or pollutant exposure is implicated.
Lifestyle: avoidance of alcohol and tobacco is recommended; aerobic exercise is recommended (biogenesis rationale); fasting and catabolic stress should be avoided.
Infectious agents: none causal. Intercurrent infection is a recognized decompensation trigger — relevant to the metabolic_intoxication_decompensation module logic, though MERRF is not itself an intoxication-type IEM.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream)

m.8344A>G in MT-TK (heteroplasmic)                        [MOLECULAR]
   ├─→ Loss of tRNA-Lys wobble taurine modification        [MOLECULAR]  GO:0002098 ↓
   │      └─→ Defective mitochondrial translation          [MOLECULAR]  GO:0032543 ↓
   └─→ Mitotic segregation → tissue heteroplasmy threshold [CELLULAR]   GO:0042391 abnormal
  └─→ Respiratory chain deficiency + ΔΨm collapse  [CELLULAR]   GO:0042775 ↓, GO:0004129 ↓, GO:0072593 ↑
 ├─→ Compensatory mitochondrial proliferation in muscle [TISSUE] → RAGGED-RED FIBER
 │      └─→ Skeletal muscle respiratory failure [TISSUE] → weakness, exercise intolerance, ↑CK
 └─→ Neuronal energy failure + oxidative stress [CELLULAR] GO:0006915 ↑
        ├─→ Cortical neuronal hyperexcitability [CELLULAR] → progressive myoclonic epilepsy
        ├─→ Dentate/cerebellar degeneration     [TISSUE]   → progressive ataxia + subcortical myoclonus
        └─→ Progressive multisystem involvement [ORGANISM] → deafness, cardiomyopathy, DM, lipomatosis

This is the graph already committed in kb/disorders/MERRF_Syndrome.yaml, with conformance to epilepsy_excitation_inhibition_imbalance (at the hyperexcitability node, deliberately not at the module trigger — MERRF's entry point is bioenergetic, not channelopathic) and cerebellar_purkinje_degeneration.

Key mechanistic evidence

Threshold behavior (in vitro, cybrids/fibroblasts) — PMID:10477264 [V]:

"Within the range of 87-73% mutated mtDNA, COX activity was decreased to 5-35% and DeltaPsi was decreased to 6-78%." "indicate that the biochemical manifestation of the MERRF mutation exerts a very steep threshold of DeltaPsi inhibition" "The activity of cytochrome c oxidase (COX) in patient fibroblasts with 89% mutated mtDNA was decreased to 20% of the control levels."

Causal sufficiency of the tRNA lesion (rescue experiment) — PMID:15317755 [V]:

"import of tRNALys is accompanied by a partial rescue of mitochondrial functions affected by the mutation such as mitochondrial translation, activity of respiratory complexes, electrochemical potential across the mitochondrial membrane and respiration rate" "Import of a tRNALys with a mutation in the anticodon preventing recognition of the lysine codons does not lead to any rescue, whereas downregulation of the transgenic tRNAs by small interfering RNA (siRNA) transiently abolishes the functional rescue, showing that this rescue is due to the import."

Neuronal-level mechanism, human iPSC model (NEW — not in KB) — Wu et al., J Biomed Sci 2023, PMID:37605213 [V]:

"MERRF neural cells harboring the m.8344A > G mutation exhibited impaired mitochondrial bioenergetic function, elevated ROS levels and imbalanced expression of antioxidant enzymes." "Our findings indicate that neural immaturity and synaptic protein loss led to the impairment of neuronal activity and plasticity in MERRF neurons harboring the m.8344A > G mutation." "neurons harboring a high level of the m.8344A > G mutation exhibited impairment of the spontaneous and evoked potential-stimulated neuronal activities."

Quantitative [S — from full text, verify]: ATP-coupled respiration 50.1% of control in high-mutation iNSCs; H₂O₂ elevated 307–446%; synaptophysin, vGLUT2 and AMPAR reduced. This paper supplies a mechanistic bridge dismech currently lacks: bioenergetic deficit → synaptic protein loss → impaired plasticity → network-level dysfunction. It is the strongest available in-human-cell support for the "Cortical Neuronal Hyperexcitability" node.

Regional selectivity — the unresolved core problem (NEW evidence for the KB's existing KNOWLEDGE_GAP) — Zhou, Chomyn, Attardi & Miller, J Neurosci 1997, PMID:9315896 [V]:

"Neurons and the surrounding neuropil and glia from all CNS regions that were analyzed exhibited high proportions of mutant mtDNA, ranging from 97.6 +/- 0.7% in Purkinje cells to 80.6 +/- 2.8% in the anterior horn cells." "Surprisingly, as compared with controls, neuronal loss ranged from 7% of the Purkinje cells to 46% of the neurons of the dentate nucleus in MERRF cerebellum." "Thus, factors other than the high proportion of mutant mtDNA, in particular nuclear-controlled neuronal differences among various regions of the CNS, seem to contribute to the mitochondrial dysfunction and ultimate cell death."

This is a near-perfect adjudication of the merrf_regional_selectivity_gap discussion: Purkinje cells had the highest mutant load (97.6%) and the least loss (7%); dentate neurons had lower load and the most loss (46%). Single-cell heteroplasmy was already measured, and it does not explain selectivity. The proposed experiment in the KB should be updated to reflect that this measurement exists and was negative — the open question is now which nuclear/cell-intrinsic factor, not whether load explains it.

Neuropathology — PMID:3128314 [V]: "degeneration of dentate nucleus, red nucleus, globus pallidus, subthalamic nucleus and pontine tegmentum"; "degeneration of substantia nigra, locus ceruleus, cerebellar cortex and inferior olivary nucleus"; distribution "different from those of dentato-rubropallidoluysian atrophy, Joseph's disease or Friedreich's ataxia."

Mitochondrial vasculopathy: intramuscular vessels show the same SDH-strong/COX-deficient pattern (PMID:8186718, "Evidence of a mitochondrial vasculopathy in muscle biopsies" [S — verify]; the vascular finding is quoted in KB from PMID:25337734).

Molecular pathway / process annotations

Layer	GO / other
tRNA modification	GO:0002098 tRNA wobble uridine modification ✓ (DECREASED)
Translation	GO:0032543 mitochondrial translation ✓ (DECREASED)
OXPHOS	GO:0042775 mitochondrial ATP synthesis coupled electron transport ✓ (DECREASED); GO:0006119 oxidative phosphorylation ⚠
Terminal oxidase	GO:0004129 cytochrome-c oxidase activity ✓ (DECREASED)
ROS	GO:0072593 reactive oxygen species metabolic process ✓ (INCREASED); GO:0006979 response to oxidative stress ⚠
Membrane potential	GO:0042391 regulation of membrane potential ✓ (ABNORMAL)
Cell death	GO:0006915 apoptotic process ✓ (INCREASED)
Mitophagy (therapeutic axis)	GO:0000422 autophagy of mitochondrion ⚠
Biogenesis (failed therapeutic axis)	GO:0007005 mitochondrion organization ⚠
Synaptic (NEW, from iPSC paper)	GO:0048167 regulation of synaptic plasticity ⚠
Pathways	KEGG hsa00190 (Oxidative phosphorylation); Reactome R-HSA-5368287 (Mitochondrial translation) ⚠

Metabolic changes: blocked electron flow → NADH accumulation → pyruvate diverted to lactate → elevated blood/CSF lactate (CHEBI:24996 ✓) and elevated lactate:pyruvate ratio; secondary carnitine depletion; MR spectroscopy shows elevated lactate and reduced N-acetylaspartate [S].

Immune involvement: none primary. No autoimmunity, no immunodeficiency. Secondary neuroinflammation is plausible but not documented in MERRF specifically.

Molecular profiling available: transcriptomic/proteomic/metabolomic MERRF-specific datasets are sparse. The iPSC study (PMID:37605213) provides targeted protein-level data (synaptophysin, vGLUT2, AMPAR, antioxidant enzymes). No published single-cell or spatial transcriptomic MERRF atlas was found — a genuine gap. No CRISPR/RNAi functional-genomics screen specific to MERRF; DepMap has no MERRF context.

7. Anatomical Structures Affected

Organ level (primary): central nervous system (cerebellum and its output nuclei, cerebrum), skeletal muscle. Secondary/multisystem: heart (cardiomyopathy, conduction — WPW), inner ear (cochlea), eye (optic nerve, retina, levator palpebrae/extraocular), peripheral nerve, endocrine pancreas, adipose tissue (symmetric lipomatosis), GI tract, respiratory system.

Body systems: nervous (central + peripheral), musculoskeletal, cardiovascular, special sense, endocrine, gastrointestinal, respiratory.

Anatomical term suggestions (UBERON)

Structure	UBERON
cerebellum	UBERON:0002037 ✓
dentate nucleus	UBERON:0002688 ⚠
inferior olivary nucleus	UBERON:0002298 ⚠
red nucleus	UBERON:0002038 ⚠
globus pallidus	UBERON:0001875 ⚠
subthalamic nucleus	UBERON:0001882 ⚠
superior cerebellar peduncle (imaging target)	UBERON:0002807 ⚠
pontine tegmentum / brainstem	UBERON:0002550 ⚠ / UBERON:0002298 ⚠
skeletal muscle tissue	UBERON:0001134 ⚠
optic nerve	UBERON:0000941 ⚠
cochlea	UBERON:0001844 ⚠
heart	UBERON:0000948 ⚠

Cell types (CL)

Cell type	CL	Note
neuron	CL:0000540 ✓	generic energy-failure node
Purkinje cell	CL:0000121 ✓	highest mutant load, least loss (PMID:9315896)
pyramidal neuron	CL:0000598 ✓	cortical hyperexcitability node
skeletal muscle fiber	CL:0008002 ✓	RRF substrate
glutamatergic neuron	CL:0000679 ⚠	the iPSC model's cell type
cardiac muscle cell	CL:0000746 ⚠	cardiomyopathy
type B pancreatic cell	CL:0000169 ⚠	diabetes
retinal ganglion cell	CL:0000740 ⚠	optic atrophy
endothelial cell	CL:0000115 ⚠	intramuscular vasculopathy

Subcellular (GO CC)

GO:0005739 mitochondrion ⚠; GO:0005743 mitochondrial inner membrane ⚠ (site of the respiratory chain and ΔΨm); GO:0005759 mitochondrial matrix ⚠ (site of mitochondrial translation); subsarcolemmal mitochondrial accumulation is the histological localization of the RRF.

Lateralization: bilateral and broadly symmetric. Neuropathological and imaging findings are symmetric; MERRF has no lateralized presentation (unlike MELAS stroke-like episodes, which are focal and asymmetric — a useful differential handle).

8. Temporal Development

Onset

Normal early development, then onset: "Onset can occur from childhood to adulthood, occurring after normal early development." — PMID:20301693 [V]
Adult cohort: mean symptom onset 24.5 ± 10.9 years (range 6–48); adult onset in 75% (PMID:26995359 [V]).
Pediatric cohort: median onset 5.00 (IQR 2.75–9.00) years (PMID:39429077 [V]).
Pooled published cases: clinical picture characterized "at the mean age of approximately 35 years" (PMID:23635963 [V]).
Onset pattern: insidious/chronic, occasionally punctuated by subacute decompensation during catabolic stress.
Onset order: myoclonus first in classical MERRF; but cerebellar ataxia was the first symptom in all three patients in the imaging series (PMID:17989367 [V]) — consistent with the "myoclonic ataxia" reframing.

Progression

Course: chronic, lifelong, progressive; not relapsing-remitting, not self-limited. This is what places MERRF in the progressive myoclonic epilepsy group rather than among the stable genetic generalized epilepsies.
"Myoclonus presented and worsened progressively in all 15 MERRF children, with 10 as the initial symptom" — PMID:39429077 [V]
Rate: highly variable, even within families. mitoNET explicitly documents "large clinical variability between carriers of the same mutation, even within families" [V].
Staging: no formal MERRF staging system exists. NMDAS is the practical progression instrument.
Remission: none spontaneous; treatment-induced improvement is symptomatic (myoclonus control) only.
Critical intervention window (hypothesis, not established): the rapamycin cell data show complete bioenergetic rescue at intermediate mutant load but only marginal effect at high load — implying a window that closes (PMID:35922766 [V]). This is the mechanistic argument for early intervention and is already curated as a KNOWLEDGE_GAP in the entry.

9. Inheritance and Population

Epidemiology

Measure	Value	Source
mtDNA disease (all causes), adults, NE England	~20 per 100,000 (1 in 5,000)	Gorman et al., PMID:25652200 [V] — "The minimum prevalence rate for mtDNA mutations was 1 in 5,000 (20 per 100,000)". This is an upper bound on MERRF, not a MERRF rate.
m.8344A>G, NE England adults	0.28 per 100,000 (95% CI 0.02–0.54)	GeneReviews-cited [S] ⚠ verify primary source
m.8344A>G, northern Finland (n=353,895)	0 per 100,000 (95% CI 0–1.5)	Remes et al. 2003, PMID:12876264 (PubMed record has no abstract text — figures are from secondary citation [S])
m.8344A>G, pediatric western Sweden	0–0.25 per 100,000	GeneReviews-cited [S]
MERRF syndrome (clinical)	probably < 1 per 100,000	StatPearls [S]

Suggested dismech prevalence records: keep the existing Gorman upper-bound record, and add a m.8344A>G-specific record with measure_type: POINT_PREVALENCE, prevalence_class: BELOW_1_IN_1000000… actually 0.28/100,000 = 2.8 per million → BAND_1_9_PER_1000000, rate_per_100000: 0.28, population "Adults in North East England", with the caveat that this is variant prevalence, not syndrome prevalence.

Inheritance

Maternal (mitochondrial) inheritance with heteroplasmy. HPO: HP:0001427 Mitochondrial inheritance ✓.
"MERRF is caused by pathogenic variants in mtDNA and is transmitted by maternal inheritance." — PMID:20301693 [V]
"A female with a mtDNA pathogenic variant (whether symptomatic or asymptomatic) transmits the pathogenic variant to all of her offspring." — PMID:20301693 [V]
Affected males transmit nothing.
Penetrance: incomplete and unpredictable; asymptomatic carriers with high mutant load are documented ("high proportions of mutant genomes (up to 63%) were found in asymptomatic relatives" — PMID:9272179 [V]).
Expressivity: extremely variable, within and between families.
Anticipation: not a repeat-expansion disease; apparent anticipation can occur through bottleneck-driven load increase across generations, but is not a formal genetic anticipation mechanism.
Germline mosaicism / bottleneck: the mtDNA genetic bottleneck in oogenesis is the operative mechanism — the child's mutant load is drawn stochastically and is not predictable from the mother's.
Founder effects: none established; m.8344A>G arises recurrently on multiple haplogroup backgrounds.
Consanguinity: irrelevant (not autosomal recessive).
Carrier frequency: not a meaningful concept in the Mendelian sense; population heteroplasmic allele frequency ~0.011% in gnomAD v4.1.0 [S].

The heteroplasmy–phenotype disconnect (curate as CONTROVERSY — already in the entry)

Three independent lines converge: - "Although there seems to be a gene dosage effect in MERRF, we found no absolute relationship between the relative proportion of mutant genomes in blood and clinical severity." — PMID:9272179 [V] - "heteroplasmy in blood was high both in symptomatic (mean 64.5%, range 41-82%) and asymptomatic individuals (mean 53.1%, range 21-78%)" — PMID:32577866 [V] - "There was no correlation between the heteroplasmy level in blood and age at onset or clinical phenotype." — mitoNET, PMID:26995359 [V] ← new, independent, registry-scale confirmation; add to the controversy evidence block - Counter-directional single case: "the m.8344A>G variant may manifest milder and with a later onset in the homoplasmic as compared to the heteroplasmic form" — PMID:36176839 [V] - And at the tissue level, Zhou 1997 shows load doesn't even explain regional neuronal loss (PMID:9315896 [V]).

Population demographics

Ethnic distribution: worldwide; described in European, Japanese, Chinese, and other populations. No population enrichment established.
Geographic: the Finnish zero-prevalence result vs the English 0.28/100,000 suggests real regional variation in the variant's frequency, though small-number uncertainty dominates.
Sex ratio: ~1:1. Mitochondrial inheritance means both sexes are affected equally; only transmission is sex-asymmetric. (No formal sex-ratio study found.)
Age distribution: bimodal-ish in practice — a pediatric group (median onset 5 y, enriched for Leigh/LS-MERRF overlap) and a much larger adult group (mean onset 24.5 y, 75% adult onset).

10. Diagnostics

Laboratory

Blood/CSF lactate (CHEBI:24996 ✓; LOINC 2524-7 ⚠, 32693-4 ⚠): supportive when elevated; neither sensitive nor specific, normal value does not exclude. Lactate:pyruvate ratio adds specificity.
Creatine kinase (LOINC 2157-6 ⚠): elevated in 61.5% of tRNA-Lys carriers (PMID:32577866 [V]).
Others per Mitochondrial Medicine Society consensus (PMID:25503498): plasma amino acids, acylcarnitine profile, urine organic acids, FGF-21/GDF-15 as mitochondrial-myopathy biomarkers (⚠ FGF-21/GDF-15 performance in MERRF specifically not established).

Imaging (currently a KB gap — nothing in `diagnosis` covers MRI)

Ito et al., AJNR 2008, PMID:17989367 [V]:

"Conventional brain MR imaging showed atrophy of the superior cerebellar peduncles and the cerebellum in all patients and brain stem atrophy in 2 patients." "There was a discrepancy between clinical disabilities (severe) and radiologic abnormalities (mild). This discrepancy and atrophy of the superior cerebellar peduncles and the cerebellum may be important findings suggesting a diagnosis of MERRF."

Registry-scale: "Brain MRI revealed cerebral and/or cerebellar atrophy in 43 % of our patients" (PMID:26995359 [V]).

Additional reported features [S — verify before curation]: basal ganglia/dentate calcification (better on CT), white-matter change late, signal abnormality in medial thalami/mesencephalon/posterior pons/medulla, MRS showing elevated lactate and reduced NAA. The clinico-radiological discrepancy is itself a diagnostic clue and deserves a diagnosis[] entry. NCIT: Magnetic Resonance Imaging NCIT:C16809 ⚠.

Electrophysiology

EEG (NCIT:C38054 ✓) with myoclonus correlation — separates cortical myoclonic epilepsy from subcortical myoclonus: "Electroencephalogram monitoring in the 15 MERRF children revealed myoclonic seizures in 10 children, with 6 classified as myoclonic epilepsy, and 4 as subcortical myoclonus." (PMID:39429077 [V]). Giant SSEPs and C-reflex support cortical origin (⚠ not sourced this session).
EMG/NCS: myopathic units plus axonal sensorimotor neuropathy (69.2% neuropathy — PMID:32577866 [V]).
ECG + echocardiography: for WPW and cardiomyopathy; recommended annually (GeneReviews).
Audiometry: hearing loss in 72% (mitoNET) — recommended every 2–3 years.

Biopsy / pathology

Muscle biopsy (NCIT:C51895 ✓): RRF on modified Gomori trichrome, COX-negative fibers, strong SDH — including intramuscular vessels.

"Morphological changes seen upon muscle biopsy in MERRF include a substantive proportion of RRF, muscle fibers showing a deficient activity of cytochrome c oxidase (COX)" — PMID:25337734 [V] "the presence of vessels with a strong reaction for succinate dehydrogenase and COX deficiency" — PMID:25337734 [V]

The SDH-spared/COX-deficient dissociation is the histological signature of a mitochondrially encoded translation defect: SDH (complex II) is entirely nuclear-encoded and therefore unaffected. Caveat: RRF present in only 63% of mitoNET patients — a negative biopsy does not exclude.

Genetic testing

Approach: targeted m.8344A>G testing first; if negative with high suspicion, full mtDNA sequencing with heteroplasmy quantification; then nuclear gene panel/exome for phenocopies.
Tissue matters: blood can be falsely reassuring because heteroplasmy varies by tissue and declines in blood with age. Urinary sediment or muscle is preferred when blood is negative.
Historical convenience: "The mutation alters the T psi C loop of the tRNA(Lys) gene and creates a CviJI restriction site, providing a simple molecular diagnostic test for the disease." — PMID:2112427 [V]
Not useful: karyotype, chromosomal microarray, FISH, repeat-expansion testing (all target nuclear architecture MERRF does not involve). CMA/karyotype should be explicitly marked "not applicable" in the entry.
WES caveat worth flagging: standard exome pipelines historically under-called mtDNA; mtDNA is well covered by genome sequencing and by dedicated mtDNA assays. Resources: MITOMAP, MSeqDR, ClinVar, GTR.

Omics-based diagnostics

RNA-seq, proteomics, metabolomics, and liquid biopsy have no established clinical diagnostic role in MERRF. Research-grade only.

Clinical criteria

Four canonical features (PMID:25337734 [V]):

"Diagnostic criteria for MERRF include typical manifestations of the disease: myoclonus, generalized epilepsy, cerebellar ataxia and ragged red fibers (RRF) on muscle biopsy."

⚠ But the criteria are now known to be poorly calibrated against the genotype — applying them strictly misses most m.8344A>G carriers (PMID:23635963, PMID:26995359, PMID:32577866). A "MERRF Classification: Implications for Diagnosis and Clinical Trials" paper exists (Pediatr Neurol — ⚠ PMID unresolved) addressing exactly this.

Differential diagnosis

Condition	MONDO	Distinguishing
MELAS	MONDO:0010789 ✓	m.3243A>G in MT-TL1; stroke-like episodes in non-vascular territories; codon-selective (not complete) decoding failure
Leigh syndrome	MONDO:0009723 ✓	Same m.8344A>G can cause it — symmetric necrotizing basal ganglia/brainstem lesions; earlier onset with regression. Overlap syndrome (LS-MERRF) is real: "Fifteen children had myoclonic epilepsy with ragged-red fibers (MERRF), 3 had Leigh syndrome (LS), and 4 had LS-MERRF overlap syndrome (LS-MERRF)." (PMID:39429077 [V])
Lafora disease	MONDO:0009697 ✓	AR EPM2A/NHLRC1; PAS+ Lafora bodies; occipital seizures; rapid cognitive collapse
Unverricht-Lundborg	MONDO:0009698 ✓	AR CSTB dodecamer expansion; preserved cognition; no myopathy
Sialidosis type I	⚠	cherry-red spot, NEU1, urinary oligosaccharides
Neuronal ceroid lipofuscinoses	⚠	visual failure first, storage material on EM
DRPLA	⚠	AD CAG expansion in ATN1; overlapping dentatorubral anatomy but different distribution (explicitly distinguished in PMID:3128314 [V])
KSS / CPEO	⚠	large-scale mtDNA deletion; ophthalmoplegia dominant; a MERRF/KSS overlap due to m.3291T>C is reported

Screening

No newborn screening. Not on the RUSP; no biochemical marker with adequate sensitivity.
Cascade testing of maternal relatives is the correct family strategy. GeneReviews: at-risk relatives get molecular testing if the family variant is known; otherwise complete neurologic, ophthalmologic and audiology evaluation plus EKG, echocardiogram and blood lactate [S].
Carrier screening: not applicable in the Mendelian sense.

11. Outcome / Prognosis

Honest summary: MERRF-specific survival statistics are weak. No dedicated natural-history/survival study of MERRF was found.

The most-cited adult mitochondrial-myopathy outcome cohort (Mayo Clinic, n=94, Brain Commun 2024, DOI 10.1093/braincomms/fcae041) reports "Thirty patients died, with median survival of 33.4 years from symptom onset and 10.9 years from diagnosis. Median age at death was 55 years" [V] — but this is the whole mitochondrial-myopathy cohort, dominated by MT-TL1 and POLG; MERRF-specific survival was not separately reported. Do not curate "median age at death 55" as a MERRF figure. Also from that cohort: "Cardiac involvement was associated with increased mortality [hazard ratio 2.36 (1.05, 5.29)]" and "There was no difference in survival based on genotype or phenotype."
Prognostic factors (qualitative, well-supported): cardiac involvement (cardiomyopathy, conduction disease); respiratory dysfunction (45% in mitoNET); dysphagia (35%) with aspiration risk; earlier onset generally worse; higher mutant load associated with more severe manifestations at the family level (but see the disconnect above).
Morbidity/disability: progressive; disability is driven by action myoclonus, ataxia, weakness, deafness and cognitive decline. Median time to gait assistance in the broader mitochondrial-myopathy cohort was 5.5 years from diagnosis / 17 years from onset [V] — again, cohort-wide, not MERRF-specific.
Complications: status myoclonicus/status epilepticus, aspiration pneumonia, respiratory failure, cardiac arrhythmia and sudden death (WPW), diabetes complications, falls/fracture from ataxia, hepatic failure if valproate is given.
Recovery potential: none — no disease-modifying therapy exists; the neuronal loss is not reversible. Symptomatic myoclonus control can meaningfully improve function.
Prognostic biomarkers: none validated. Blood heteroplasmy explicitly fails as a prognostic marker (PMID:26995359 [V]). GDF-15/FGF-21 are candidate severity markers in mitochondrial disease generally ⚠.

12. Treatment

There is no disease-modifying therapy. All current care is symptomatic and supportive.

"Therapy is currently limited to symptomatic management of myoclonic epilepsy, and supportive measures to counteract muscle weakness with co-factors/supplements." — PMID:35922766 [V]

Pharmacotherapy

Treatment	Agent (CHEBI)	NCIT action	Modality	Evidence
Levetiracetam — first choice for myoclonus	levetiracetam CHEBI:6437 ✓	Pharmacotherapy NCIT:C15986 ✓	SMALL_MOLECULE	"LEV may benefit myoclonus in PME of mitochondrial origin without altering mitochondrial function, and it could be considered the drug of first choice for the treatment of myoclonus in MERRF." — PMID:16414077 [V]
Clonazepam	clonazepam CHEBI:3756 ✓	NCIT:C15986 ✓	SMALL_MOLECULE	"levetiracetam or clonazepam for myoclonus" — PMID:20301693 [V]
Other AEDs for generalized seizures (lamotrigine, topiramate, zonisamide, perampanel) ⚠	⚠	NCIT:C15986	SMALL_MOLECULE	not MERRF-specific; ⚠ unsourced this session
Avoid valproate (+ aminoglycosides, linezolid, tobacco, alcohol)	valproic acid CHEBI:39867 ⚠	Supportive Care NCIT:C15747 ✓	BEHAVIORAL	"VPA should be used with caution in PME due to mitochondrial dysfunction, i.e. in MERRF… because of its interaction with mitochondrial respiration and metabolism." — PMID:16414077 [V]
Cofactor/supplement "mito cocktail"	coenzyme Q10 CHEBI:46245 ✓, L-carnitine CHEBI:16347 ✓, α-lipoic acid ⚠, vitamin E ⚠, B vitamins ⚠, creatine ⚠, riboflavin ⚠	Nutritional Support NCIT:C15433 ✓	SMALL_MOLECULE (not BEHAVIORAL — see the CLAUDE.md warning about NCIT:C15433)	"Coenzyme Q10 (50-200 mg 2-3x/day), L-carnitine (1000 mg 2-3x/day), alpha lipoic acid, vitamin E, vitamin B supplements, and creatine… have been of modest benefit in some individuals." — PMID:20301693 [V]. GeneReviews also lists ubiquinol [S]. No controlled trial establishes disease modification.

Pharmacogenomics: the relevant interaction is genotype-driven drug avoidance (valproate, aminoglycosides, linezolid) rather than metabolizer-status dosing. No PharmGKB/CPIC guideline exists for MERRF. ⚠ Worth noting: POLG-related disease has the hardest valproate contraindication; the MERRF contraindication is mechanistically analogous but based on weaker evidence.

Advanced / experimental therapeutics (none in patients)

1. Mitochondrial tRNA import — proof of concept, in vitro (PMID:15317755 [V]) Nuclear-encoded tRNA-Lys targeted into mitochondria partially rescued translation, complex activity, ΔΨm and respiration; rescue was abolished by siRNA knockdown of the transgene, proving specificity.

2. Mitophagy stimulation (rapamycin) — in vitro (PMID:35922766 [V])

"The second approach, when administered chronically (4 weeks), induced a slight increase of mitochondrial respiration in fibroblasts with high-mutation load, and a significant improvement in fibroblasts with intermediate-mutation load, rescuing completely the bioenergetics defect." "This suggests that induction of mitochondrial biogenesis may not be sufficient to rescue mitochondrial dysfunction in MERRF cells with high-mutation load." (The failed arm — PGC-1α overexpression / nicotinic acid — is as informative as the successful one.) CHEBI: sirolimus ⚠.

3. Heteroplasmy-shifting nucleases — in vitro, MERRF-specific (NEW, a genuine KB gap) Pereira, Bacman, … Moraes, EMBO Mol Med 2018, PMID:30012581 [V]:

"We tested whether molecular hybrids (mitoTev-TALEs) could specifically bind and cleave mtDNA of patient-derived cybrids harboring different levels of the m.8344A>G mtDNA point mutation, associated with myoclonic epilepsy with ragged-red fibers (MERRF). We tested two mitoTev-TALE designs, one of which robustly shifted the mtDNA ratio toward the wild type. When this mitoTev-TALE was tested in a clone with high levels of the MERRF mutation (91% mutant), the shift in heteroplasmy resulted in an improvement of oxidative phosphorylation function." "mitoTALENs are dimeric and relatively large, making it difficult to package their coding genes into viral vectors, limiting their clinical application."

Related platform work: mitoTALENs generally (Bacman et al., Nat Med 2013, PMID:23913125 — note this paper targeted a large deletion and m.14459G>A, not m.8344A>G; do not miscite it); in vivo mitoTALEN in the m.5024C>T mouse (Nat Med 2018); mtZFN tandem architecture (EMBO Mol Med 2025) ⚠. Key mechanistic limitation for MERRF: DdCBE-type base editors perform C•G→T•A conversions, so reverting an A→G transition requires an adenine-capable mitochondrial editor (TALED-class), which remains preclinical.

4. Systemic drug candidates in trial (not MERRF-specific) - KL1333 (NAD⁺ modulator, oral) — Brain 2025, PMID:39657714 [V]: "KL1333 aims to normalize the NAD+:NADH ratio that is critical for ATP production… Results indicate KL1333 is safe and well tolerated, with dose-dependent gastrointestinal side effects, and validate potential novel outcome measures in primary mitochondrial disease including the 30-s Sit to Stand, and the patient-reported fatigue scales." Phase 2 pivotal study ongoing; open-label extension NCT07514338 ⚠. Development explicitly names MERRF among target indications [S]. - Sonlicromanol (KH176) — phase 2 reported in Brain; primarily studied in m.3243A>G ⚠. - Elamipretide — FDA-approved for Barth syndrome (2025) [S]; not approved for MERRF but establishes regulatory precedent. - Vatiquinone (PTC743) — inherited mitochondrial disease trials, incl. NCT05218655 ⚠.

⚠ No interventional trial recruiting MERRF specifically was confirmed this session. Any clinical_trials block should be built by querying ClinicalTrials.gov for "MERRF" directly and validating with just fetch-reference NCT….

Surgical / device / rehabilitative / supportive

Cochlear implantation for severe sensorineural hearing loss (mitochondrial deafness responds well) ⚠; hearing aids.
Cardiac: pacemaker/ICD for conduction disease; ablation for symptomatic WPW ⚠.
Ptosis surgery / ptosis crutches ⚠.
Gastrostomy for dysphagia; non-invasive ventilation for respiratory dysfunction (45% affected).
Debulking of symptomatic lipomas ⚠.
Physical therapy and aerobic exercise (NCIT:C15302 ✓): "physical therapy to improve any impaired motor function; aerobic exercise" — PMID:20301693 [V]. Occupational (NCIT:C121351) and speech therapy (NCIT:C159273) for dysarthria/dysphagia.
Genetic counseling (NCIT:C15240 ✓) — see §13.

Surveillance (GeneReviews [S], worth curating as a management block)

Annual neurologic, ophthalmologic, cardiologic (ECG + echocardiogram) and endocrinologic evaluation; audiology every 2–3 years.

13. Prevention

Primary prevention of the disease: not possible — the variant is present from conception. The only true primary prevention is reproductive.
Reproductive options and their limits:

"because the mutational load in tissues sampled prenatally may shift in utero or after birth as a result of random mitotic segregation, prediction of the phenotype from prenatal studies is not possible." — PMID:20301693 [V]

Prenatal diagnosis and PGT are technically feasible and are offered, but cannot forecast phenotype. Mitochondrial replacement therapy / mitochondrial donation (licensed in the UK, and with first outcome reports published) is the only intervention that prevents transmission outright ⚠ — not confirmed against a primary source this session, but should be curated once verified, as it is the single most consequential preventive option for this disease class. - Secondary prevention: cascade testing of maternal relatives; baseline and periodic cardiac (ECG/echo — asymptomatic WPW is silent until it isn't), audiologic, ophthalmologic and diabetes screening in identified carriers. - Tertiary prevention (preventing complications) — the practically important arm: - Avoid valproate, aminoglycosides, linezolid, tobacco, alcohol. - Avoid prolonged fasting; aggressive management of intercurrent illness and dehydration; careful perioperative/anesthetic planning. - Treat WPW and cardiomyopathy before they cause events. - Aspiration precautions once dysphagia appears. - Immunization: no MERRF-specific vaccine issue; routine immunization is encouraged because infection is a decompensation trigger. - Newborn/population screening: none, and none justified at this prevalence with no disease-modifying therapy. - Public health / environmental interventions: not applicable.

14. Other Species / Natural Disease

Taxonomy: Homo sapiens NCBITaxon:9606. No naturally occurring animal disease equivalent to MERRF is documented. OMIA has no MERRF entry (⚠ not directly queried this session — verify). This is expected: pathogenic heteroplasmic mt-tRNA point variants are purged efficiently by the germline bottleneck in most species and are essentially absent as spontaneous veterinary disease.
Orthologous gene: mouse mt-Tk (mitochondrially encoded tRNA lysine) ⚠ — NCBI Gene ID not confirmed this session; do not curate an ID without checking.
Evolutionary conservation: high. The mitochondrial genome's 22-tRNA translation system and the wobble taurine modification are deeply conserved across metazoa, which is why the mechanism generalizes — and why the absence of a natural animal model is a limitation rather than a biological difference.
Zoonotic potential / cross-species transmission: not applicable (genetic disease).
Comparative pathology: the closest comparative material is engineered — the heteroplasmic mouse mt-tRNA-Ala model (below), which reproduces the class of lesion (mt-tRNA point mutation, heteroplasmy, translation failure) in a different tRNA and a different target organ.

15. Model Organisms

The honest headline: there is no mouse model of MERRF.

No transmitochondrial mouse carrying m.8344A>G (or a mt-tRNA-Lys equivalent) exists. Introducing defined point variants into mtDNA in vivo remains extremely difficult, and this is the field's central experimental bottleneck. Every mechanistic claim about MERRF in a whole organism therefore rests on human tissue.

What actually exists

Model	Type	What it captures	What it misses
Cytoplasmic hybrids (cybrids) — patient mtDNA into ρ⁰ recipient cells	IN_VITRO, human	The cleanest demonstration that the tRNA lesion alone is sufficient, independent of nuclear background; supports precise heteroplasmy titration (PMID:10477264 [V])	Dividing cells; no tissue architecture; no neurons
Patient fibroblasts	IN_VITRO, human	Threshold behavior, COX kinetics, ΔΨm, drug response (rapamycin — PMID:35922766 [V])	Not a post-mitotic, energy-limited cell
iPSC-derived NPCs and cortical glutamatergic neurons	IN_VITRO, human	The best current model. Retains patient heteroplasmy; reproduces bioenergetic deficit, ROS, antioxidant imbalance, neural immaturity, synaptic protein loss, and impaired spontaneous/evoked activity (PMID:37605213 [V])	Immature/fetal-like; no cerebellar dentate neurons; no aging; heteroplasmy can drift in culture
mitoTev-TALE / mitoTALEN-engineered MERRF cybrid clones	IN_VITRO, human	Heteroplasmy manipulation as an experimental variable and a therapeutic readout (PMID:30012581 [V])	Delivery, in vivo behavior untested for this variant
m.5024C>T mt-tRNA-Ala mouse (Kauppila 2016 ⚠)	MODEL_ORGANISM	The class model: heteroplasmic mt-tRNA point mutation → reduced steady-state mt-tRNA → impaired mitochondrial translation → hypertrophic cardiomyopathy; the standard platform for testing mitoTALEN/mtZFN/DdCBE in vivo	Wrong tRNA, wrong target organ (heart, not cerebellum/cortex), no myoclonus, no epilepsy. Any MERRF claim drawn from it is an extrapolation and should be marked `HUMAN_MODEL_MISMATCH`, not `MODEL_ORGANISM` support for a human phenotype

Genetic model types available

Knockout/knock-in/conditional/transgenic approaches used routinely for nuclear genes do not transfer to mtDNA: mtDNA is not amenable to homologous recombination, and there is no germline mtDNA transgenesis. Available genetic manipulations are limited to (a) cybrid transfer, (b) nuclease-based heteroplasmy shifting, (c) allotopic/nuclear-encoded rescue constructs, and (d) mtDNA-targeted base editors (C→T only, so not capable of reverting m.8344A>G as of this writing).

Research applications and databases

Applications: threshold biology, drug screening (the iPSC platform is explicitly proposed for this — PMID:37605213 [V]), heteroplasmy-shifting therapeutics, synaptic/network consequences of bioenergetic failure. Resources: MGI (for mt-Tk ⚠), IMSR, Cellosaurus (for MERRF cybrid lines ⚠), MITOMAP/MSeqDR for variant-level curation.

Curation notes for the dismech entry

Highest-value additions to kb/disorders/MERRF_Syndrome.yaml, ranked:

PMID:26995359 (mitoNET, n=34) — supplies six frequency-quantified phenotypes the entry lacks (migraine 52%, psychiatric 54%, respiratory dysfunction 45%, GI 38%, dysarthria 36%, dysphagia 35%), a registry-scale onset figure (24.5 ± 10.9 y, 75% adult onset), a brain-atrophy frequency (43%), and — importantly — a third independent statement of the heteroplasmy–phenotype disconnect for the existing CONTROVERSY block.
PMID:23635963 (Italian, n=42 + 321 pooled) — the full frequency ladder at mean age ~35, and the "myoclonic ataxia rather than myoclonic epilepsy" reframing, which directly supports the nosological arm of the existing controversy.
PMID:9315896 (Zhou/Attardi autopsy) — nearly resolves the merrf_regional_selectivity_gap: single-cell regional heteroplasmy has already been measured and is inversely related to loss (Purkinje 97.6% load / 7% loss vs dentate / 46% loss). The proposed experiment in that discussion should be revised accordingly.
PMID:37605213 (iPSC cortical neurons) — human-cell mechanistic bridge from bioenergetics to synaptic dysfunction; strengthens the Cortical Neuronal Hyperexcitability node, which currently rests on EEG phenomenology.
PMID:17989367 (AJNR MRI) — the entry has no imaging diagnosis entry at all; superior-cerebellar-peduncle atrophy plus the clinico-radiological discrepancy is a distinctive diagnostic clue.
PMID:30012581 (mitoTev-TALE) — a MERRF-specific heteroplasmy-shifting result that belongs in the merrf_disease_modifying_therapy_gap discussion alongside the tRNA-import and rapamycin evidence (and makes the "two independent routes" framing into three).
PMID:39657714 (KL1333 phase 1a/1b) — the only trial-grade therapeutic evidence touching this disease class; also validates outcome measures.
A m.8344A>G-specific prevalence record (0.28/100,000 NE England; 0/100,000 northern Finland) distinct from the existing mtDNA-class upper bound.

Before committing any of the above: run just fetch-reference for every PMID marked [S] or ⚠, verify each snippet is an exact substring of the cached abstract, seed and validate all new HP/GO/CL/UBERON/CHEBI/NCIT terms with just validate-terms, and run the full just qc. Two citation hazards found in this session are worth remembering: PMID:23913125 (Bacman 2013 mitoTALEN) did not target m.8344A>G* despite being widely cited as MERRF gene-therapy work, and the Brain Commun 2024 "median age at death 55 years" figure is cohort-wide, not MERRF-specific* — both are exactly the kind of plausible-but-wrong claim that survives snippet validation.

Ask OpenScientist

OpenScientist Report

Classifications

Mappings

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Histopathology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Biochemical Markers

Diagnosis

Progression

Prevalence

Differential Diagnoses

Source YAML

References & Deep Research

References

Deep Research

1. Disease Information

Overview

Identifiers

Synonyms

Data provenance type

2. Etiology

Primary causal factor

Genetic risk factors

Environmental risk factors

Protective factors

Gene–environment interactions

3. Phenotypes

The central finding of the modern literature: the classical tetrad is the exception

Phenotype table with HPO suggestions and frequency evidence

Quality of life

4. Genetic / Molecular Information

Causal gene

Pathogenic variants

Functional consequence — the molecular core

Modifier genes

Epigenetics

Chromosomal abnormalities

5. Environmental Information

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream)

Key mechanistic evidence

Molecular pathway / process annotations

7. Anatomical Structures Affected

Anatomical term suggestions (UBERON)

Cell types (CL)

Subcellular (GO CC)

8. Temporal Development

Onset

Progression

9. Inheritance and Population

Epidemiology

Inheritance

The heteroplasmy–phenotype disconnect (curate as CONTROVERSY — already in the entry)

Population demographics

10. Diagnostics

Laboratory

Imaging (currently a KB gap — nothing in diagnosis covers MRI)

Electrophysiology

Biopsy / pathology

Genetic testing

Omics-based diagnostics

Clinical criteria

Differential diagnosis

Screening

11. Outcome / Prognosis

12. Treatment

Pharmacotherapy

Advanced / experimental therapeutics (none in patients)

Surgical / device / rehabilitative / supportive

Surveillance (GeneReviews [S], worth curating as a management block)

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

The honest headline: there is no mouse model of MERRF.

Imaging (currently a KB gap — nothing in `diagnosis` covers MRI)